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Scope of thesis
The major aim of this thesis is to get a better understanding of resistance in glioma, both against chemotherapy and immunotherapy. Gliomas arise in an immunosuppressive 
environment consisting of soluble factors, cell surface molecule and suppressive immune 
cells. Better understanding of these suppressive mechanisms paves the way for more effec-
tive immunotherapy. Up till now, there are no good treatment options for patients with a 
glioma. Improving treatment either by making radio- and chemotherapy more effective, or 
by novel therapies like immunotherapy is essential for improving the prognosis for patients 
with a glioma.
As already briefly discussed in the introduction, there are many ways in which gliomas can 
acquire Temozolomide (TMZ) resistance. In Chapter 3, we investigate a novel mechanisms 
of TMZ resistance. Connexin 43 (Cx43) is a protein of the gap junction family and can be 
upregulated in glioma cells. Cx43 can form functional hemichannels and gap junctions and 
has been associated in pro-apoptotic and anti-apoptotic acitvities, presumably due to the 
bystander effect. Here we show that Cx43 induces TMZ resistance in vitro which is in part 
mediated by both channel dependent and independent mechanisms. This chemoresistance 
appears to be mediated by modulating the mitochondrial apoptosis pathway.
Due to the multiple mechanisms for TMZ resistance that can develop, other therapies are 
required to improve glioma prognosis. For various tumours, immunotherapy has resulted 
in improved patient survival and the Journal Science declared the use of checkpoint inhibi-
tors the scientific breakthrough of 2013 (Couzin-Frankel 2013). To further improve immuno-
therapeutic protocols for glioma, it is of great importance to better understand the immu-
nosuppressive mechanisms exploited by the tumour. In Chapter 4, we set out to determine 
the prevalence of myeloid derived suppressor cells (MDSCs) in blood and tumour of glioma 
patients. We found that two populations of MDSCs (both M-MDSCs and PMN-MDSCs) were 
increased in the blood of glioma patients, but that mainly the PMN-MDSCs were present 
within the glioma tissue. 
In Chapter 5, we investigate the MDSC activation state of in MDSCs from blood and tumour 
tissue from glioma patients. We provide evidence for systemic immune suppression, which 
is already observed in the blood of low grade glioma patients. Furthermore we show that 
the myeloid cells from glioma patients have increased expression of intracellular S100A8/9 
and that arginase expression in the blood is correlated to the PMN-MDSCs prevalence. Ad-
ditionally, we show that these PMN-MDSCs highly suppress T cell function. 
In Chapter 6, we continue exploring the cell surface of MDSCs. In this chapter, we focus on 
the sialic acid-binding Ig-like super family of lectins (Siglecs), a receptor family involved in 
the recognition of “self”, which is exploited by various neoplasms. We determine the ex-
pression pattern of Siglec receptors on human MDSCs of both healthy donors and glioma 
patients. MDSCs express Siglec-3, -5, -7 and -9, which al contain one or more immunorecep-
tor tyrosine-based inhibition motive (ITIM) in their cytoplasmic tail receptors. These Siglecs 
can bind sialylated glycans which can result in recruitment of tyrosine phosphatases at the 
ITIM motives and subsequently a suppressive signal in the cell, possibly rendering the MD-
SCs more suppressive. We show that the glioma cells express multiple ligands on their cell 
surface for the siglecs expressed on MDSCs from blood and tumour.
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The final Chapter 7 summarizes the findings of this thesis and discusses their implications 
for glioma therapy, especially immunotherapy.  
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gliomas.
Immune Responses to Tumours in the CNS
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Abstract
After a brief introduction into gliomas, the pathways involved in resistance against Te-mozolomide, the chemotherapeutic used as a standard of care for glioma, will be 
briefly covered. Subsequently, the immune cell infiltration into gliomas will be described. 
Afterwards, immunobiological aspects of immune responses to glioma will be covered, in-
cluding the nature and role of different immune cells and molecules involved in these pro-
cesses. In the last part of this chapter, a brief summary of different immunotherapeutic 
approaches for glioma as well as some results obtained in this field so far are presented. 
Hopefully, further elucidation of the pathobiology of immune responses to glioma will 
ultimately lead to therapeutic strategies that do not just inhibit tumour growth, but effec-
tively ‘search and destroy’ tumour cells, especially in tumours that to date are incurable 
because of their relentless proliferation and migration into the central nervous system 
(CNS) tissue.
Tumours of the CNS
Compared to tumours elsewhere in the human body, the diversity and complexity of CNS tumours have been described as being unrivalled. Based on systematic histopathologi-
cal analysis for more than a century, a World Health Organization (WHO) scheme of CNS 
tumours has emerged that is now accepted worldwide as the gold standard for classification 
of these neoplasms (Louis, Ohgaki et al. 2007). An important distinction in the spectrum of 
CNS tumours is that of primary (i.e. arising from the CNS or its coverings) versus second-
ary neoplasms (i.e. metastases in or around the CNS from malignant tumours elsewhere in 
the body). Although primary tumours are much less common than CNS metastases of, for 
example, lung and breast cancer, they are on the top of the list of ‘average number of years 
of life lost’ by cancer (Burnet, Jefferies et al. 2005). This can be explained by two important 
facts: (i) the most frequent primary brain tumour is glioma, and most gliomas show very ex-
tensive, diffuse infiltrative growth in the surrounding CNS parenchyma, precluding curative 
therapy (Claes, Idema et al. 2007); and (ii) CNS tumours are relatively frequent in children, 
and many of those are highly aggressive.
Increased knowledge about the genetic and molecular aberrations underlying oncogenesis 
has accumulated in a landmark article summarizing the tasks that a cancer cell generally 
needs to accomplish to successfully survive and grow as a tumour: sustain proliferative sig-
nalling, evade growth suppressors, resist cell death, enable replicative immortality, induce 
angiogenesis and activate invasion and metastasis (Hanahan and Weinberg 2000). More 
recently, conceptual progress resulted in the addition of two hallmarks: reprogramming of 
energy metabolism and evading of immune destruction. Furthermore, it was acknowledged 
that genome instability in tumour cells and inflammation are characteristics facilitating or 
even enabling the hallmarks just listed (Hanahan and Weinberg 2011).
Glioma
Gliomas are considered to originate from glial cells or their precursors and may show astrocytic, oligodendroglial or ependymal differentiation or a combination thereof. In 
adult patients, most gliomas belong to the category of ‘diffuse gliomas’ (i.e. glial tumours 
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showing extensive, diffuse, infiltrative growth in the surrounding brain parenchyma). The 
diffuse gliomas are astrocytic, oligodendroglial or mixed oligoastrocytic in nature. Based on 
histopathological parameters such as marked mitotic activity, a peculiar form of angiogene-
sis (‘florid’ or even ‘glomeruloid’ microvascular proliferation) and/or necrosis, a malignancy 
grade can be assigned to these tumours. The least malignant diffuse glioma is designated as 
WHO grade II, and the most malignant (and unfortunately also the most frequent) astrocytic 
tumour is traditionally coined as glioblastoma (WHO grade IV) (figure 1). In between these is 
a category of anaplastic (WHO grade III) diffuse gliomas. Both low-grade (WHO grade II) and 
high-grade (WHO grade III and IV) diffuse gliomas occur in all age groups, but glioblastomas 
are relatively frequent in patients older than 50 years of age, whereas young adults are 
more often diagnosed with a diffuse low-grade glioma. Unfortunately, these latter tumours 
have a strong tendency to progress to more malignant neoplasms in the course of years. 
Important other groups of gliomas include the ependymomas and ‘variant astrocytic glio-
mas’. These ‘other’ gliomas tend to show more circumscribed growth and to occur much 
more frequently in the paediatric and young adult age group. Although ependymomas can 
be low- or high-grade malignant, most ‘variant astrocytic gliomas’ are low grade (WHO 
grade I or II) and, in contrast to diffuse gliomas, do not show progression to a more aggres-
sive lesion in the course of time. By far the most frequent ‘variant glioma’ in the paediatric 
age group is pilocytic astrocytoma, a WHO grade I lesion that most frequently occurs in the 
cerebellum, the hypothalamic region and/or the optic nerve. 
Although gliomas have been, up till now, classified based on their histopathological char-
acteristics, during the last decade insight into the molecular aberrations underlying their 
oncogenesis has increased in a revolutionary way. It is increasingly clear that a combina-
Figure 1. The frequency of primary tumors of the CNS. Relative frequency of primary tumours of the CNS in 
311,202 patients from 2005 to 2009 as registered by the Central Brain Tumour Registry of the United States (CB-
TRUS) (see (Dolecek, Propp et al. 2012)).
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tion of morphological and molecular characteristics will soon allow for a much more robust 
and clinically meaningful ‘taxonomy’ (typing and grading) of gliomas. About 5 years ago it 
was demonstrated that WHO grade II and III diffuse gliomas in adult patients often carry 
an isocitrate dehydrogenase 1 (IDH1) or (less frequently) IDH2 mutation. Earlier, complete 
co-deletion of the short arm of chromosome 1 and of the long arm of chromosome 19 (com-
plete 1p19q co-deletion) was reported as a characteristic molecular aberration for oligoden-
droglial tumours, whereas high copy amplification of the epidermal growth factor receptor 
(EGFR) and the presence of its variant III (EGFRvIII) are typically found in glioblastomas (Rie-
menschneider, Jeuken et al. 2010). 
Using gene expression data from the Cancer Genome Atlas Project, gliomas can be divided 
into four subgroups: classical, neural, proneural and mesenchymal. These subtypes are as-
sociated with aberrations of EGFR, neurofibromin-1 (NF1), platelet-derived growth factor 
receptor alpha (PDGFRA) and IDH1. Furthermore, a link was described with response to 
therapy, with aggressive treatment being the most effective for the classical subtype and 
having a more limited effect on tumours of the proneural subtype (Verhaak, Hoadley et al. 
2010).
Blood-brain barrier in CNS tumours
A very important aspect in clinical neuro-oncology is the fact that the CNS microvascula-ture normally forms a blood–brain barrier (BBB). This barrier is elicited by the interac-
tion between the microvascular endothelial cells and the perivascular astrocytic end feet. 
The barrier function is established by a combination of tight junctions between the en-
dothelial cells, only limited trans-endothelial transport via pinocytotic vesicles and the pres-
ence of transporter molecules on the endothelial cells that are specialized in keeping out 
compounds that are harmful for the brain parenchyma (Daneman 2012). Understandably, 
this barrier function contributes to reduced efficacy of chemotherapeutic compounds for 
CNS tumours. Furthermore, because of the presence of the BBB, the CNS has for many years 
been considered as an immune-privileged site (de Micco 1989; Mitchell, Fecci et al. 2008). 
When performing T1-weighted magnetic resonance imaging (MRI) after intravenous injec-
tion of the paramagnetic contrast agent gadolinium–diethylenetriaminepentacetate (gado-
linium–DTPA, an agent that passes the blood vessel wall only when the BBB is defective), 
contrast enhancement of a CNS tumour unequivocally means loss of the barrier function in 
the enhancing area. In diffuse low-grade gliomas, contrast enhancement is generally absent, 
indicating that the infiltrating glioma cells in the brain parenchyma leave the BBB relatively 
unaffected. In many other CNS tumours, however, the BBB function is incomplete or even 
lost (Claes, Idema et al. 2007). This is true not only for high-grade malignant tumours lo-
cated in the brain parenchyma (‘intra-axially’) such as high-grade gliomas and metastases, 
but also for benign and WHO grade I neoplasms such as pilocytic astrocytomas.
Temozolomide
Due to the growth pattern of diffuse gliomas, complete surgical resection is not feasible. Therefore, GBM patients are often treated with radio- and chemotherapy after surgery, 
to kill remaining tumour cells. The main chemotherapeutic used to treat glioma is Temozolo-
mide (TMZ), which increases the 2 year survival in combination with radiotherapy to 27.2% 
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versus 10.9% for radiotherapy alone (Stupp, Mason et al. 2005; Stupp, Hegi et al. 2009). 
Despite this multimodal treatment, responses are often only short-lived resulting in a me-
dian survival for GBM patients of approximately 14.5 months after diagnosis (Stupp, Hegi et 
al. 2009; Gousias, Markou et al. 2010). Up till now, no other chemotherapeutic agents have 
been found which have an improved effect over TMZ. One of the difficulties for finding a 
proper drug is the Blood-Brain Barrier (BBB), which excludes harmful compounds from the 
brain parenchyma and thereby can prevent drug delivery to the tumour site. 
TMZ is a small lipophilic molecule which crosses the BBB (Newlands, Stevens et al. 1997) 
and concentrations in the central nervous system reach up to approximately 30% of the 
plasma concentration (Agarwala and Kirkwood 2000; Ostermann, Csajka et al. 2004; Zhou 
and Gallo 2009). Following oral absorption, TMZ is rapidly hydrolysed to methyl-triazeno-
imidazole-carboxamine (MTIC), which is converted to the 5-aminoimidzole-4-carboxamide 
(AIC) and the electrophilic alkylating methyldiazonium cation, that can transfer a methyl 
group to DNA (Newlands, Stevens et al. 1997; Villano, Seery et al. 2009). About 70% of the 
DNA-methyl adducts are placed on the N-7 position of guanine, a modification which is be-
lieved to have little to no cytotoxicity. The main TMZ cytotoxicity is caused by approximately 
5% of the DNA-methyl adducts, which are placed on the O-6 residue of guanine in the DNA. 
This modification initiates a mismatch during DNA replication which cannot be removed by 
the mismatch repair (MMR) system resulting in futile cycling of the MMR system and sub-
sequently double strand DNA adducts.  However, clinical responses toward TMZ is generally 
short-lived as tumour cell heterogeneity, transformation, genetic instability and selective 
pressure contribute to the development of chemoresistant tumours (Giese, Bjerkvig et al. 
2003; Salvati, D’Elia et al. 2009).
There are multiple ways in which gliomas can become resistant to TMZ. The most important 
route is by transcription of MGMT, the gene expressing the enzyme AGT which can remove 
the methyl adduct on the O-6 position of the guanine base (Fan, Liu et al. 2013). Hyper-
methylation of the MGMT promotor prevents MGMT transcription and has been described 
as a predictor for TMZ response. Additionally, a defective MMR system is also presumed to 
cause tolerance to the O-6 methyl-guanine mismatch (Sarkaria, Kitange et al. 2008). One of 
the proteins that comprise the MMR complex is mutS homolog 6 (MSH6), of which a loss of 
expression is associated with tumour progression during TMZ treatment (Cahill, Levine et al. 
2007). Loss of MSH6 results in a deficient MMR system and results in increased mutations 
during replication, causing a hypermutation phenotype (Hunter, Smith et al. 2006). A third 
DNA repair system, the base excision repair (BER) can also be involved in TMZ resistance. 
Although the methylation on the N7 position of guanine is not crucial for TMZ cytotoxicity, 
it may result in an abasic site by release of the 7-methylguanine by alkyladenine-DNA gly-
cosylase (AAG)(Engelward, Boosalis et al. 1993; Fu, Calvo et al. 2012). In double stand DNA, 
abasic sites will be repaired by the BER pathway [Newlands 1997, Sarkaria 2008] and unre-
paired sites can result in DNA strand breaks. Upregulation of AAG in glioma cells was shown 
to increase the TMZ induced cytotoxicity [Trivedi et al. 2005]. Beside these DNA repair sys-
tems, multiple other mechanisms have been described to contribute to TMZ resistance and 
not all mechanisms have been elucidated yet (Sarkaria, Kitange et al. 2008; Villano, Seery et 
al. 2009; Messaoudi, Clavreul et al. 2015)
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THE INFLAMMATORY INFILTRATE IN CNS TUMOURS
A traditional neuropathologist’s perspective
Based on examination of haematoxylin-and-eosin (H&E)-stained sections, neuropatholo-gists are well aware of the fact that striking inflammatory infiltrates may occur in CNS 
tumours with a highly variable contribution of lymphocytes, plasma cells, macrophages and 
neutrophilic and/or eosinophilic granulocytes. Generally, the presence or absence of such 
an infiltrate does not have an impact on the diagnosis. Rather, the histopathological diag-
nosis is based on the characteristics of the tumour cells themselves and on the results of 
some other tumour–microenvironment interactions such as infiltrative growth, necrosis and 
microvascular changes, whereas the inflammatory infiltrate is often considered as some-
thing that ‘just happens’. This is especially true in cases where inflammatory cells can be 
explained as a logical consequence of, for example, hypoxia and necrosis (macrophages). 
Microglial cells, the resident, antigen-presenting cells (APCs) of the CNS, are inconspicuous 
in most routinely performed histochemical stainings. Some gliomas are well known for the 
occurrence of a particularly prominent lymphocytic infiltration. Examples are diffuse astro-
cytic tumours with gemistocytic change (i.e. ‘ballooning’ of the cytoplasm of the astrocytic 
tumour cells because of accumulation of glial fibrillary acidic protein (GFAP) filaments) and 
‘variant’ gliomas such as pleomorphopic xanthoastrocytoma and ganglioglioma that often 
show dispersed, prominent perivascular cuffs of small lymphocytes.
Revelations by immunochemistry
Soon after immunohistochemical staining became available, it was clear that the number of inflammatory cells in gliomas was often much higher than had been recognized in 
H&E-stained sections (Figure 2). For instance, in an immunohistochemical study using anti-
bodies for microglial cells and macrophages, large numbers of these cells could be demon-
strated in gliomas (Roggendorf, Strupp et al. 1996). Furthermore, the inflammatory cells in 
CNS tumours could be further characterized, and differences between different (sub)types 
of tumours could be investigated. For example, in a study of glioblastomas and pilocytic 
astrocytomas, glioblastomas exhibited significantly higher perivascular cytotoxic CD8+ T cell 
infiltration, as well as more perivascular and intratumoural CD56+ natural killer (NK) cells 
and CD68+ macrophages. The CD3, CD20 and leukocyte common antigen (LCA)-positive 
cells did not differ between glioblastoma and pilocytic astrocytoma (Yang, Han et al. 2011). 
The same group reported that a relatively high CD8+ T cell infiltrate in newly diagnosed glio-
Figure 2. Examples of immunohistochemical detection of immune cells in glioblastoma. Examples of immunohis-
tochemical detection of immune cells in glioblastoma; histological sections of formalin-fixed, paraffin-embedded 
tumour tissue showing the presence of T cells (CD3), cytotoxic T cells (CD8), granulocytic cells (CD15) and microglia 
and macrophages (CD14, MHC-II).
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blastoma was associated with prolonged survival (Yang, Tihan et al. 2010). In another study, 
a moderate but not significant inverse association between regulatory T cells (Tregs) and 
survival was noted in glioblastoma patients (Jacobs, Idema et al. 2010).
Using fluorescence-activated cell sorting of freshly obtained human glioblastoma tissue, mi-
croglial cells and macrophages were reported to be the predominant immune cell type in 
gliomas (about 1% of total number of cells)(Hussain, Yang et al. 2006). Using gene expression 
data from the Cancer Genome Atlas Project and the Gene Expression Omnibus database, an 
enrichment of immune response–related gene expression was found in the ‘mesenchymal’ 
subtype of adult patients with glioblastoma that is associated with poor prognosis. Immu-
nostaining of these tumours indeed revealed significantly higher cell numbers of microglial 
cells and macrophages in this subtype(Engler, Robinson et al. 2012). 
In one study investigating a series of 67 intracranial neoplasms including glioblastomas, 
meningiomas, medulloblastomas, metastases of carcinoma and melanoma, the level of 
CD68+ microglial cells and macrophages was higher in glioblastomas and adenocarcinomas 
than in medulloblastomas and meningiomas. Lymphocytes (as detected by staining for LCA) 
were described to be rare in all tumour types, generally not exceeding 2% of tumour cells 
and not bound to morphologically distinct tumour regions (Strik, Stoll et al. 2004). Jacobs et 
al. (2009) reported that the percentage of Tregs (characterized as being CD4+ FoxP3+ CD25 
high and CD127 low) in a spectrum of brain tumours showed a strong correlation with WHO 
grade.
BIOLOGY OF IMMUNE RESPONSES TO CNS TUMOURS
Potency of gliomas to be recognized by the immune system
The CNS has been considered as an immune-privileged site because immune cells were thought to less easily pass the BBB and because of the lack of an obvious lymphatic 
drainage system in the brain. However, animal studies showed that antigens from the brain 
can be drained to the cervical lymph nodes (Cserr and Knopf 1992). Nowadays, it is generally 
accepted that continuous immunosurveillance is also present in normal brain tissue, and it 
is an open question if tumour tolerance in the brain is really fundamentally different from 
that of non-CNS sites of tumourigenesis (Johnson and O’Neill 2012), especially since the 
recent discovery of functional lymphatic vessels lining the dural sinuses(Louveau, Smirnov 
et al. 2015).
Based on recent advances in understanding CNS immunity, it is more accurate to regard 
the CNS as an immunologically specialized site which can be divided into three different 
compartments: the brain parenchyma, the ventricles containing choroid plexus and cer-
ebrospinal fluid, and the meninges. Whereas the immune reactivity within the ventricles 
and meninges is more similar to that elsewhere in the body, within the brain parenchyma 
immune responses are often delayed or even abrogated (Grauer, Wesseling et al. 2009). 
This might be related to the absence of MHC II+ dendritic cells (DCs) in the healthy brain 
parenchyma (Hart and Fabre 1981), whereas these cells are present in the choroid plexus 
and meninges (McMahon, Bailey et al. 2006). Different DC subsets do accumulate within 
the brain parenchyma under various inflammatory conditions, suggesting a role in antigen 
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presentation. The exact role of microglia cells, in modulating intracranial immune responses 
is still unclear, but it may be much more diverse and dynamic than previously thought and 
result in containment as well as aggravation of the disease process (Graeber, Scheithauer et 
al. 2002; Hanisch and Kettenmann 2007; Yang, Han et al. 2010). 
Humoral responses against CNS tumours may be elicited against tumour associated anti-
gens. Examples of such antigens are cancer–germ line genes (CGGs) and cancer–testis genes 
which are physiologically expressed in germ line cells, self-antigens with protein expression 
restricted to glioma, differentiation antigens which are normally expressed only in particular 
phases of cell differentiation, and stromal antigens which are expressed on stromal compo-
nents of the tumour (Zhang, Eguchi et al. 2007).
In some patients, T cells directed against some of the antigens mentioned here were found 
(Liu, Ying et al. 2004). Necrosis in the CNS may well facilitate antigen drainage and activate 
T cells that can enter the brain parenchyma. Destruction of the BBB makes the neoplasm 
even more accessible to the immune system. The attraction of immune cells is directed by 
a number of molecules, which may well be produced by oxygen-deprived tumour cells sur-
rounding necrosis. Hypoxia inducible factor-1α (HIF1α) has been identified as a key factor 
in recruiting immune cells to gliomas via chemokines including C–X–C motif ligand (CXCL)5, 
CXCL8–IL-8, CXCL12–stromal cell–derived factor-1 and different members of the C–C motif 
ligand (CCL) family (Grauer, Wesseling et al. 2009). A recent study demonstrated increased 
infiltration of all T cell subsets in high-grade gliomas, and within glioblastomas a significant 
correlation between elevated numbers of effector T cells (Teffs) and better survival was seen 
(Lohr, Ratliff et al. 2011).
Permissive glioma immunobiology
Although gliomas express various antigens against which an immune reaction might be beneficial to attack the tumour, not all targets might be potent enough to do so. Al-
though tumours expressing CGGs tend to co-express different CGG antigens, these antigens 
may be present in only a small percentage of the total population of tumour cells. Also, 
efficient immune recognition of CGG antigens on glioma cells may be compromised by the 
limited presence or even absence of classical MHC-molecules and/or inefficient processing 
and presentation of such antigens (Grauer, Wesseling et al. 2009). Importantly, these genes 
are generally expressed intracellular and therefore more difficult to target with antibodies. 
Tumours can also diminish expression of self-antigens expressed on the cell surface to avoid 
detection by the immune system, either by down-regulation or by decreased trafficking to 
the cell surface. In a study using EGFRvIII as a target molecule, it was found that the majority 
of the recurrent tumours had lost EGFRvIII expression (Sampson, Heimberger et al. 2010), 
indicating the need for multi-target approaches. The value of antigens that are the product 
of differentiation genes as targets for anti-glioma therapy might be limited, as these anti-
gens often are expressed in a broader range of tissues. 
Apart from evading the immune system, gliomas can also directly and indirectly contribute to 
an immunosuppressive microenvironment via production of soluble factors, enzymes and/
or surface molecules (Grauer, Wesseling et al. 2009). Glioma cells were reported to produce 
immunosuppressive soluble factors like vascular endothelial growth factor (VEGF), IL-10, 
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transforming growth factor beta (TGFβ) and enzymes such as indoleamin-2,3-dioxygenase 
(IDO), cyclooxygenase-2 (COX2) and inducible nitric oxide synthase (iNOS), whereas produc-
tion of immune-stimulatory molecules like IL-12, IL-18, and interferon gamma by these cells 
is relatively lacking. Immune inhibitory molecules that are abundantly expressed on the 
surface of glioma cells include the non-classical MHC molecules HLA-G and HLA-E, the co-
inhibitory molecule programmed cell death-1 ligand-1 (PDL1) (also known as B7 homolog-1 
(B7H1)), minor brain gangliosides like GM2 and GM3, and galectin-1 and -3. Gliomas can 
also express other members of the B7 family, including B7H3 and B7H4. There are reports 
of low expression of costimulatory B7 molecules (CD80/86) on glioma cells which may an-
tagonize immunity by inducing T cell anergy (Anderson, Anderson et al. 2007). Although 
functional analysis demonstrated that glioma-infiltrating microglial cells and macrophages 
may have a few intact innate immune functions, their capacity to be stimulated via Toll-like 
receptors (TLRs), secrete cytokines, up-regulate costimulatory molecules and in turn acti-
vate anti-tumour T cells is apparently not sufficient to initiate effective immune responses 
(Hussain, Yang et al. 2006).
Recent evidence suggests that glioma cells may exploit rather than be inhibited by micro-
glial cells. In vitro studies revealed that the glioma-derived chemokine CCL2 acts upon C–C 
chemokine receptor (CCR)-2-bearing microglia, which then produce IL-6 to stimulate the 
invasiveness of gliomas in a three-dimensional gel matrix (Zhang, Sarkar et al. 2012). Also, 
the presence of lymphocytes in glial tumours was originally considered as an attempt of the 
body to attack the tumour cells and thus a beneficial response. The occurrence of perivas-
cular lymphocytic infiltrates in ‘variant gliomas’ with a relatively indolent clinical behaviour 
might be considered as evidence for this hypothesis. However, gemistocytic astrocytomas 
also are known for prominent perivascular lymphocytic infiltrates but tend to carry a poorer 
prognosis compared to their non-gemistocytic counterpart of the same malignancy grade. 
Indeed, the correlation between the presence of different immune cell infiltrates in the 
tumour tissue and the clinical course of glioma patients is not clear. Although it was found 
that elevated numbers of Teffs correlate with better survival in glioblastoma patients, it is 
also known that when these cells reach the CNS parenchyma through the intact or damaged 
BBB, resident CNS cells such as astrocytes and microglial cells are able to suppress T cell 
proliferation and to induce T cell anergy or apoptosis, by the secretion of immunosuppres-
sive molecules and the expression of death receptor ligands such as Fas ligand (FasL). T cell 
effector functions in the brain (including crossing of the BBB) may be further impeded by 
constitutive immunosuppressive factors such as TGFβ (Lohr, Ratliff et al. 2011).
Furthermore, Teffs in and around gliomas are confronted with other populations of immune 
cells with suppressor activity that are attracted to the tumour site (Grauer, Wesseling et 
al. 2009; Lindau, Gielen et al. 2013) (Figure 3). Detailed immunohistological and functional 
analyses of diffuse gliomas demonstrated that CD4+ Tregs infiltrate and accumulate within 
gliomas. Tregs are well known to suppress an effective cytotoxic response of other T cells. 
Tregs have been reported to differ in homing receptor expression and chemokine respon-
siveness. The Treg accumulation in glioblastomas might be explained by the fact that (in 
contrast to other tumour-infiltrating lymphocytes) these cells have a high level of expres-
sion of the CCR4 chemokine receptor, whereas its ligand CCL22 is secreted by glioblastoma 
cells (Jacobs, Idema et al. 2009; Jacobs, Idema et al. 2010). More recently, an important role 
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in creating an immunosuppressive microenvironment was attributed to myeloid-derived 
suppressor cells (MDSCs). MDSCs represent a heterogeneous population in which generally 
monocytic and granulocytic subpopulations are recognized. These cells have been reported 
within the tumour of both the de novo and transplantable syngeneic GL261 cell line mouse 
models where depletion of these cells inhibited the development of gliomas (Kohanbash 
and Okada 2012). Although until now there were no reports of infiltrating MDSCs in human 
gliomas, granulocytic MDSCs were reported to be increased within the peripheral blood of 
glioma patients (Raychaudhuri, Rayman et al. 2011). In patients with other cancers (breast 
and gastrointestinal), MDSCs levels were found to be correlated with tumour stage and/or 
Treg levels. Recent studies indicate that MDSCs can promote induction of Tregs. The partially 
overlapping target cell populations of both suppressor cell types indicate flexibility in im-
mune suppression under pathological conditions (Lindau, Gielen et al. 2013).
Systemic aspects
Apart from the accumulation of ‘immune cells’ in the CNS tumour tissue, these tumours may also exert systemic effects on the immune status of the patients. Patients with glio-
blastomas are reported to suffer from a decreased systemic activity of their immune system 
(Gousias, Markou et al. 2010), a phenomenon that is ascribed to the immunosuppressive 
effect of cytokines released by the tumour cells. More precisely, reduced cellular immune 
Figure 3. Simplified scheme of crosstalk between cells in a glioblastoma microenvironment. Simplified scheme 
of crosstalk between cells in a glioblastoma microenvironment suppressing an effective T cell response. Suppres-
sive cells can activate one another, resulting in multiple ways of suppressing Teff cells.
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responses in brain tumour patients were reported with profound depression of CD4+ helper 
lymphocytes. Although the absolute count of both CD4+ and CD4+ Tregs is diminished in 
glioma patients, the Tregs frequently represent an increased proportion within the CD4+ 
compartment (Fecci, Mitchell et al. 2006). This predominance of Tregs may partly explain 
the immunological defects that have been described in glioma patients, such as abnormal 
delayed hypersensitivity responses, depressed mitogen responsiveness of T and B cells, de-
creased antibody responses and impaired T cell cytotoxicity. A recent study provided further 
evidence of systemic immune suppression by showing accumulation of MDSCs in peripheral 
blood and increased arginase activity (arginase known to be an immunosuppressive en-
zyme) within the serum of glioma patients (Raychaudhuri, Rayman et al. 2011).
IMMUNOTHERAPY OF CNS TUMOURS
Different strategies
There is ample evidence that in glioma patients, the differentiation, maturation and func-tion of tumour-infiltrating DCs and other APCs, the generation and activation of immune 
effector cells, and the cytolytic activity of macrophages, NK cells and cytotoxic T cells are 
suppressed. The ultimate goal of anti-tumour immunotherapy is to induce an immune re-
sponse leading to the complete eradication of tumour cells without serious negative side ef-
fects. For gliomas, passive, adoptive and active immunotherapeutic approaches have been 
evaluated (for detailed information, see (Mitchell, Fecci et al. 2008; Grauer, Wesseling et al. 
2009; Xu, Stockhammer et al. 2012) and references therein). (Figure 4)
Passive immunotherapy
To target glioma-specific structures by passive immunotherapy, different monoclonal an-tibodies (Mabs) have been designed that are coupled to radionucleotides (radio-immu-
noconjugates) or exotoxins (immunotoxins) and that are administered locally. An ideal tar-
get for immunotherapy is an antigen that is specifically and stably expressed by the tumour, 
absent from normal tissues and crucial for the survival of the cancer cell. Furthermore, a 
disadvantage of this approach is that the penetration of these molecules into the tumour 
tissue appears to be quite limited, due to high interstitial pressure in the tumour and its sur-
rounding tissue. Intra-tumoural inoculation and convection-enhanced delivery (CED) might 
be needed to efficiently deliver these molecules to the more peripheral parts of diffuse 
infiltrative gliomas.
Cetuximab is a recombinant human/mouse chimeric anti-EGFRvIII used for the treatment of 
metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck can-
cer (Subramaniam, He et al. 2015). The use of cetuximab for patients with a recurrent pri-
mary glioblastoma was explored in a phase II study where it was combined with Bevacizum-
ab and irinotecan, a monoclonal antibody against VEGF and an inhibitor of topoisomerase 1 
respectively(Hasselbalch, Lassen et al. 2010). In this trial, Cetuximab was well tolerated, but 
the combination was not superior to Bevacizumab and irinotecan alone. Currently, clinical 
trials are ongoing exploring the intra-arterial cerebral infusion of Cetuximab (NCT01238237) 
and the immunoconjugate anti-EGFRvIII human mAb with the cytotoxic maytansinoid DM1 
(NCT01475006). 
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Beside antigens on the tumour cell, antibodies directed against antigens on immune cells 
are potent treatment options. Immunomodulatory receptors PD-L1 (programmed death-
ligand 1) and PD-L2 can be expressed by both tumour and immune cells, and ligation to cell 
surface receptor PD-1 expressed by cytotoxic T lymphocytes induces immune suppression. 
Nivolumab is a fully human monoclonal antibody that blocks the interaction of PD-1 and 
its ligands, thereby enhancing T cell activation. Efficacy of Nivolumab is currently tested 
for patients with a glioma in combination with ipilimumab, a monoclonal antibody against 
the complementary checkpoint protein of PD-1, cytotoxic T-lymphocyte-associate antigen-4 
(CTLA-4) (NCT02017717). Checkpoint inhibitors have shown great potency in the treatment 
of melanoma (Couzin-Frankel 2013; Eggermont, Maio et al. 2015) and the presence of in-
filtrating T lymphocytes and the expression of PD-1 in glioma suggest targets for immune 
checkpoints for patients with a glioma(Nicholas, Mathios et al. 2013).
 Adoptive immunotherapy
Using adoptive immunotherapy, transfer of ex vivo expanded and activated effector cells into the patients with malignant gliomas has been investigated. Treatment approaches 
have differed in the types of cells administered, the route of administration and the activa-
tion status of the cells. An advantage of adoptive immunotherapy is that it circumvents 
deficits of anti-tumour effector cell populations in the host. Lymphokine activated killer cells 
(LAKs) are autologous stimulated peripheral blood lymphocytes stimulated in vitro with IL-2 
and have been safely administered within the CNS (Hayes, Koslow et al. 1995). Intracranial 
administration after primary treatment resulted in longer survival in GBM patients treated 
with a higher dose of LAK cells (Dillman, Duma et al. 2009). Cell therapy alone has been 
utilized less frequent due to the high cost of ex vivo cell expansion and the short duration of 
anti-tumour activity in vivo (Ishikawa, Takano et al. 2012). Moreover, the non-specific adop-
tive cell therapies for treatment of patients with a glioma has evolved to more tumour spe-
cific adoptive cell treatments over time, i.e. virus specific cytotoxic T lymphocytes and chi-
meric antigen receptor (CAR) modified T cells. CARs are genetically engineered autologous T 
cells expressing a novel T cell receptor, which can specifically recognize a tumour-associated 
antigen(Hegde, Bielamowicz et al. 2014). CARs, sometimes referred to as ‘T-bodies’, can 
recognize intact cell surface antigens and selectively kill the tumour cells in a way that is 
independent of HLA recognition (Essand and Loskog 2013). CARs have been developed to 
recognize EGFRvIII (Morgan, Johnson et al. 2012), and a clinical trial is ongoing using CARs 
targeting HER2 in glioblastoma patients (NCT01109095).
Active immunotherapy
Active immunization of patients with malignant gliomas is regarded as a powerful strat-egy to induce a potent long lasting anti-tumour response. As a vaccine, autologous 
inactivated tumour cells have been used, either gene-modified or applied together with 
cytokine-secreting fibroblasts. Alternatively, tumour-specific peptide vaccines targeting 
EGFRvIII have been administrated intradermally along with granulocyte–monocyte colony 
stimulating factor as adjuvants. Rindopepimut is a EGFRvIII peptide vaccine where the pep-
tide is coupled to a KLH molecule to elicits EGFRvIII-specific humoral and cellular immune re-
sponses in glioma patients (Babu and Adamson 2012). Phase II and III clinical trials showed 
higher progression free survival and overall survival of patients with an EGFRvIII expressing 
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glioblastoma with minimal side effects (Babu and Adamson 2012; Zussman and Engh 2015).
Another promising approach to amplify tumour specific T cell responses is to use ex vivo–
generated, autologous tumour antigen-loaded DCs as a vaccine. The induction of effective 
immune responses is dependent upon proper DC maturation. Tumour antigen loading with 
tumour lysate, tumour RNA or synthetic tumour-specific peptides occurs at either the im-
mature or mature DC stage. Mature, tumour antigen–loaded DCs are then injected back 
into patients. Several phase I and II studies have been performed with this approach, and 
although these clinical trials differed in terms of DC generation, loading of tumour antigens 
and the route of application, robust intra-tumoural cytotoxic and memory T cell infiltration 
could be detected in patients who underwent re-operation after vaccination (Grauer, Sut-
muller et al. 2008; Wheeler and Black 2011). Data from a phase I/II clinical study treating 77 
newly diagnosed glioblastoma patients with autologous moDCs showed a median overall 
survival of 18.3 months which is favourably to the survival data reported by Stupp et al. with 
a median overall survival of 14.6 months (Stupp, Mason et al. 2005; Ardon, Van Gool et al. 
2012). DC vaccinations appeared to be mainly beneficial for younger patients with minimal 
residual tumour burden and with low levels of TGFβ2 expression. Another study revealed in-
creased patient survival following DC vaccination, especially for patients who had a glioblas-
toma with the mesenchymal gene expression signature, and that these tumours harboured 
higher numbers of CD3 and CD8 positive TILs compared to glioblastomas with other gene 
expression signatures (Prins, Soto et al. 2011).
Improving efficacy
To improve the efficacy of glioma immunotherapy, preferably higher numbers and more potent glioma-specific effector cells should be induced that home into the glioma, in-
cluding into the peripheral, diffusely infiltrative areas. Some clinical studies indicate that ad-
ditional intra-tumoural DC application is more beneficial in the treatment of glioma patients 
than intradermal DC injections alone. Furthermore, targeting multiple antigens reduces the 
risk of creating a target-antigen negative tumour cell (Sampson, Heimberger et al. 2010). 
The immunogenicity of DCs may also be enhanced by including immune response modi-
fiers, such as TLR agonists, into the maturation cocktail and/or by local administration of 
(combinations of) TLR agonists (Mailliard, Wankowicz-Kalinska et al. 2004; Prins, Soto et al. 
2011). However, as such agonists induce not only beneficial activating but also potentially 
suppressive effector responses (like up-regulation of PDL1 on DCs), selective inhibition of 
immunosuppressive molecules induced during TLR immunotherapy may be needed (e.g. by 
anti-PDL1 antibodies).
Different strategies have been used to eliminate Tregs in preclinical murine models, includ-
ing CD25-specific mAbs, immunotoxins or different chemotherapeutic agents. In a GL261 
murine glioma model, treatment with anti-CD25 mAb resulted in elimination of Tregs with-
in the brain and complete protection against orthotopic GL261 tumour challenge. Treat-
ed mice showed infiltration of CD11b+ myeloid cells in the brain which were identified as 
F4/80+ macrophages and granulocytes and not as MDSCs (Maes, Verschuere et al. 2013). 
Another interesting approach to reduce the number of tumour-infiltrating Tregs is to se-
lectively block their trafficking to the tumour site. Similarly, blocking MDSC development /
accumulation, trafficking or activation will induce immunotherapeutic potency (Ahn, Pollack 
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et al. 2013; Wesolowski, Markowitz et al. 2013). Currently, various compounds are or have 
been under clinical investigation for patients with various solid tumours to induce differen-
tiation of MDSCs into mature cells (ATRA (NCT02403778), Vitamin D3 (Lathers, Clark et al. 
2004)), inhibit MDSC migration (CSF-1R inhibitor (NCT02452424, NCY01346358)) or inhibit 
MDSC functioning (arginase and nitric oxygen inhibitor PDE-5 (NCT01697800)). 
Currently, various clinical trials are exploring the use of Bevacizumab, an anti-angiogenic 
treatment, in combination with various immunotherapeutic approaches (NTC02010606, 
NCT01498328, NCT01814813, NCT01903330). Bevacizumab is a monoclonal antibody tar-
geting VEGF, thereby inhibiting angiogenesis. This monoclonal antibody is approved as a 
monotherapy for recurrent glioblastoma. Two clinical trials explored its use in patients with 
newly diagnosed glioblastoma being added to best standard therapy (radiation and TMZ), 
both showing a 3 to 4 month prolongation of progression free survival compared to stand-
ard therapy only, but no significant effect on overall survival (Chinot, Wick et al. 2014; Gil-
bert, Dignam et al. 2014). It will be important to further evaluate the effects of Bevacizumab 
on the quality of life in newly diagnosed glioma patients (Gilbert, Sulman et al. 2014). Addi-
tionally, future studies are needed to examine whether subgroups of patients may be more 
sensitive to bevacizumab treatment (Poulsen, Urup et al. 2014). Whether it may improve 
immunotherapeutic therapy is currently under investigation.
Direct targeting of immunosuppressive molecules such as TGFβ2 within the tumour micro-
environment may be exploited to overcome glioma-induced tolerance mechanisms as well 
(Lohr, Ratliff et al. 2011). Several phase I and II studies have been performed applying TGFβ2-
antisense-oligonucleotides intratumourally by CED in patients with high-grade gliomas and 
confirmed the safety of this approach as well as long-term clinical benefit in several indi-
vidual patients. An alternative approach is to prevent downstream signalling by interfering 
with TGFβ receptor kinase activities. Furthermore, targeting of other immunosuppressive 
molecules and enzymes such as signal transducers and activators of transcription 3 (Stat3), 
IDO and COX2 may improve antitumour immunity against gliomas. Selective iNOS inhibitors 
such as SD3651 or arginase inhibitors might be attractive to restore Teff cell functions. 
Recent data show that tumour cell death triggered by chemotherapy or radiotherapy initi-
ates an immune-adjuvant pathway that contributes to the success of cytotoxic treatment 
(Kepp, Galluzzi et al. 2011). Numerous endogenous danger signals transferred by dying tu-
mour cells to innate immune effector cells may account for the immunogenicity of tumour 
cell death. Alkylating chemotherapeutics such as TMZ have been shown to induce immuno-
genic cell death by triggering innate receptors such as TLRs, thereby enhancing the ability 
of DCs to present tumour antigens from dying tumour cells to T and B cells (Kim, Kim et 
al. 2010). Moreover, activation of innate immune receptors leads to the up-regulation of 
MHC molecules on tumour cells, thus increasing their sensitivity to T cell–mediated killing. 
The concept of tumour-specific immunization at the time of immune reconstitution after 
chemotherapy has been successfully tested in different animal models and phase I and II 
clinical studies, demonstrating that the availability of tumour antigens during homeostatic 
T cell proliferation leads to effective anti-tumour immunity and enhanced memory T cell 
responses. 
Conclusions
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Although our understanding of the molecular biology of glial tumours of the CNS is rapid-ly growing, our knowledge about the complex pathological interactions within the local 
tumour microenvironment is still far from complete. Further elucidation of the functional 
and spatio-temporal organization of the different players in tumour-induced immunosup-
pression is of utmost importance for improving intervention strategies that boost potent 
anti-tumour responses. Current vaccination protocols are still of limited efficacy for sup-
pressing glioma growth and need to be improved (e.g. by a combination of therapeutic 
strategies aimed at breaking the local immunosuppressive environment of gliomas without 
inducing autoimmunity). With further unravelling of glioma immunobiology, immunothera-
peutic strategies have the opportunity to become a standard component in the multimodal 
treatment of malignant gliomas. Elucidation of the underlying mechanisms of immune eva-
sion in individual patients is critical as it will ultimately enable the development of tailored 
therapies to overcome these mechanisms. 
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Abstract 
Myeloid-derived suppressor cells (MDSC) and regulatory T (Treg) cells are major com-ponents of the immune suppressive tumour microenvironment (TME). Both cell 
types expand systematically in preclinical tumour models and promote T-cell dysfunction 
that in turn favours tumour progression. Clinical reports show a positive correlation be-
tween elevated levels of both suppressors and tumour burden. Recent studies further 
revealed that MDSCs can modulate the de novo development and induction of Treg cells. 
The overlapping target cell population of Treg cells and MDSCs is indicative for the impor-
tance and flexibility of immune suppression under pathological conditions. It also sug-
gests the existence of common pathways that can be used for clinical interventions aiming 
to manipulate the TME. Elimination or reprogramming of the immune suppressive TME 
is one of the major current challenges in immunotherapy of cancer. Interestingly, recent 
findings suggest that natural killer T (NKT) cells can acquire the ability to convert immu-
nosuppressive MDSCs into immunity-promoting antigen-presenting cells. Here we will 
review the cross-talk between MDSCs and other immune cells, focusing on Treg cells and 
NKT cells. We will consider its impact on basic and applied cancer research and discuss 
how targeting MDSCs may pave the way for future immunocombination therapies.
Introduction
Immunotherapy is a promising treatment modality for many different types of cancer (Dougan and Dranoff 2009). Several tumour-associated antigens recognized by specific 
monoclonal antibodies (mAb) and T cells have been identified, providing essential tools for 
the development of immunotherapies, including dendritic cell (DC) -based vaccination and 
adoptive T-cell transfer. Sipuleucel-T is the first US Food and Drug Administration-approved 
vaccine immunotherapeutic for prostate cancer, consisting of an autologous DC-enriched 
fraction loaded with tumour antigen (Kantoff, Higano et al. 2010). Such studies stimulate 
the entire field to sustain current efforts for identifying the optimal antigen-presenting cell 
(APC), antigens, format, dose, route and adjuvants (Nierkens, den Brok et al. 2009; Tacken, 
Zeelenberg et al. 2011). The presence of vaccine-induced immune effector cells with anti-
tumour reactivity, however, does not always correlate with clinical benefit. Indeed, many 
different local and systemic mechanisms and regulatory pathways exist that can antagonize 
cancer-directed immune responses (Hanahan and Weinberg 2011). Tumours have evolved 
mechanisms to create an immunosuppressive network enriched for soluble mediators, re-
ceptors and cells that negatively influence immunotherapy (Fig 1)(Hanahan and Weinberg 
2011). Although tumour-infiltrating T cells (TIL) are present in many cancers, often their lytic 
machinery is impaired or they are unable to effectively attack tumour cells. This is a result of 
the presence of co-inhibitory molecules or the down-regulation of either tumour antigens 
or MHC (Vesely, Kershaw et al. 2011). As the absolute reduction of MHC class I (MHC-I) 
would favour tumour recognition by natural killer (NK) cells (Vivier, Ugolini et al. 2012), 
tumours adjust MCH levels as well as the expression of NK receptors to minimize TIL and 
NK cell recognition (Platonova, Cherfils-Vicini et al. 2011; Vesely, Kershaw et al. 2011; Vivi-
er, Ugolini et al. 2012). Furthermore, proper effector functions of effector T (Teff) cells are 
counteracted by immunosuppressive lymphocytes. CD4+CD25hiFoxP3+ Treg cells (Jacobs, 
Idema et al. 2009; Jacobs, Nierkens et al. 2012), CD8+CD25+ Treg cells (Kiniwa, Miyahara et 
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al. 2007), CD19+CD25hi regulatory B cells (Olkhanud, Damdinsuren et al. 2011) and inter-
leukin-13 (IL-13) -producing NKT cells (Hix, Shi et al. 2011) have all been documented in the 
tumour microenvironment (TME) of pre-clinical models and in cancer patients. Additionally, 
the TME conditions the local myeloid cells to become immunosuppressive, as evidenced by 
the presence of Tie2-expressing monocytes (De Palma, Venneri et al. 2005), tolerogenic DC 
(Watkins, Zhu et al. 2011), tumour-associated macrophages (TAM) and tumour-associated 
neutrophils (TAN)(Fridlender, Sun et al. 2009; Biswas and Mantovani 2010). More recently, 
another prominent effect of growing tumours has been elucidated: the aberrant activation 
of myelopoiesis resulting in the expansion and recruitment of immature myeloid cells (Ga-
brilovich and Nagaraj 2009; Gabrilovich, Ostrand-Rosenberg et al. 2012). During the early 
phase of infection, trauma or stress these immature myeloid cells are believed to play an 
important role in replenishing DC, macrophages or neutrophils, whereas in the later phase 
they can prevent immune pathology (Gabrilovich and Nagaraj 2009). In tumour-bearing pa-
tients this development process appears to be defective and results in the accumulation 
and retention of highly immunosuppressive myeloid-derived suppressor cells (MDSC)(Ga-
brilovich, Ostrand-Rosenberg et al. 2012). Their proliferation, aberrant activation and per-
sistence is induced by chronic inflammation in the TME (Meyer, Sevko et al. 2011). They are 
further characterized by the continuous production of inflammatory mediators, including 
IL-1, IL-6, reactive oxygen species (ROS) and nitric oxide (NO)(Gabrilovich and Nagaraj 2009; 
Figure 1. The Immunosuppressive Tumor Microenvironment. In the tumour network, several different immune 
and non-immune cells respond to tumour stimuli and exhibit complex regulatory or immunosuppressive functions, 
either in a cell–cell contact-dependent manner or through the secretion of soluble mediators. ARG-1, arginase-1; 
Breg, regulatory B cell; DC, dendritic cell; PMN-MDSC and M-MDSC, granulocytic and myeloid-derived suppressor 
cells; IFN, interferon; IL, interleukin; NKT cells, natural killer T cells; NOS, nitric oxide species; ROS, reactive oxygen 
species; TAM, tumour-associated macrophage; TAN, tumour-associated neutrophil; TGF, transforming growth fac-
tor; TNF, tumour necrosis factor; Treg, regulatory T cell; TSC, tumour stromal cell; VEGF, vascular endothelial growth 
factor.
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Gabrilovich, Ostrand-Rosenberg et al. 2012). Furthermore the cells and factors present in 
the tumour create a microenvironment that is characterized by hypoxia, lactic acid build-up 
and adenosine accumulation, which in sum prevents APC maturation (Corzo, Condamine et 
al. 2010; Hanahan and Weinberg 2011; Gabrilovich, Ostrand-Rosenberg et al. 2012). Hence, 
the TME is highly effective in counteracting the tumoricidal function of activated immune 
effector cells attempting to eradicate the tumour. In this review we will focus on the immu-
nosuppressive function of MDSC and their cross-talk with Treg cells and NKT cells. Further-
more, we will discuss new developments that could potentially be used to reprogramme the 
hostile TME into an immune potentiating environment.
Myeloid-derived suppressor cells
The MDSC consist of immature myeloid cells and have a bewildering diversity of pheno-types, which provides both opportunities and frustrations for scientists. In tumour-bear-
ing mice two main MDSC subtypes have been reported, granulocytic / polymorphonuclear 
(PMN-MDSC) and monocytic (M-MDSC). The PMN-MDSC are defined by the combinatory 
expression of CD11b+Gr-1hiLy-6G+Ly-6CloCD49d-, whereas the M-MDSC are characterized 
by the phenotype CD11b+Gr-1hiLy-6G-Ly-6ChiCD49d+ (Gabrilovich, Ostrand-Rosenberg et 
al. 2012). In humans the situation is even more complex (Table 1), but M-MDSC are predom-
inantly CD14+ and PMN-MDSC are CD15+, both being CD33+HLA-DR- (Schmielau and Finn 
2001; Zea, Rodriguez et al. 2005; Mirza, Fishman et al. 2006; Filipazzi, Valenti et al. 2007; 
Mandruzzato, Solito et al. 2009; Poschke, Mougiakakos et al. 2010; Gowda, Godder et al. 
2011). In both mice and humans the PMN-MDSC represent the major subset of circulating 
and expanding MDSC (Gabrilovich, Ostrand-Rosenberg et al. 2012). Almost all patients and 
animal models with cancer reveal approximately 75% PMN-MDSC compared with approxi-
mately 25% M-MDSC (Schmielau and Finn 2001; Kusmartsev, Nefedova et al. 2004; Youn, 
Nagaraj et al. 2008; Rodriguez, Ernstoff et al. 2009). Increased production of intratumoural 
granulocyte (G-CSF) or granulocyte–macrophage (GM-CSF) colony-stimulating factors may 
account for the difference seen in PMN-MDSC and M-MDSC levels (Dolcetti, Peranzoni et al. 
2010; Meyer, Sevko et al. 2011). Inappropriate levels of G-CSF have been reported for many 
different human tumours, including pancreatic, oesophageal, gastric and glioma (Gabitass, 
Annels et al. 2011; Raychaudhuri, Rayman et al. 2011). Waight et al. (Waight, Hu et al. 2011) 
identified tumour-derived G-CSF as a key driver of PMN-MDSC accumulation in mice. The 
relative abundance of the PMN-MDSC does, however, not necessarily mean that they are 
more important for suppression as M-MDSC have been proposed to be more immunosup-
pressive than PMN-MDSC on a per cell basis (Movahedi, Guilliams et al. 2008; Youn, Nagaraj 
et al. 2008; Dolcetti, Peranzoni et al. 2010). It has been previously proposed that MDSC en-
tering the TME can differentiate into TAM or TAN in mice (Fridlender, Sun et al. 2009; Biswas 
and Mantovani 2010; Corzo, Condamine et al. 2010; Fridlender, Sun et al. 2012; Gabrilovich, 
Ostrand-Rosenberg et al. 2012). However, as no definitive marker set has been established, 
it remains difficult to discriminate whether TAN are PMN-MDSC recruited from the spleen 
or the bone marrow, or rather represent mature neutrophils polarized to a pro-tumorigenic 
N2 phenotype through high intratumoural concentrations of transforming growth factor-β 
(TGF-β)(Fridlender, Sun et al. 2009). New transcriptomic data by Fridlender et al. (Fridlender, 
Sun et al. 2012) revealed that the expression signature of blood derived neutrophils and 
CD11b+Ly-6G+ PMN-MDSC in mice is more closely related to each other than to the TAN. 
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MDSC phenotype MDSC data Cancer type Ref.
CD11b+CD33+
HLA-DR−Lin−/lo
Circulating MDSC levels 
correlated with cancer stage 
and chemotherapy sensitiv-
ity
breast cancer (Diaz-Montero, 
Salem et al. 
2009)
CD14+CD15+CD124+ IL4Rα expression correlated 
with immunosuppressive 
activity
colon carci-
noma
(Mandruz-
zato, Solito et al. 
2009)
CD14+HLA-DR−/lo 
S100A9+
TLR4L/IFN-γ stimulation 
induced NO synthase 2 
colon carci-
noma
(Zhao, Hoechst 
et al. 2012)
CD14+HLA-DR−/lo ARG-1+ MDSCs suppressed 
autologous T cells and  NK 
cells, induced Treg in vitro
hepatocellular (Hoechst, Voigt-
laender et al. 
2009)
CD14+HLA-DR−/lo
StathiCD80+ 
CD83+DC-Sign+
Stathi MDSCs produce ARG-
1 to suppress T cells, failed 
to induce Treg in vitro
melanoma (Poschke, Mou-
giakakos et al. 
2010)
CD14+HLA-DR−/lo Increased levels of MDSCs 
and Tregs, decreased levels 
of DCs
melanoma (Brimnes, Vang-
sted et al. 2010)
CD33+Lin−HLA-DR− ATRA/IL-2 treatment im-
proved myeloid/DC ratio, DC 
function and Ag-specific T 
cell response
RCC (Mirza, Fishman 
et al. 2006)
CD14+HLA-DR−SSCint MDSCs suppressed T cells 
via TGF-β
melanoma (Filipazzi, Valenti 
et al. 2007)
CD14+HLA-DR−/lo MDSCs were shown to be 
negatively associated with 
survival in RCC patients
RCC (Walter, Wein-
schenk et al. 
2012)CD11b
+CD14−CD15+
CD11b+CD14−CD15+ Depletion of ARG-1+  
PMN-MDSCs restored T 
cell proliferation, CD3zeta 
chain expression and IFN-γ 
production in vitro
RCC (Zea, Rodriguez 
et al. 2005)
CD15+FSCloSSChi MDSC levels correlated 
with elevated plasma levels 
of ROS markers, low levels 
of CD3zeta chain and Th1 
cytokines
adenocarci-
noma of pan-
creas, colon and 
breast
(Schmielau and 
Finn 2001)
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CD11b+CD33+
HLA-DR−
Low risk patients have in-
creased levels of MDSCs and 
higher serum titers of IL-10, 
IL-1β and monocyte chemo-
tactic protein-1 compared to 
high risk patients
neuroblastoma (Gowda, Godder 
et al. 2011)
CD14+CD33+
HLA-DR−/lo 
MDSCs suppressed IFN-γ by 
T cells, increased ARG-1 and 
G-CSF plasma levels in pa-
tients, depletion of MDSCs 
significantly restored Teff
glioma (Raychaudhuri, 
Rayman et al. 
2011)
CD15+CD33+HLA-DR−
CD11b+CD33+
HLA-DR−Lin1−/lo
MDSC levels correlated with 
ARG-1 and IL-13 production, 
increased Treg levels, and an 
increased risk of death
gastric, pancre-
as, esophageal,
carcinoma
(Gabitass, An-
nels et al. 2011)
CD11b+CD14+CD33+ 
HLA-DR−/lo
IL-6 correlated with CD15+ 
and IL-10 with CD15− MD-
SCs, increased percent-
age of CD14+ and CD15+ 
MDSCs was associated with 
increased risk of death. MD-
SCs led to reduced IFN-α re-
sponsiveness of total PBMC 
and CD4+ T cells in vitro
gastrointestinal 
malignancies
(Mundy-Bosse, 
Young et al. 
2011)
CD11b+CD15+CD33+
HLA-DR-
CD11b+HLA-DR−Lin1− CD11b+ and CD14+HLA-DR−
Lin1− were resistant to cryo-
preservation; all subsets lost 
their suppressive capacity.
head and neck 
squamous cell 
carcinoma, 
melanoma
(Kotsakis, Hara-
symczuk et al. 
2012)
CD14+HLA-DR−Lin1−
CD15+HLA-DR−Lin1−
CD33+HLA-DR−Lin1−
Table 1. A comprehensive overview of human MDSC studies. ARG-1, arginase-1; DC, dendritic cell; G-CSF, granu-
locyte colony-stimulating factor; G-MDSC and M-MDSC, granulocytic and myeloid-derived suppressor cells; IFN, 
interferon; IL, interleukin; NK cells, natural killer cells; NOS, nitric oxide species; PBMC, peripheral blood mono-
nuclear cells; ROS, reactive oxygen species; TGF, transforming growth factor; Th1, T helper type 1; TLR, Toll-like 
receptor; TNF, tumour necrosis factor; Treg, regulatory T cell; TSC, tumour stromal cell; VEGF, vascular endothelial 
growth factor.
Many immune-related genes such as MHC-II, tumour necrosis factor and IL-1 were highly 
expressed in PMN-MDSC, and further up-regulated in TAN compared with neutrophils. An-
giogenic factors, matrix-degrading enzymes and genes related to cell cytotoxicity, including 
ROS production, were down-regulated in TAN compared with neutrophils (Fridlender, Sun et 
al. 2012). In parallel, Ly-6ChiCX3CR1hi monocytes have been proposed as precursors of two, 
molecularly and functionally distinct Ly-6Cint TAM subsets in three different tumour models 
(Movahedi, Laoui et al. 2010). Of these, MHC-IIlo TAM were enriched in hypoxic regions 
of the TME and showed a superior pro-angiogenic activity in vivo, whereas MHC-IIhi TAM 
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were mainly normoxic, but both subsets equally efficiently suppressed Teff cells (Movahedi, 
Laoui et al. 2010). Indeed, hypoxia and hypoxia-inducible factor-1a within the TME seem to 
be responsible for the up-regulation of arginase-1 (ARG-1) and NOS in CD11b+Gr-1+ MDSC 
and their differentiation into TAM (Corzo, Condamine et al. 2010). Collectively, these find-
ings indicate that myeloid cells may have the plasticity to interconvert between different 
phenotypes, and that the TME can have a major effect on their phenotype and function 
(Biswas and Mantovani 2010; Gabrilovich, Ostrand-Rosenberg et al. 2012). However, the 
exact nature of the combination of tumour-derived factors that induce the mobilization and 
abnormal activation and expansion of MDSC is far from complete. Therefore, direct ex vivo 
studies are important but are limited because human MDSC appear to rapidly lose their 
suppressive capacity after cryopreservation (Kotsakis, Harasymczuk et al. 2012). Especially 
the conditions determining the differences in MDSC phenotypes, how they are affected by 
intratumoural inflammation and the presence of TIL should ultimately be answered using 
sophisticated in vivo strategies. The definition of specific markers for MDSC subsets, es-
pecially in humans, remains another important issue. So far, expression of the transcrip-
tion factor CCAAT enhancer-binding protein b (C/EBPb) in mouse PMN-MDSC and M-MDSC 
(Marigo, Bosio et al. 2010), and the signal transducer and activator of transcription 3 (STAT3) 
-mediated up-regulation of the myeloid-related protein S100A9 on human CD14+HLA-DR-/
lo M-MDSC (Zhao, Hoechst et al. 2012) have been proposed. Although these results provide 
important clues, it is still an open question how these molecular MDSC markers relate to 
their suppressive function, and whether they are common to MDSC from different tumours. 
The most definitive identification of MDSC still remains their immunosuppressive function.
Immunosuppressive mechanisms of MDSC
Both M-MDSC and PMN-MDSC apply antigen-specific and antigen non-specific mecha-nisms to regulate immune responses (Fig. 2). Interestingly, PMN-MDSC and M-MDSC 
can inhibit Teff cells through different modes of action, although these mechanisms are not 
exclusively used by one of the two subtypes (Gabrilovich and Nagaraj 2009; Gabrilovich, 
Ostrand-Rosenberg et al. 2012). Production of ROS has been predominantly established for 
PMN-MDSC, whereas the generation of NO and secretion of ARG-1 is mainly used by M-
MDSC (Movahedi, Guilliams et al. 2008; Youn, Nagaraj et al. 2008; Dolcetti, Peranzoni et al. 
2010). Production of ROS by MDSC is mediated through the increased activity of NADPH 
oxidase (NOX) 2. This membrane-bound enzyme complex is assembled during a respiratory 
burst to catalyse the one electron reduction of oxygen to superoxide anion using electrons 
provided by NADPH. Corzo et al. (Corzo, Cotter et al. 2009) identified up-regulation of ROS 
by Gr-1+CD11b+ MDSC isolated from seven different tumour models and by CD11b+CD14-
CD33+ MDSC in patients with head and neck cancer. These MDSC showed significantly high-
er expression of the NOX2 subunits p47phox and gp91phox compared with immature my-
eloid cells from tumour-free mice (Corzo, Cotter et al. 2009). In the absence of NOX2 activity, 
MDSC lost the ability to control T-cell hyporesponsiveness and differentiated into mature 
DC (Corzo, Cotter et al. 2009). Indeed, MDSC from gp91-/- mice are not able to induce T-cell 
tolerance (Nagaraj, Gupta et al. 2007), confirming the role of ROS in T-cell suppression. The 
cooperative activity of ROS with NO forms peroxynitrite (Kusmartsev, Nefedova et al. 2004; 
Gabrilovich and Nagaraj 2009; Gabrilovich, Ostrand-Rosenberg et al. 2012). Peroxynitrite 
leads to the nitration of tyrosines in the T-cell receptor (TCR)-CD8 complex (Nagaraj, Gupta 
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et al. 2007). This reaction might affect the conformational flexibility of TCR-CD8 and its in-
teraction with peptide-loaded MHC-I, rendering the CD8+ T cells (cytotoxic T lymphocytes; 
CTL) unresponsive to antigen-specific stimulation (Nagaraj, Gupta et al. 2007). Indeed, ni-
tration inhibits the binding of processed peptides to tumour cell-associated MHC, and as a 
result, tumour cells become resistant to antigen-specific TIL (Lu, Ramakrishnan et al. 2011). 
Peroxynitrite can damage proteins in a wide array of different processes in both tumour and 
immune cells including those regulating MHC-II expression and T-cell apoptosis (Gabrilovich 
and Nagaraj 2009; Gabrilovich, Ostrand-Rosenberg et al. 2012). Furthermore, peroxynitrite 
leads to the nitration of CCL2 chemokines thereby inhibiting TIL trafficking into the tumour, 
resulting in trapping of antigen-specific CTL in the tumour-surrounding stroma (Molon, Ugel 
et al. 2011). Another mechanism by which MDSC can interfere with T-cell trafficking is the 
expression of the disintegrin and metalloproteinase domain (ADAM) 17, which decreases 
CD62 ligand expression and renders T cells immobile (Gabrilovich, Ostrand-Rosenberg et 
al. 2012). The suppressive activity of ARG-1 is based on its fundamental role in the hepatic 
urea cycle, metabolizing L-arginine to L-ornithine. Expression of ARG-1 has been reported 
to down-regulate TCR cell surface expression by decreasing CD3 ζ-chain biosynthesis (Rod-
riguez, Zea et al. 2002). This effect is not a result of apoptosis, instead the diminished ex-
pression of CD3ζ protein is paralleled by a decrease in CD3ζ mRNA caused by a significantly 
shorter CD3ζ mRNA half-life. This provokes an arrest of T cells in the G0–G1 phase of the cell 
Figure 2. Schematic representation of tsuppressive mechanisms employed by MDSC. Schematic representation 
of the different suppressive mechanisms employed by myeloid-derived suppressor cells (MDSC). ADAM, disintegrin 
and metalloproteinase domain; ARG-1, arginase-1; IL, interleukin; iNOS, inducible nitric oxide synthase; MDSC, my-
eloid derived suppressor cell; NO, nitric oxide; PD, programmed death receptor; PD-L, programmed death receptor 
ligand; ROS, reactive oxygen species; S100A8/9, heterodimer S100A8/9 protein; STAT, signal transducers and activa-
tors of transcription; TGF, transforming growth factor; TLR, toll-like receptor.
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cycle, associated with a deficiency of protein kinase complexes that are important for G1 
phase progression (Rodriguez, Ernstoff et al. 2009). In vitro, this phenomenon is completely 
reversed by the replenishment of L-arginine but not other amino acids (Rodriguez, Zea et 
al. 2002). In vivo, the depletion of CD14-CD15+ PMN-MDSC re-established CD3ζ -chain bio-
synthesis and T-cell growth; further emphasizing the detrimental role that these MDSC play 
in cancer (Zea, Rodriguez et al. 2005). Cancer-expanded MDSC can also induce anergy in 
NK cells through membrane bound TGF-β, STAT5 activity, ARG-1 or via the NKp30 receptor 
(Liu, Yu et al. 2007; Hoechst, Voigtlaender et al. 2009; Li, Han et al. 2009; Oberlies, Watzl et 
al. 2009). The MDSC can suppress NK cell cytotoxicity by inhibiting NKG2D and interferon-γ 
(IFN-γ) production in models of glioma (Alizadeh, Zhang et al. 2010). Another type of immu-
nosuppression modulated by MDSC is the activation and expansion of Treg cells, which will 
be described in detail in the next section. Collectively, the data show that MDSC can employ 
a diverse set of distinct mechanisms to affect tumour cells, endothelial cells and immune 
cells to create a local environment that sustains tumour growth and survival while suppress-
ing anti-tumour immune responses.
MDSC and Treg-cell subsets
In addition to infiltrating myeloid cells, tumours harbour immunosuppressive CD4+CD25hiFoxP3+ Treg cells. They include both thymus-derived natural Treg (nTreg) and 
locally induced Treg (iTreg) cells. Both subsets incorporate contact-dependent and contact-
independent mechanisms to constrain the activation of effector T cells, and have been re-
viewed elsewhere (Jacobs, Nierkens et al. 2012). Naive CD4+CD25- T cells can be converted 
into iTreg cells as a consequence of exposure to antigen in the presence of immunosup-
pressive conditions, including the presence of TGF-β or IL-10 (Chen, Jin et al. 2003; Ghiring-
helli, Puig et al. 2005; Yu, Lee et al. 2005). Although they express distinct TCR repertoires, 
potentially use different suppressive mechanisms and show different survival and prolif-
eration properties, phenotypical discrimination of these two Treg-cell subsets remains a 
major challenge (Kim, Bhairavabhotla et al. 2012). It will be extremely important to inves-
tigate the role of different myeloid cells, including MDSC, in the attraction and activation 
of Treg-cell subsets in general, and the induction of iTreg cells in particular. Mouse studies 
in vivo suggested that MDSC support the de novo development of Treg cells through TGF-
β-dependent (Huang, Pan et al. 2006; Yang, Cai et al. 2006) and -independent pathways 
(Serafini, Mgebroff et al. 2008). Yang et al. (Yang, Cai et al. 2006) reported that suppression 
of Gr-1+CD11b+ MDSC isolated from ovarian-carcinoma-bearing mice was dependent on 
the presence of CD80 on the MDSC and involved CD4+CD25+ Treg cells and CD152, sug-
gesting a relationship between MDSC and Treg cells. In a mouse colon carcinoma model, 
IFN-γ activated Gr-1+CD115+ M-MDSC were shown to up-regulate MHC-II and produce IL-
10 and TGF-β to mediate the development of tumour-induced CD4+CD25+ Treg cells. The 
production of NO by Gr-1+CD115+ M-MDSC was required to suppress antigen-associated 
activation of tumour-specific T cells but was dispensable for Treg-cell induction (Huang, 
Pan et al. 2006). In this study, Gr-1+CD115- PMN-MDSC did not induce the activation of 
tumour-specific Foxp3+ Treg cells (Huang, Pan et al. 2006). In a B-cell lymphoma model, 
MDSC were identified as tolerogenic APC capable of antigen uptake and presentation to 
tumour-specific Treg cells. These CD11b+CD11cloMHC-IIlo MDSC expressed ARG-1 to medi-
ate the expansion of nTreg cells (Serafini, Mgebroff et al. 2008). The Gr-1+CD115+ M-MDSC 
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from CD40-deficient mice were not able to support tumour-specific Treg-cell expansion, 
implicating CD40/CD40L interactions between the two immunosuppressors (Pan, Ma et al. 
2010). These data exemplify the relationship between MDSC and Treg cells. It will be im-
portant to further dissect the relative contributions of nTreg and iTreg cells in dampening 
T-cell immunity and the role that MDSC play in this process Recently Helios, a member of 
the Ikaros transcription factor family, was identified as a potential marker to discriminate 
between nTreg cells (Helios+) and iTreg cells (Helios-)(Thornton, Korty et al. 2010). However, 
its use to distinguish both lineages has been challenged because of the inconsistent expres-
sion on iTreg cells in different disease models (Thornton, Korty et al. 2010; Akimova, Beier 
et al. 2011; Gottschalk, Corse et al. 2012). Two other studies reported that the cell surface 
molecule Neuropilin-1 (Nrp-1) is present at high levels on nTreg cells, whereas peripherally 
generated FoxP3+ iTreg cells lack Nrp-1 expression (Weiss, Bilate et al. 2012; Yadav, Louvet 
et al. 2012). By tracing nTreg and iTreg cells, Weiss et al. (Weiss, Bilate et al. 2012) showed 
that intraperitoneal MCA38 colon adenocarcinomas are heavily infiltrated with FoxP3+Nrp-
1loHelioslo iTreg cells. A subcutaneously growing 4T1 breast cancer cell line contained sig-
nificant amounts of both FoxP3+Nrp-1- iTreg cells and nTreg cells. These findings imply that 
different tumours exhibit different nTreg : iTreg ratios. Analysing both Treg-cell and MDSC 
subsets in different tumour settings is therefore important to uncover the conditions that 
determine the attraction and de novo generation of Treg cells. It will be a major challenge 
to change or alter the immunosuppressive MDSC and Treg cells that accumulate in the pres-
ence of a tumour. Depletion of Treg cells has been applied to enhance anti-cancer treat-
ments aiming to boost tumour immune responses in mice and with some success in men 
(Onizuka, Tawara et al. 1999; Grauer, Sutmuller et al. 2008; Jacobs, Punt et al. 2010). Other 
approaches that directly or indirectly affect or modulate immunosuppressive cells include 
ipilimumab and MDX-1106 mAb therapy that antagonize CTLA-4 and Programmed Death 1 
(PD-1), respectively (Brahmer, Drake et al. 2010; Hodi, O’Day et al. 2010). Blocking members 
of the B7 family inhibitory molecules and/or their ligands (PDL-1 and PDL-2) may be highly 
beneficial as they are expressed not only on Treg cells but also on MDSC, tolerogenic DC and 
TIL (Jacobs, Idema et al. 2009; Ozao-Choy, Ma et al. 2009; Scarlett, Cubillos-Ruiz et al. 2009; 
Norde, Maas et al. 2011). Recent multicentre phase 1 trials revealed durable tumour regres-
sion and prolonged disease stabilization in cancer patients by modulation of the PD-1–PD-L1 
pathway (Brahmer, Tykodi et al. 2012; Topalian, Hodi et al. 2012). Likewise, strengthening 
the response of DC-based vaccines or adoptive TIL therapy could be dramatically enhanced 
by eliminating of MDSC or by converting them into stimulatory APC. Ultimately, effective 
immunocombination therapy may require the induction of potent immunity and attacking 
both suppressors simultaneously, as each subset may compensate for the other.
MDSC and NKT cells
Immune cells that are activated in response to bacterial and viral antigens presented by the MHC-I-like molecule CD1d have been classified as type I and type II NKT cells (Vivier, 
Ugolini et al. 2012). Type I NKT cells express a semi-invariant TCR-αβ encoded by the Vα14 
(Vα24 in humans) and Jα18 gene segments, and therefore are also known as invariant NKT 
(iNKT) cells. In contrast, type II NKT (non-iNKT) cells express variable non-Vα14Jα18 TCR, 
are distinct from the Vα14+ iNKT cells, and potentially recognize a wider profile of glycolipid 
ligands (Bendelac, Lantz et al. 1995; Kinjo, Wu et al. 2005). In mice and humans, iNKT cells 
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have been identified using CD1d tetramers loaded with α-galactosyl ceramide (GalCer). Non-
iNKT cells are less well characterized and have only been indirectly studied by comparing im-
mune responses in mice either deficient in both subsets (CD1d-/-) or only iNKT cells (Jα18-
/-)(Vivier, Ugolini et al. 2012). Stimulation of iNKT cells has been shown to be beneficial for 
the downstream activation of T and NK cells in experimental tumour models (Nowak, Arred-
ouani et al. 2010; Vivier, Ugolini et al. 2012), whereas the activation of non-iNKT cells seems 
to be deleterious (Ambrosino, Terabe et al. 2007; Vivier, Ugolini et al. 2012). This differential 
effect on tumours may be explained by cytokine profiles generated following the activation 
of each cell type. For example, presentation of α-GalCer by a DC to the TCR of iNKT cells led 
to the generation of IL-12, IFN-γ, tumour necrosis factor and the subsequent activation of 
anti-tumorigenic CTL (Fujii, Shimizu et al. 2003). In contrast, the activation of non-iNKT cells 
through endogenous ligands, such as lysophosphatidylcholines (Chang, Deng et al. 2008), 
leads to the production of IL-4, IL-13 and TGF-β, which subsequently impairs CTL and NK cell 
functions (Ambrosino, Terabe et al. 2007; Crane, Han et al. 2010). Interleukin-13 has been 
reported to mediate its effect via the IL-4R-STAT6 pathway and can induce TGF-β-producing 
CD11b+Gr-1+ MDSC (Terabe, Matsui et al. 2000; Terabe, Matsui et al. 2003). Instead, Ko et 
al. (Ko, Lee et al. 2009) showed that iNKT cells activated by α-GalCer-loaded CD11b+Gr-1+ 
MDSC could convert these MDSC into stimulatory APC. Such reprogrammed MDSC up-reg-
ulated the expression of CD11b, CD11c and CD86, did not suppress Teff cells and thereby 
supported the generation of antigen-specific CTL immunity without increasing Treg-cell lev-
els. The mechanism is not completely understood, but may involve soluble mediators and 
cell-to-cell contact interactions. Indeed, production of IFN-γ by α-GalCer-activated iNKT cells 
required direct CD40/CD40L interactions with DC. This interaction enhanced IL-12 secretion 
by DC and further functions to transactivate iNKT cells (Kitamura, Iwakabe et al. 1999). In 
a mouse model of breast cancer, anti-tumour efficacy of CTL was partly dependent on the 
presence of ex vivo expanded iNKT cells that rendered these CTL more resistant to the im-
munosuppressive actions of MDSC (Kmieciak, Basu et al. 2011). Furthermore, it has been 
proposed that activated iNKT cells can limit the growth of human neuroblastomas in NOD/
SCID xenografts by selectively killing IL-6-producing CD1d+CD68+ TAM (Song, Asgharzadeh 
et al. 2009). Additionally, it might be rewarding to investigate the interaction between iNKT 
cells and TAN, because iNKT cells from melanoma patients have been reported to modulate 
the suppressive capacity of serum amyloid A (SAA) -1 differentiated IL-10-secreting neutro-
phils by increasing the IL-12 production of these cells (De Santo, Arscott et al. 2010). SAA-
1 promotes the interaction between iNKT cells and neutrophils in a CD1d-dependent and 
CD40-dependent manner, suggesting that iNKT cells can modulate the expansion and differ-
entiation of neutrophils, possibly by interacting with CD1d+ immature myeloid cells in the 
bone marrow (De Santo, Arscott et al. 2010). In contrast, mature neutrophils can modulate 
IFN-γ, tumour necrosis factor and IL-4 production by iNKT cells in mice and humans (Wing-
ender, Hiss et al. 2012). Therefore, depending on the context, iNKT cells are able to potenti-
ate proinflammatory neutrophil functions whereas neutrophils can down-regulate iNKT cell 
responses. To examine the interaction between iNKT cells and DC during the generation of 
anti-tumour immunity, Gillessen et al. (Gillessen, Naumov et al. 2003) vaccinated wild-type 
(WT), CD1d-/- and Jα18-/- mice with irradiated GM-CSF-secreting B16F10 melanoma cells. 
This vaccination strategy enhanced tumour antigen presentation by recruited CD8a-CD11c+ 
DC in WT mice. These DC expressed high levels of CD1d and macrophage inflammatory 
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protein-2, a chemokine involved in iNKT cell recruitment (Faunce, Sonoda et al. 2001). In-
deed, GM-CSF augmented the numbers of CD1d-restricted iNKT cells in vivo. In contrast, 
the vaccinated CD1d-/- and Jα18-/- mice lacked iNKT cell-mediated anti-tumour immunity 
and DC from CD1d-/- mice showed compromised maturation and function. These results 
provide further evidence for a role of iNKT–myeloid cell cross-talk shaping anti-tumour im-
munity (Gillessen, Naumov et al. 2003). Furthermore, influenza A virus  infected CD1d-/- 
mice provoke an expansion of immunosuppressive CD11b+Ly-6G+Ly-6C+ cells, which inhib-
its antigen-specific immune responses (De Santo, Salio et al. 2008). In this model, adoptive 
transfer of iNKT cells abolished the suppressive activity of MDSC through CD1d-dependent 
and CD40-dependent interactions. As patients with cancer often have lower frequencies of 
iNKT cells than healthy donors (Dhodapkar, Geller et al. 2003; Molling, Langius et al. 2007), 
adoptive transfer of activated iNKT cells could become part of a treatment modality for 
cancer. Collectively, these findings show that NKT cells are potent immunomodulators of 
myeloid cells. Given their potential to influence anti-tumour effector activities, iNKT cells 
may represent an underestimated immune population to be used in cancer immunotherapy 
(Vivier, Ugolini et al. 2012).
MDSC in patients with cancer
The impact of MDSC on cancer progression is increasingly well understood, as is its dia-logue with the TME that supports their proliferation, function and persistence. MDSC 
can synergize with Treg cells to prevent tumour immunity, whereas reciprocal communi-
cations with NKT cells can be either anti-tumorigenic or pro-tumorigenic. Most of these 
findings come from animal studies and it will be extremely important to determine wheth-
er they can be extrapolated to the human setting. Brimnes et al. (Brimnes, Vangsted et 
al. 2010) revealed the presence of increased levels of CD14+HLADR-/lo M-MDSC and of 
CD4+Foxp3+ Treg cells in the blood of multiple myeloma patients at diagnosis relative to 
patients in remission. Functional data regarding the suppressive nature of the cells was, 
however, limited to the effects of Treg cells on CD4+ and CD8+ T cells. Levels of peripherally 
circulating CD11b+CD33+HLA-DR-Lineage-/lo MDSC have also been reported to correlate 
with clinical stage in breast cancer and gastrointestinal malignancies (Diaz-Montero, Salem 
et al. 2009; Mundy-Bosse, Young et al. 2011). Furthermore, in patients with gastrointestinal 
malignancies CD15+ MDSC levels correlated with elevated plasma levels of IL-6 whereas 
the CD15- MDSC subset revealed a strong correlation with IL-10 (Mundy-Bosse, Young et al. 
2011). Similarly, elevated levels of CD11b+CD33+HLA-DR-Lineage-/lo MDSC may represent 
an independent prognostic factor in pancreatic, oesophageal and gastric cancers, which 
correlated with increased ARG-1 levels and significant production of the T helper type 2 
cytokine IL-13, increased Treg-cell numbers, and increased risk of death (Gabitass, Annels et 
al. 2011). Although these human studies still provide little functional analysis on MDSC sub-
sets and only marginally provide information on the cross-talk of MDSC, Treg cells and iNKT 
cells, they are among the first to discuss the prognostic significance of CD11b+CD33+HLA-
DR-Lin1-/lo MDSC in tumour-bearing patients, and their potential role as markers for sever-
ity of the disease. Two clinical studies recently reported on specific immune responses to 
a renal cell carcinoma vaccine consisting of a multiple peptide cocktail (IMA901). Extensive 
pre-vaccination and post-vaccination immunophenotyping revealed that the presence of 
T-cell responses was associated with better disease control and lower numbers of pre-vac-
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cine FoxP3+ Treg cells (Walter, Weinschenk et al. 2012). In addition, CD14+HLA-DR-/lo and 
CD11b+CD14-CD15+ MDSC cells were shown to be negatively associated with survival in 
these patients with renal cell carcinomas. A comprehensive overview of the human studies 
is presented in Table 1. Future studies should provide further evidence for the prognostic 
and predictive value of the levels of the MDSC subsets in patients with cancer. It may indeed 
turn out to be highly rewarding to define the patients’ initial immune status, including the 
level of inflammation, frequencies of immunosuppressive cells as well as the quality of Teff 
cells, APC and NKT cells. Such an immunoscreening could aid in determining eligibility for 
therapies, including cancer immunotherapy.
Immunocombination therapy to modulate the immunosuppressive net-
work
It will be a significant challenge to design combination therapies that target the tumour and eliminate or revert the immunosuppressive TME. To develop effective immunocombination 
therapy targeting MDSC, it is essential to dissect the signals and their pathways within the 
TME. For example, the tyrosine kinase inhibitor sunitinib represents a first-line treatment in 
advanced renal cell carcinoma that has been shown to decrease Treg-cell numbers in mice 
and humans (Finke, Rini et al. 2008; Hipp, Hilf et al. 2008), as well as the generation and 
suppressive activity of CD33+HLA-DR- and CD15+CD14- MDSC (Ko, Zea et al. 2009). Another 
stimulating agent for MDSC differentiation is all-trans-retinoic acid because it lowers the 
number of CD33+HLA-DR-Lin1- MDSC and improves DC to promote tumour-specific T-cell 
responses in patients with metastatic kidney cancer (Mirza, Fishman et al. 2006). Potentially, 
reprogramming MDSC into stimulatory APC might be highly effective in combination with 
tumour antigen-specific immune cell activation by cancer vaccines. It will therefore be es-
sential to identify interactions or pathways in the TME which should one target to eliminate 
or alter MDSC in immunocombination therapies? Based on the available murine data, iNKT 
cells could be part of such an approach (Ko, Lee et al. 2009; Lee, Seo et al. 2012). Also CD40/
CD40L interactions may represent an interesting target to disturb MDSC/Treg-cell interac-
tions or to mature MDSC (Ko, Lee et al. 2009; De Santo, Arscott et al. 2010; Thornton, Korty 
et al. 2010). Macrophages activated by an agonist CD40 mAb can rapidly infiltrate tumours, 
become tumoricidal, and facilitate the depletion of tumour stroma independent from T 
cells and gemcitabine chemotherapy (Beatty, Chiorean et al. 2011). The CD11b+Gr-1+ MDSC 
are known to interact with antigen-specific CTL via the integrins CD11b, CD18 and CD29. 
Blocking of these integrins with specific mAb could be exploited as this was shown to ab-
rogate ROS production and MDSC-mediated suppression of CTL (Kusmartsev, Nefedova et 
al. 2004). For reprogramming of MDSC, toll-like receptors (TLR) may be important because 
they provide an important link between innate and adaptive immunity. TLR-targeted thera-
peutics are increasingly used in the development of cancer vaccines and could therefore 
potentially be used to boost immune responses and to attack the TME (Kanzler, Barrat et 
al. 2007). Interestingly, expression of TLR signalling genes is low in mature neutrophils but 
appear to be up-regulated in PMN-MDSC (Fridlender, Sun et al. 2012). Furthermore, expo-
sure of CD11b+Ly-6G+Ly-6C+ MDSC to TLR3, TLR7/8 or TLR9 agonists relieved or at least 
diminished their suppressive activity on T cells (De Santo, Salio et al. 2008). The TLR ligand 
(TLRL) with the most potential for inducing the differentiation and blocking the immunosup-
pressive activity of mouse MDSC so far appears to be the TLR9L CpG (Chen, Jin et al. 2003; 
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Zoglmeier, Bauer et al. 2011; Shirota, Shirota et al. 2012). TLR9-expressing CD11b+Ly-6G-
Ly-6Chi M-MDSC respond to CpG stimulation by losing their ability to suppress Teff cells, 
producing Th1 cytokines, and differentiating into anti-tumorigenic macrophages (Shirota, 
Shirota et al. 2012). Zoglmeiner et al. (Zoglmeier, Bauer et al. 2011) could show that IFN-α 
produced by plasmacytoid DC after CpG stimulation in vitro or IFN-α treatment alone in 
vivo seems to be responsible for reprogramming CD11b+Gr-1+Ly-6Ghi MDSC. Therefore, 
TLR agonists that induce the production of IFN-α seem to have the capacity to change MDSC 
into non-suppressive APC, whereas TLR4L promote their inflammation-driven suppressive 
activity (Gabrilovich, Ostrand-Rosenberg et al. 2012; Zhao, Hoechst et al. 2012). Scarlett et 
al. (Scarlett, Cubillos-Ruiz et al. 2009) merged the best of both worlds and co-administered 
synergistic CD40/TLR3 agonists to transform tolerogenic DC into immunostimulatory APC. 
In detail, in situ co-stimulation of CD40 and TLR3 on tolerogenic DC decreased their ARG-1 
activity, enhanced their type I IFN and IL-12 production, promoted their ability to process 
antigen, and up-regulated CD40, CD70, CD80 and CD86 expression in vivo in mice and in vit-
ro in human dissociated tumours. The transformation of these tolerogenic DC into APC fur-
ther augmented their migration from tumours to lymph nodes, enhanced T-cell-mediated 
anti-tumour immunity and finally led to the rejection of intraperitoneal ovarian carcinomas 
in mice. Two recent pre-clinical studies highlight the TME complexity in pancreatic ductal 
adenocarcinoma (Bayne, Beatty et al. 2012; Pylayeva-Gupta, Lee et al. 2012). Both studies 
show that pancreas-specific oncogenic KRAS gene mutations initiate a molecular and cel-
lular cascade in which the TME is forced to produce GM-CSF. This tumour-derived GM-CSF 
engages stromal Gr-1+CD11b+ MDSC to inhibit CTL by ARG-1 and NOS production. Abro-
gation of GM-CSF with short hairpin RNA at the transcriptional level or anti-GM-CSF mAb 
reduced tumour growth and limited MDSC recruitment to the tumour site. These findings 
suggest that disruption of the cross-talk within the TME by targeting MDSC or the cytokines 
that regulate their recruitment may be beneficial for patients with pancreatic duct adeno-
carcinoma. In summary, effective immunocombination therapy may require induction of po-
tent anti-tumour immunity and the elimination or reprogramming of the immunosuppres-
sive and tumour-potentiating local environment. Treatment with differentiating/activating 
agents should possibly target Treg cells, NKT cells and MDSC in addition to tumour cells to 
make the TME more sensitive to cancer therapies, including immunotherapy.
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Abstract
Glioblastoma (GBM) is the most aggressive astrocytoma, and therapeutic options are generally limited to surgical resection, radiotherapy, and Temozolomide (TMZ) 
chemotherapy. TMZ is a DNA alkylating agent that causes DNA damage and induces cell 
death. Unfortunately, glioma cells often develop resistance to TMZ treatment, with DNA 
de-methylation of the MGMT promoter identified as the primary reason. However, the 
contributions from proteins that normally protect cells against cytotoxic stress in TMZ-in-
duced apoptosis have not been extensively explored. Here, we showed that increasing the 
level of the gap junction protein, Cx43, in human LN18 and LN229 glioma cells enhances 
resistance to TMZ treatment while knockdown of Cx43 in these same cells sensitizes them 
to TMZ treatment. By expressing a channel-dead or a C-terminal truncation mutant of 
Cx43, we show that Cx43-mediated TMZ resistance involves both channel dependent and 
independent functions. Expression of Cx43 in LN229 cells decreases TMZ-induced apop-
tosis, as determined by Annexin V staining. Cx43-mediated chemoresistance appears to 
be acting via a mitochondrial apoptosis pathway as manifested by the reduction in Bax/
Bcl-2 ratio and the release of cytochrome C. Our findings highlight additional mechanisms 
and proteins that contribute to TMZ resistance, and raise the possibility of increasing TMZ 
efficiency by targeting Cx43 protein.
Introduction
Gliomas are the most common neoplasm of the central nervous system. The most aggres-sive subtype is glioblastoma (GBM), a World Health Organization grade IV astrocytoma 
that is associated with very poor prognosis, with only 3-5% of patients surviving more than 
3 years (Krex, Klink et al. 2007). With a median survival of approximately 14 months, GBM 
is considered the most lethal type of primary brain tumours in adults (Stupp, Mason et al. 
2005). GBM patients generally receive a multimodal approach of surgical resection, radio-
therapy and chemotherapy using the DNA alkylating agent Temozolomide (TMZ). Although 
neurosurgery can remove more than 90% of a tumour mass (Hentschel and Sawaya 2003; 
Lesniak, Klem et al. 2003), cells migrating away from the core often establish secondary 
tumours that are accountable for high GBM mortality. TMZ is currently the most effective 
chemotherapeutic demonstrating excellent CNS bioavailability (Stupp, Mason et al. 2005; 
Neyns, Tosoni et al. 2010), causing DNA methyl adducts on the N7 of guanine, N3 of ad-
enine and O6 position of guanine, about 70%, 9% and 5% respectively (Villano, Seery et al. 
2009). The latter DNA adduct is primarily responsible for the cytotoxic effect, however, clini-
cal response toward TMZ is generally short-lived as tumour cell heterogeneity, transforma-
tion, genetic instability and selective pressures (Salvati, D’Elia et al. 2009) contribute to the 
development of chemoresistant tumours (Giese, Bjerkvig et al. 2003). O-6-methylguanine-
DNA methyltransferase (MGMT) can remove toxic TMZ-induced DNA methylation and its 
expression is correlated to poor TMZ response (Esteller, Garcia-Foncillas et al. 2000). More 
recently, a role was found for the mismatch repair (MMR) pathway and the base excision 
repair (BER) pathway in TMZ resistance (Sarkaria, Kitange et al. 2008; Yip, Miao et al. 2009). 
Additional pathways, such as activation of DNA damage checkpoint response and the chang-
es in mitochondria DNA and electron transport chain may contribute to TMZ resistance 
(Frosina 2009; Oliva, Nozell et al. 2010). In fact, chemoresistance in gliomas is associated 
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with reduction of reactive oxygen species (ROS) and the activity of cytochrome C oxidase 
(Oliva, Moellering et al. 2011). In this way, TMZ reduces the viability of glioblastoma cells by 
triggering apoptosis, which is accompanied by increased loss of mitochondrial-membrane 
potential, cytochrome C (Cyt C) release, caspase activation and caspase-dependent apopto-
sis (Wagner, Marschall et al. 2013). 
The connexins are tetra-span integral plasma membrane proteins, comprised of two ex-
tracellular loops and one intracellular loop along with cytoplasmic amino (NH2) and car-
boxyl-terminal (CT) tail domains. Required for a broad range of physiological processes 
(Naus, Elisevich et al. 1992; Sabarinathan, Mahalakshmi et al. 2010), gap junctions (GJs) 
form intercellular ion channel arrays that permit the passage of small ions and molecules 
to pass between neighbouring cells (Simon and Goodenough 1998; Goldberg, Lampe et 
al. 1999; Fry, Evans et al. 2001). There are two mutually inclusive mechanisms that can 
explain the regulatory functions linked to connexins. The most traditional view, first noted 
by Loewenstein and Kann, acknowledges their role as channels involved with direct cell-cell 
communication that is frequently lost or reduced in cancer cells (Loewenstein and Kanno 
1966). Connexins facilitate communication between the cytosol and the extracellular space 
through GJ “hemichannels” located at the plasma membrane surface (Goodenough and 
Paul 2003). Such channel-forming roles could include the transmission of factors that sup-
press growth and dispersion of tumour promoting agents with neighbouring cells and/or 
extracellular space. In the second mechanism, connexins execute their tumour suppressor 
properties through channel-independent pathways (Goodenough and Paul 2003; Naus and 
Laird 2010). For example, the GJ protein connexin43 (Cx43) has been shown to reverse the 
oncogenicity of human glioma cells in the absence of gap junctional intercellular communi-
cation (GJIC) (Huang, Fan et al. 1998). The non-channel mechanism of action likely involve 
the protein’s long cytoplasmic CT tail (Giepmans 2004; Herve, Bourmeyster et al. 2004) that 
not only serves as a platform for protein-protein interaction and supermolecular assembly, 
but regulation by posttranslational modification and proteolytic cleavage (Chen, Kristensen 
et al. 2012). 
Various studies in gliomas have demonstrated a role of Cx43 in glioma growth control and 
migration [reviewed in (Sin, Crespin et al. 2012)]. The reduction of GJIC in tumour cells is of-
ten attributed to reduced Cx43 expression (Mesnil, Crespin et al. 2005). Therefore, introduc-
tion of oncogenes and mitogens to cultured cells interfere with GJIC by reducing the num-
ber of connexin-containing GJ plaques and/or alter its trafficking to the plasma membrane 
(Laird, Castillo et al. 1995; Naus and Laird 2010). The role of Cx43 in apoptosis is less well 
studied and it remains controversial whether GJIC is pro- or anti-apoptotic (Sin, Crespin et 
al. 2012). Recent evidence suggests the hemichannel activity of Cx43 may have a more sig-
nificant role than intercellular channel activity in affecting cell death (Retamal, Cortes et al. 
2006; De Vuyst, Wang et al. 2009; Decrock, De Vuyst et al. 2009), and identification of Cx43 
in mitochondria suggests GJ proteins may influence pathways linked to apoptosis control 
(Ruiz-Meana, Rodriguez-Sinovas et al. 2008; Lu, Haider et al. 2010). Here, we show for the 
first time that Cx43 expression is linked to TMZ-acquired resistance in human glioma cells. 
Using a Cx43 channel defective (T154A) mutant and a CT truncated Cx43 mutant terminated 
at amino acid 243 (TrCx43), we demonstrate that Cx43-dependent TMZ resistance depends 
on both its channel properties and channel-independent mechanisms. We further show 
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that Cx43 alters mitochondrial apoptotic pathways by regulating levels of Bax2 and Bcl-2, as 
well as Cyt C release from the mitochondria following TMZ treatment.
Materials and methods
Reagents and antibodies
Rabbit polyclonal anti-Cx43 (Sigma, St Louis, USA C6219), mouse monoclonal anti-GAPDH (HyTest Ltd, mAb 6C5), rabbit anti Bcl-2 (Santa Cruz), rabbit anti-Bax (Cell Signalling), HR-
PO-conjugated donkey anti-rabbit/mouse IgG (Sigma) and anti-cytochrome C (Santa Cruz, 
clone 7H8) were used in this study. TMZ (≥98% purity, T2577) was obtained from Sigma. Un-
less otherwise stated, all other reagents and buffers were obtained at biotechnology grade 
from ThermoFisher Scientific (Nepean, ON, Canada).
Immunohistochemistry
Human brain tumour and normal tissue microarray slides (GL2083 from US Biomax) con-taining 208 tissue cores were processed by Wax-it Histology Services Inc. (Vancouver, 
Canada). Briefly, formalin-fixed paraffin embedded tissue sections of 1 mm core diameter 
and 5 mm thick were deparaffinised in xylene and rehydrated in graded alcohols. Sections 
were boiled in sodium citrate buffer, pH 6.0, for 15 min for antigen retrieval, then treated 
with 3% hydrogen peroxide in methanol for 30 min to eliminate endogenous peroxidase ac-
tivity, and blocked with protein block (DAKO) to reduce background staining. Sections were 
then incubated with anti-Cx43 antibody (Sigma) overnight at 4 oC. The following day, the 
sections were incubated with the Envision + System-Horse Radish Peroxidase Labelled Pol-
ymer. Cx43 immunoreactivity was visualized with diaminobenzidine (DAB). Sections were 
counterstained in Mayer’s haematoxylin, blued in lithium carbonate, dehydrated in graded 
alcohols, cleared in xylene, and mounted with permount (Fisher Scientific). Slides were visu-
alized with Aperio ImageScope of the ScanScope digital slide scanner.
Cell culture and generation of stable cell lines
Human LN229 glioma cells (ATCC, Manassas, VA, USA) were infected with retroviral pM-SCVpuro vectors with either wild-type Cx43 (designated as Cx43), Cx43 truncated at 
amino acid 243 (TrCx43), or with an empty plasmid (Mock) as described previously (Crespin, 
Bechberger et al. 2010). The channel dead Cx43 mutant (T154A) (Beahm, Oshima et al. 
2006) was generated using a site directed mutagenesis kit (Qiagen) with the primer pair 
(forward: 5’ GGCTTGCTGAGAGCCTACATCATCAGCATCC 3’; reverse complement: 5’ GGAT-
GCTGATGATGTAGGCTCTCAGCAAGCC 3’) and inserted into a pMSCV vector (Clontech). Cells 
were cultured in media consisting of high glucose DMEM (Sigma, St Louis, USA) supple-
mented with 5% (v/v) fetal bovine serum (HyClone/ThermoFisher Scientific), puromycin (2 
mg/ml), 1% (100 mg/ml) penicillin-streptomycin (10,000 mg/ml, Invitrogen, Burlington, On, 
Canada). Human LN18 glioma cells (ATCC) were cultured in low glucose DMEM (Sigma) sup-
plemented with 10% (v/v) fetal bovine serum and puromycin (800 mg/ml) as previously 
described (Crespin, Bechberger et al. 2010). All cells were incubated at 37 oC in a 5% CO2 at-
mosphere (Thermo Forma, model 310). Cells were passaged every three days after washing 
with PBS (50 mM sodium phosphate buffer, pH 7.4, 0.9% NaCl solution) using trypsine0.25% 
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EDTA (Invitrogen). For shRNA knockdown experiments, LN229-Cx43 cells were treated with 
two rounds of infection with retrovirus containing a scrambled sequence and a Cx43-shRNA 
sequence as reported by Bates et al. (Bates, Sin et al. 2007). After 48 h, Cx43-shRNA cells 
were selected in the presence of 40 mg/ml hygromycin.
Dye coupling assay
Evaluation of GJIC was examined as previously described (Bates, Sin et al. 2007) with some modifications. LN229 control and mutant cell lines were grown to confluency. Donor cells 
were treated with a solution of Calcein AM (Molecular Probes) and DiI (Sigma) and incu-
bated for 20 min. The donor cells were then loaded onto another confluent plate of recipi-
ent cells at 1:100 ratio, and incubated for 2 h at 37 oC. The plates were rinsed with DMEM 
media to remove unattached donor cells. The cells were visualized under epifluorescence 
microscope to quantify coupling between cells.
Cytotoxic assay
TMZ was dissolved in DMSO to 0.1648 M as a stock solution and stored in aliquots at -20 oC prior to use. For the cytotoxic assay, cells were plated in a 96-well plate (Costar, 
Corning, USA) at 5000 cells per well in medium as described above. After 24 h, various con-
centrations of TMZ dispersed in medium were added to the cells. Control cells were treated 
with the corresponding volume of DMSO. After 72 h, the cells were washed twice with PBS 
and fixed for 10 min with 10% buffered formalin phosphate. Cells were stained with 0.05% 
crystal violet for 30 min. Excess stain was removed by washing with water. Crystal Violet was 
solubilized in isopropanol with 0.1% Igepal CA-630 and 0.033% HCl. Absorbance was meas-
ured after 10 min firm shaking at 562 nm on an ELx808 Ultra microplate reader (Bio-Tek, 
Ottawa, Canada) for data analysis by two-way ANOVA.
For Cx43 phosphorylation studies, cells were plated overnight in a 6-well plate (BD Falcon, 
Franklin lakes, USA) at 250,000 cells per well in cell culture media. The next day, TMZ was 
dissolved to 100 mM and 1000 mM in cell culture media and placed on cells. Control cells 
were exposed to corresponding volume of DMSO to various TMZ concentrations. After 16 h, 
cells were rinsed with PBS and lysed in buffer comprised of 20 mM Tris-HCl, pH 8.0, 140 mM 
NaCl, 1% Triton X-100, 10% glycerol, 1 mM EGTA, 1.5 mM MgCl2, containing broad spectrum 
protease (Complete, Roche, City, State) and phosphatase (Phosphatase Inhibitor Cocktail II, 
Sigma) inhibitors. 
Western analysis
Cell lysates were sonicated followed by brief centrifugation at 20,000g, and protein con-centration determination (BCATM Protein Assay Kit, Pierce, Rockford, IL). Sample pro-
teins (12.5 mg) were separated electrophoretically in 10% polyacrylamide gels and trans-
blotted to polyvinylidene difluoride membranes (Bio-Rad, Mississauga, On, Canada) in 
standard Tris-Glycine transfer buffer containing 0.5% SDS. Membranes were blocked over 
night at 4 oC in TBST (20 mM Tris-HCl, pH 7.4, 150 mM NaCl with 0.2% Tween-20) containing 
5% nonfat milk powder. After a brief wash, membranes were incubated for 2 h at room tem-
perature (RT) with rabbit polyclonal anti-Cx43 (1:5000; 0.1 mg/ml), mouse monoclonal anti-
GAPDH (1:5000; 1.56 mg/ml), rabbit anti Bcl-2 (1:200; 1 mg/ml), rabbit anti-Bax (1:1000) an-
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tibodies in TBST containing 1% nonfat milk powder, washed three times in TBST for 30 min, 
and incubated with horseradish peroxidase conjugated goat anti-rabbit IgG or anti-mouse 
IgG respectively diluted (1:3000) in TBST containing 1% nonfat milk powder. Membranes 
were finally washed with TBST for 30 min, and bands were resolved by chemiluminescence 
(GEHealthcare, Quebec, Canada). Band intensity was measured using ImageJ software for 
t-test analysis. For membranes requiring reprobe, membrane were incubated in RestoreTM 
(Pierce/ThermoFisher) stripping buffer for 15 min at 37 oC. Membranes were shaken for 5 
min at RT. Membranes were taken through 6 washes (10 min/wash) with TBST. Membranes 
were blocked and incubated with antibody as described above.
Cytochrome C release assay
The release of Cyt C to the cytoplasm from the mitochondria was assayed with Cellomics ArrayScan VTI HCS reader, which measured the extent of colocalization of Cyt C with a 
marker for mitochondria. Briefly, cells were plated in 96-well plate. MitoTracker red (Inv-
itrogen) was added 1:10,000 prior to fixation. 500 ng/ml Hoechst staining was added 10 
min prior to fixation and incubated at 37 oC. Cells were fixed with 3% paraformaldehyde at 
room temperature for 20 min, blocked in 2% BSA, 0.3% Triton X-100 in PBS for 30 min and 
incubated with anti-Cyt C primary antibody (1:200; 1 mg/ml) for 1 h at room temperature, 
followed by incubation with Alexa 488 conjugated goat anti-mouse antibody (Invitrogen) for 
1 h at room temperature.
Hoechst nuclear staining 
Cells were seeded in a 24-well plate at 60,000 per well, and treated with TMZ for 72 h. Cells were then washed twice with PBS, and incubated in culture media containing Hoe-
chst 33342 (Sigma) at a final concentration of 4 mg/ml for 20 min. Cells were fixed with 4% 
paraformaldehyde and examined with fluorescence microscopy. Apoptotic cells with con-
densed nuclear morphology were counted, and presented as a ratio to the total number of 
nuclei in each field. At least 10 fields per condition were analysed.
Annexin V/propidium iodide staining
Cells were seeded in a 24-well plate at 60,000 cells per well. After 24 h, TMZ were added to the cells. 24 h after TMZ treatment, cells were washed twice with PBS, harvested with 
trypsin and resuspended in binding buffer (140mMNaCl; 4mMKCl; 0.75 mM MgCl2; 10 mM 
HEPES; 2.5 mM CaCl2). Annexin V CF405M conjugate (Biotium) and propidium iodide (PI, 
Sigma) were added to the cell suspension to a final concentration of 2.5 mg/ml and 1 mg/
ml, respectively. The mixture was incubated at RT in the dark for 10 min and then analysed 
with the BD LSRII flow cytometer (Becton Dickinson, San Jose, CA, USA). The number of cells 
in early apoptosis was calculated as the percentage of Annexin V-positive cells gated in the 
PI-negative fractions.
Statistical analysis
Data are shown as (mean +/- SEM) or (relative value +/- SEM). Relative values were cal-culated by averaging the values collected within a group, and normalized this averaged 
value to the value of the Control group at the initial condition of 0 h or 0 TMZ concentration. 
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Figure 1. Localized expression of Cx43 in human gliomas. (A) White bars: percentage of grade III/IV astrocytomas 
(n ¼ 372) with deleted Cx43 (42/372), Cx30 (40/372) or PTEN (242/372) genes obtained at the public TCGA data 
portal (Genome wide SNP) at http://cancergenome.nih.gov/ (as of Feb 2012). Hatched bars: percentage of GBM 
(n ¼ 424) with more than 2-fold reduction in mRNA level compared to normal tissues queried from TCGA Agilent 
G4502A dataset. Cross-hatched bars: percentage of GBM (n ¼ 424) with more than 2-fold increase in mRNA level 
compared to normal tissues. (B) Sixteen cores of 1 mm diameter from grade I and grade IV astrocytomas were 
stained with anti-Cx43 antibody (brown).
At least 3 independent experiments were carried out. Unless otherwise stated, statistical 
analysis was carried out with student’s 2 tailed t test to compare means of 2 cell lines (Cx43 
vs control) in different experimental conditions. p < 0.05 was considered statistically signifi-
cant.
Results
Preferential upregulation of Cx43 in malignant glioma 
Cx43 and Cx30 are two of the most abundant connexin proteins detected in adult astro-cytes (Nagy and Rash 2000). We queried the glioma repository of The Cancer Genome 
Atlas (TCGA) (Cancer Genome Atlas Research 2008) to examine the DNA copy number and 
mRNA expression profile of Cx43 and Cx30 in 424 grade III/IV astrocytomas. Both Cx43/GJA1 
(11.3%) and Cx30/GJB6 (16.1%) have a tendency to be deleted in GBM (Fig. 1A), although 
at a lower frequency than a well-es-
tablished tumour suppressor PTEN 
(65.1%). Cx30 and PTEN mRNA profile 
mirrored their DNA profile, with 96.7% 
and 34.7% of GBMs showing more than 
a 2-fold reduction, respectively (Fig. 
1A). Interestingly, while 27.3% of the 
TCGA dataset exhibits a 2-fold down-
regulation of Cx43 mRNA compared to 
normal tissues, 20.3% of GBM show a 
2-fold upregulation of Cx43 mRNA (Fig. 
1A). A screen of a brain tumour tissue 
array confirmed minimal Cx43 protein 
levels in malignant grade IV gliomas 
(Fig. 1B). Interestingly, we noticed 
heterogeneous expression of Cx43 in 
a subset of grade IV gliomas (Fig. 1B). 
Taken together, our findings raise the 
possibility that re-expression of Cx43 
protein may provide survival advan-
tage to glioma cells. Because TMZ is a 
standard therapy for glioma, we asked 
the question whether Cx43 protects 
glioma cells from TMZ treatment.
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Increased expression of Cx43 reduces sensitivity of human glioma cells to TMZ
LN18 human glioma cells have a low endogenous Cx43 expression (Crespin, Bechberger et al. 2010). We previously showed that forced Cx43 expression in LN18 cells did not affect 
their proliferation rate, but enhanced their migration rate (Crespin, Bechberger et al. 2010). 
To determine whether Cx43 protein will provide a survival advantage of glioma cells by in-
creasing their resistance to TMZ-induced cell death, we treated LN18 cells with a range of 
TMZ concentrations, starting at 100 mM, a concentration often used in in vitro glioma stud-
ies (Hirose, Berger et al. 2001; Kanzawa, Germano et al. 2004; Kitange, Carlson et al. 2009; 
Zhang, Stevens et al. 2010; 
Zhang, Wang et al. 2010; 
Schafer, Teufel et al. 2012). 
Although we did not observe 
any significant change in 
cell survival measured by a 
crystal violet cytotoxic assay 
(Saotome, Morita et al. 1989) 
when cells were exposed to 
100 mM TMZ (Fig. 2), Cx43 
overexpressing LN18 cells 
showed significant cell sur-
vival compared to untreated 
cells when TMZ concentra-
tion was increased to 250 
mM and 500 mM. Our results 
show that Cx43 has a protec-
tive effect in TMZ-induced 
cell death.
Cx43 requires intact channel activity and CT tail to mediate TMZ chemoresistance
We suspect that the lack of Cx43-dependent TMZ resistance at low TMZ concentration may be due to expression of MGMT by LN18 cells (Hermes, Geisler et al. 2008). To 
further explore the cyto-protective function of Cx43, we used LN229 cells, a glioma cell 
line with hypermethylated MGMT promoter (Hermes, Geisler et al. 2008). LN229 cells ex-
pressed low levels of endogenous Cx43 (Fig. 3A). To determine the relative contribution of 
different domains of Cx43, we introduced a full length wild-type Cx43, a Cx43 mutant with a 
truncated CT (TrCx43) (Crespin, Bechberger et al. 2010), or a channel-defective mutant Cx43 
(T154A), into parental LN229 cells. Western blot analysis confirmed the expression of exog-
enous Cx43 and mutants in LN229 cells (Fig. 3A). Dye coupling assay showed the increase 
in intercellular coupling in wild-type Cx43-expressing cells but none in T154A-expressing 
cells (Fig. 3B). Exposure of these LN229 cell lines to different TMZ concentrations resulted 
in a dose-dependent decrease in cell viability (Fig. 3C). LN229 Cx43 cells were less sensitive 
to TMZ than mock-transfected LN229 cells at concentrations as low as 100 mM (Fig. 3C). 
At higher concentrations, the LN229 Cx43 cells were also more resistant than the LN229 
Mock cells. Interestingly, the protective effect of Cx43 was partially abolished in LN229 lines 
Figure 2. Increased Cx43 expression in LN18 cells increases their TMZ re-
sistance. Cytotoxic assay results of LN18 cells treated with 100, 250 and 
500 mM TMZ for 72 h. Analysis was carried out with two-way ANOVA (*: P 
< 0.05, ***: P < 0.001).
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expressing the CT truncated TrCx43 or the channel-defective T154A mutants (Fig. 3C), in-
dicating that an intact CT tail and channel function are necessary for Cx43 to mediate TMZ 
resistance. Although some evidence suggests that increasing cell migration or decreasing 
cell proliferation are linked to chemoresistance (Giese, Bjerkvig et al. 2003), we did not find 
differences in the growth rate (Supplementary Fig. 1A) and migration rate (Supplementary 
Fig. 1B) of LN229 cells expressing various mutants. Taken together, our results demonstrate 
that Cx43 mediates TMZ chemoresistance requiring a functional channel and an intact cy-
toplasmic CT tail.
Figure 3.  Channel activity and CT tail of Cx43 contribute to TMZ chemoresistance. (A) Western blot showing the 
expression of full length wild-type Cx43 (Cx43), CT truncated Cx43 encompassing amino acid 1e242 (TrCx43) and 
channel defective Cx43 mutant (T154A) in LN229 cells probed with an antibody that recognized the CT (top panel) 
and N-terminal of Cx43 (middle panel) respectively. GAPDH was used as a loading control. (B) Dye coupling ability 
of parental, Cx43, TrCx43 and T154A expressing LN229 cells. Transfer of GJ-permeable calcein dye (green) from 
donor GL261 cells labeled with lipophilic membrane dye DiI (red) to recipient monolayer was absent in T154A-
expressing cells. Scale bar, 50 mm. (C) Cell viability of LN229 expressing Cx43 mutants shown in A) treated with 
100, 250 and 500 mM TMZ for 72 h. Relative absorbance was normalized with values from DMSO treated controls. 
Analysis was carried out with two-way ANOVA (*: P < 0.05, **: P < 0.01, ***: P < 0.001).
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Knockdown of Cx43 increases LN229 sensi-
tivity to TMZ
To confirm TMZ resistance is mediated by Cx43, we knocked down exogenous Cx43 
in LN229 with a Cx43-shRNA (Bates, Sin et 
al. 2007), and a control shRNA vector (Fig. 
4A). The reduced Cx43 expression in these 
cells resulted in a significant increase in sen-
sitivity to TMZ treatment at concentrations 
ranging from 100 mM to 500 mM (Fig. 4B). 
Exposure to DMSO vehicle did not alter the 
survival of LN229 cells (Fig. 4C). Therefore 
our results confirm a significant role of Cx43 
in TMZ resistance in human glioma cells. 
Cx43 phosphorylation is minimally affected 
by TMZ
Recent analysis of Cx43 phospho-sites demonstrates GJ subunits undergoes 
signal integration via multi-site phospho-
rylation at consensus residues, suggesting 
the protein integrates with multiple signal-
ling cascades, including MAPK, PKC, GSK3, 
SRC, Cdk5, and CaMII (Chen, Gouw et al. 
2013). As a well-characterized phospho-
protein, properly trafficking Cx43 generates 
multiple bands between 37 and 48 kDa re-
solved by SDS-PAGE/western-blot where the 
fastest moving species is recognized as the 
non-phosphorylated species (Lampe and 
Lau 2000). Low endogenous levels of Cx43 
phosphorylation have been found to cor-
relate with reduced levels of GJ assembly, 
decreased channel activity, and intracellu-
lar accumulation (Segretain and Falk 2004). 
Inhibition of GJ formation and GJIC via blockage of ER to Golgi transport with Brefeldin A 
results in the accumulation of non-phosphorylated Cx43 (Laird, Castillo et al. 1995; Chen, 
Kristensen et al. 2012). Cx43 proteins that are expressed by LN229 Cx43 cells appear to be 
predominately unphosphorylated (Fig. 5A). To determine whether signalling pathways that 
are responsible for Cx43 phosphorylation mediate TMZ chemoresistance, LN229 Cx43 cells 
were exposed to 100 mM TMZ. We observed no significant alterations in either Cx43 expres-
sion or phosphorylation levels (Fig. 5A and B). To confirm the lack of changes in Cx43 level is 
not due to reaching the limit of detection, we repeated the experiment at 1000 mM TMZ, a 
concentration that will activate additional cytotoxic-induced pathways known to affect Cx43 
Figure 4. Knockdown of Cx43 increases LN229 sensitiv-
ity to TMZ treatment. (A) Western blot showing the level 
of Cx43 protein in LN229 expressing shRNA-control and 
shRNACx43 GAPDH was used as a loading control. (B) Cell 
viability of LN229 expressing shRNA-control and shRNA-
Cx43 treated with 100, 250 and 500 mM TMZ for 72 h. 
Analysis was carried out with two-way ANOVA (**: P < 
0.01, ***: P < 0.001). (C) Cell cytotoxicity assay of LN229 
cells with different volume of DMSO corresponding to 
volume of 100, 250 and 500 mM TMZ for 72 h.
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phosphorylation (Hur, Shim et al. 2003). The sensitivity of LN229 cells to TMZ at this con-
centration is similar to that of 500 mM (data not shown). We noticed a significant parallel 
loss in Cx43 expression and phosphorylation, particularly at 8-16 h post-treatment (Fig. 5C 
and D). The reduction in Cx43 expression and phosphorylation only at 1000 mM TMZ may 
be due to increasing endoplasmic reticulum (ER)-associated degradation load at cytotoxic 
concentrations (VanSlyke and Musil 2002; Lampe and Lau 2004), or genotoxic stress may in-
voke translational checkpoints to block protein synthesis (Sheikh and Fornace 1999). Taken 
together, these findings suggest that alteration in Cx43 phosphorylation does not contribute 
to TMZ resistance.
Figure 5. Phosphorylation of Cx43 in LN229 cells is not affected by treatment of 100 mM TMZ. (A) Western blot 
for Cx43 and GAPDH expression in LN229 Cx43 cells at different time points after 100 mM TMZ treatment. (B) (Top) 
relative Cx43 expression at various time points after TMZ treatment. (Bottom) relative phosphorylation of Cx43 at 
different time points after TMZ treatment. (C)Western blot for Cx43 and GAPDH expression in LN229 Cx43 cells at 
different time points after 1000 mM TMZ treatment. (D) (Top) relative Cx43 expression at various time points after 
TMZ treatment. (Bottom) relative phosphorylation of Cx43 at different time points after TMZ treatment. Statistical 
analysis was carried out with a student t-test (*: P < 0.05, **: P < 0.01, ***: P < 0.001).
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Increased expression of Cx43 reduced TMZ-induced apoptosis in LN229 glioma cells
TMZ-induced cell death is often attributed to an increased level of apoptosis (Roos, Batis-ta et al. 2007; Zhang, Stevens et al. 2010; Zhang, Wang et al. 2010). Therefore, we char-
acterized the apoptosis of LN229 cells in response to TMZ treatment by Annexin V (Vermes, 
Haanen et al. 1995) and Hoechst staining (Allen, Hunter et al. 1997), which reveal the per-
centage of early and late apoptotic cells, respectively. Overexpression of Cx43 in LN229 cells 
showed a significant reduction in the percentage of Annexin V positive early apoptotic cells 
in the presence of 50 mM and 100 mM TMZ (Fig. 6A and B). The protective role of Cx43 in 
TMZ-induced apoptosis in glioma cells was confirmed using Hoechst staining that revealing 
significant reduction of fragmented or condensed nuclei in LN229 Cx43 compared to mock-
transfected LN229 cells (Fig. 6C and D).
Increased Bax/Bcl-2 ratio after TMZ treatment in glioma cells with reduced Cx43 level
We next determined whether Cx43 can protect cells from TMZ-induced apoptosis by af-fecting the protein levels of Bax, a pro-apoptotic protein, and Bcl-2, an anti-apoptotic 
protein (Adams 2003; Shi, Chen et al. 2010). Western blot analysis reveals higher level of 
Figure 6. Overexpression of Cx43 attenuates TMZ-induced apoptosis in LN229 cells. (A) Cytograms from flow cy-
tometric analysis showing the proportion of early apoptotic cells after 50 mM TMZ treatment for 24 h, accessed by 
FACs analysis with Annexin V/PI staining. (B) Percentage of early apoptotic cells. (*: P < 0.05). Results were pooled 
from 4 independent experiments. (C) Fluorescence images showing fragmented or condensed nuclei (arrows) in 
late apoptotic cells, as revealed by Hoechst staining after treatment of 100 mM TMZ for 72 h. Scale bar, 20 mm. (D) 
Ratio of apoptotic cells to the total number of cells was normalized to mock-transfected LN229 cells. Results were 
pooled from five independent experiments. Statistical analysis was carried out with a student t-test (*: P < 0.05).
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Bcl-2 and lower level of Bax in Cx43-expressing cells, especially after TMZ treatment (Fig. 
7A). We next quantified the Bax/Bcl-2 ratio, which is an indication for the susceptibility to 
apoptosis (Oltvai, Milliman et al. 1993; Yang and Korsmeyer 1996), in these cells (Fig. 7B). 
The Bax/Bcl-2 ratio of cells lacking Cx43 was significantly higher when exposed to 100 mM 
TMZ. These results are consistent with a role for Cx43 in preventing apoptosis via a mito-
chondrial-dependent pathway.
Cx43 prevents Cyt C release by mitochondria
Mitochondria play a centralised role in regulating apoptosis. The canonical release of Cyt C from mitochondria, a component of the mitochondrial electron transfer chain, initi-
ates the loss of mitochondrial membrane potential and the parallel activation of caspases 
within the cytoplasm (Liu, Kim et al. 1996; Wang 2001). To better understand the influence 
of Cx43 on TMZ-induced apoptosis and Cyt C release, we fluorescently labelled mitochon-
dria in LN229 cells with MitoTracker Red, and measured the colocalization of Cyt C with 
mitochondria using an imaging platform to measure fluorescence intensities within single 
cells (Fig. 8A). Here, Cx43-shRNA knockdown and Cx43 overexpressing cells were subject 
to dose-dependent exposure to TMZ (10, 20, 50, 70, 100, and 500 mM) for 24 h; carbonyl 
cyanide m-chlorophenyl hydrazone or normal growth media served as positive and nega-
tive controls, respectively. Experimental treatment of LN229 cells with TMZ demonstrated 
Cx43 knockdown cells presented a significant, dose-dependent increase of Cyt C loss from 
mitochondria at 10, 20, 50 and 70 mM of TMZ (Fig. 8B). Interestingly, we observed increased 
sensitivity of LN229 cells to TMZ concentrations of less than 100 mM, which may be due 
to the low cell density required for this assay. This is in agreement with our previous result 
demonstrating the reduction of Cx43-mediated gap junctions coupling in low-density cul-
ture increases sensitivity of cells to cisplatin, a chemotherapy drug (Hong, Wang et al. 2012). 
Taken together, our results indicate Cx43 expression in LN229 cells inhibits TMZ-induced cell 
death by modulating the mitochondrial apoptotic pathway.
Discussion
TMZ is the standard treatment for malignant high-grade glioma, but its efficacy is not consistent in all patients (Fukushima, Takeshima et al. 2009). Hypermethylation of the 
MGMT promoter is used frequently as a predictive marker to assess the responses of glio-
mas to TMZ treatment (Rivera, Pelloski et al. 2010). However, several studies have found 
Figure 7. Reduction of Cx43 levels in 
glioma cells leads to increased Bax/
Bcl-2 ratio after TMZ treatment. (A) 
Western blot showing Bax, Bcl-2 and 
GAPDH expression in Cx43 knockdown 
(shRNA) and Cx43-expressing (Cx43) 
LN229 cells after 100 mM TMZ treat-
ment for 24 h. (B) Bax/Bcl-2 ratio after 
treatment of TMZ for 24 h. DMSO is 
the vehicle control. Statistical analysis 
was carried out with a student t-test 
(*: P < 0.05).
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that additional pathways are involved in TMZ resistance (Sarkaria, Kitange et al. 2008; Yip, 
Miao et al. 2009). Although Cx43 is traditionally classified as ‘downregulated’ in malignant 
astrocytomas when compared to normal astrocytes (Sin, Crespin et al. 2012), our findings 
from the TCGA dataset and primary brain tumour tissue arrays reveal an unexpected upreg-
ulation of Cx43 levels in 20% of malignant gliomas. In this study, we demonstrate that Cx43 
expression in high grade glioma may confer an advantage to the survival of tumour cells by 
contributing to TMZ resistance. 
Our results show a correlation between Cx43 expression and TMZ resistance. This resist-
ance was in part dependent on the CT tail of Cx43 and of its channel function. It is likely 
that Cx43-mediated protective mechanisms are independent of the MGMT pathway, since 
the LN229 cells show Cx43-mediated chemoresistance in spite of not expressing MGMT 
(Hermisson, Klumpp et al. 2006). Our results point toward Cx43 affecting the mitochondrial 
apoptotic pathway in the presence of TMZ. Previous studies have suggested Cx43-mediated 
GJIC accounts for its effect on apoptosis. However, GJIC has been associated with pro-apo-
ptotic (Huang, Hossain et al. 2001) and anti-apoptotic (Nakase, Sohl et al. 2004) activities, 
presumably by allowing intercellular transfer of beneficial metabolites (Goldberg, Lampe 
et al. 1999) or drug molecules - the bystander effect (Cottin, Ghani et al. 2010). Other evi-
dence also suggests that Cx43 protects cells against injury caused by oxidative stress and 
metabolic inhibition that is dependent its hemichannel activity instead of GJIC (Lin, Yang 
et al. 2003). In addition, Cx43 can enhance cell survival via its adhesion function (Westhoff, 
Zhou et al. 2008), or the interaction of its CT tail with apoptosis signal-regulating kinase 1 
(Giardina, Mikami et al. 2007). Although an intact CT tail is required for TMZ chemoresist-
ance, phosphorylation of Cx43 does not appear to have a major role in this process. The 
relative contribution of GJIC, hemichannel activity, or adhesion in facilitating the mechanism 
of Cx43-dependent TMZ resistance, namely Bax/Bcl expression and Cyt C release, remains 
to be elucidated.
Invasive glioma cells are often more resistant to conventional cytotoxic treatments, which 
are generally directed against proliferating cells (McDonough, Tran et al. 1998; Giese, 
Bjerkvig et al. 2003). Furthermore, gene-expression profiling of migratory cells shows a cor-
relation between migration and the downregulation of proliferation and apoptosis associ-
ated genes, whereas a number of anti-apoptotic genes are upregulated (Mariani, Beaudry et 
al. 2001). Although Cx43 has also been shown to facilitate migration (Bates, Sin et al. 2007; 
Behrens, Kameritsch et al. 2010; Crespin, Bechberger et al. 2010), which may account for 
the resistance to TMZ-induced apoptosis, we find the migration rate of LN229 is not affected 
by the expression of exogenous Cx43. 
Recent identification of Cx43 in mitochondria (Ruiz-Meana, Rodriguez-Sinovas et al. 2008; 
Lu, Haider et al. 2010) suggests Cx43 may participate in mitochondrial signalling, including 
apoptosis. Overexpression of Cx43 in human glioma cells leads to increased Bcl-2 expression 
(Huang, Liu et al. 2001). Similarly, transcriptome analysis of Cx43-null astrocytes identified 
alteration in levels of expression of common apoptotic genes (Iacobas, Urban-Maldonado et 
al. 2003). Cx43 has been demonstrated to inhibit caspase-3 activation (Giardina, Mikami et 
al. 2007). Indeed, the increase in the relative ratio of Bax/Bcl-2 expression and Cyt C release 
with decreasing levels of Cx43 in glioma cells exposed to TMZ strengthens the link between 
Cx43 and mitochondrial signalling, and apoptotic response.
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TMZ is a standard therapy for glioma treatment, and there are many attempts to increase 
the drug efficiency. For example, inhibition of c-Jun N-terminal kinase (JNK) enhances TMZ-
induced cytotoxicity (Ohba, Hirose et al. 2009). Our findings identify Cx43 expression as a 
potential prognosis marker for TMZ treatment, and demonstrate Cx43 may be considered as 
a therapeutic target (Kandouz and Batist 2010) in glioma management.
Figure 8. The release of cytoplasmic Cyt C is increased in Cx43 knockdown LN229 cells. The release of cytoplasmic 
Cyt C is increased in Cx43 knockdown LN229 cells. (A) LN229 Cx43 cells were fluorescently labeled with MitoTracker 
red, in combination with anti-Cyt C/FITC-conjugated secondary antibodies to monitor the colocalization of Cyt C 
and mitochondria in TMZ (20 mM) and DMSO treated cells. Scale bar, 50 mm. (B) Extent of colocalization was nor-
malized to 0 mM TMZ. Results were pooled from three independent experiments (*: P < 0.05).
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Supplementary figure
Supplementary Figure 1. Expression of Cx43 and mutants do not affect the proliferation and migration of LN229 
glioma cells. (A) The growth curve of LN229 cells are not altered by overexpressing Cx43 and its mutants. Human 
glioma cells were initially seeded (30,000/well) in triplicates using standard 12-well plates. The number of cells/
well were evaluated on day 1, 3, 5, 6, 7, 8 and 10 using Z1 Coulter Particle Counter (Beckman Coulter). (B) Wound 
healing mobility assay. LN229 cells either mock transfected, expressing full length wild-type Cx43 (Cx43), CT trun-
cated Cx43 encompassing amino acid 1e242 (TrCx43) or channel defective Cx43 mutant (T154A), were grown to 
confluency in 35-mm dishes. The confluent monolayer was scraped using a blue tip. Cells were washed with PBS 
to remove detached cells and images were acquired immediately and after 8 hours. Migrated distance was deter-
mined using ImageJ.
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Abstract
Myeloid-derived suppressor cells (MDSCs), defined as CD33+MHC-II- cells, are in-creased in a variety of human tumours and are associated with immunosuppression. 
MDSCs can be further subdivided in CD14+ monocytic (M-MDSCs) and CD15+ granulocytic 
(PMN-MDSCs) subpopulations. Here we set out to determine the presence of MDSC sub-
sets in the blood and tumour tissue of patients with a glioma, including the most malig-
nant variant i.e. glioblastoma (GBM). CD33+MHC-II- MDSCs in blood from 21 patients with 
glioma and 12 healthy individuals were phenotyped and quantified by flowcytometry. 
Myeloid populations of M-MDSC and PMN-MDSC phenotype were both significantly in-
creased in the blood of GBM patients versus to healthy controls. The myeloid activation 
markers CD80 and PD-L1 could not be detected on either of these MDSC subsets, while 
CD124, CD86 and CD40 were detected at similar levels on MDSCs in patients with glioma 
and healthy donors. By contrast, in tumour cell suspensions, the MDSC population con-
sisted almost exclusively of CD15+ cells. Immunohistochemistry confirmed infiltration of 
CD15+MHC-II- cells in glioma tissue samples. These data support a role for cells with an 
MDSC phenotype in blood and tumour microenvironment of patients with GBM.
Introduction
Gliomas are the most common primary brain tumours, originate from glial cells or precur-sors thereof. Based on their histology, gliomas are classified and graded for malignancy 
according to guidelines of the World Health Organization (WHO) (Louis, Ohgaki et al. 2007). 
Glioblastoma (GBM) is the most malignant and, unfortunately, the most frequent glioma. 
Despite multimodal treatment (i.e. surgical resection followed by chemoradiation), the me-
dian survival for patients with a GBM is only 14.2 months (Gousias, Markou et al. 2010). 
Thus, there is an urgent need for the development of novel, more effective therapies. Im-
munotherapy is emerging as an effective therapy for the treatment of various cancers (Car-
son, Doose et al. 2006; Couzin-Frankel 2013; Gielen, van der Valk et al. 2014), but the brain 
is unique in that it is an immune-specialized site, capable of tightly regulating the immune 
response.
Multiple immunotherapeutic strategies have been exploited to treat patients with a glioma. 
Data from phase I and phase II trials have suggested that immunotherapy can produce a 
meaningful and sometimes durable beneficial response in patients with GBMs. The report-
ed studies were generally performed in only a limited number of patients, and immunologi-
cal responses could only be measured in a portion of these patients (Marsh, Goldfarb et al. 
2013). The limited efficacy of immunotherapy in patients so far might be the result of an 
immunosuppressive network implemented by the tumour (Grauer, Wesseling et al. 2009). 
Such a network encompasses soluble mediators, inhibitory receptors and suppressive cells 
that may prevent the initiation and execution of proper immune responses (Finocchiaro and 
Pellegatta 2011; Hanahan and Weinberg 2011; Lindau, Gielen et al. 2013). One of these im-
munosuppressive cell types is the regulatory T cell (Treg). We have previously reported that 
Tregs accumulate within high-grade gliomas but not in the blood of patients with glioma. 
Furthermore, Tregs isolated from glioma were shown to be able to suppress tumour-infil-
trating lymphocyte (TIL) function (Fecci, Mitchell et al. 2006; Heimberger, Abou-Ghazal et al. 
2008; Jacobs, Idema et al. 2009; Jacobs, Idema et al. 2010). 
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Recently, another immune suppressive cell type, myeloid-derived suppressor cell (MDSC), 
was found to be increased in blood and in tumour tissue of patients with various tumours 
(Diaz-Montero, Salem et al. 2009; Gabitass, Annels et al. 2011). MDSCs are a heterogeneous 
group of immature myeloid-derived cells that are capable of suppressing the immune sys-
tem. In mice, these cells are divided in a polymorphonuclear subpopulation (PMN-MDSCs), 
which is defined by expression of CD11b+Gr-1highLy-6G+Ly-6ClowCD49d-, and a monocytic 
Donor # Tumor type WHO grade age sex
PT 1 glioblastoma IV 64 f
PT 2 low grade oligodendroglioma II 52 m
PT 3 glioblastoma IV 62 m
PT 4 anaplastic oligoastrocytoma III 42 f
PT 5 glioblastoma IV 61 m
PT 6 low grade ependymoma II 29 f
PT7 anaplastic astrocytoma III 40 m
PT8 glioblastoma IV 62 f
PT9 anaplastic oligodendroglioma III 53 m
PT10 low grade glioma n.o.s. II 21 f
PT11 glioblastoma IV 67 m
PT12 glioblastoma IV 58 f
PT13 anaplastic oligodendroglioma III 45 m
PT14 glioblastoma IV 67 f
PT15 glioblastoma/gliosarcoma IV 52 m
PT16 glioblastoma IV 64 f
PT17 anaplastic oligodendroglioma III 44 f
PT18 glioblastoma IV 60 m
PT19 low grade oligoastrocytoma II 45 m
PT20 anaplastic oligodendroglioma III 49 f
PT21 glioblastoma IV 52 f
HC1  N/A 57 f 
HC2  N/A 53 m 
HC3  N/A 63 f 
HC4  N/A 49 m 
HC5  N/A 66 f 
HC6  N/A 51 m 
HC7  N/A 30 m 
HC8 N/A 64 m
HC9 N/A 39 m
HC10 N/A 62 m
HC11 N/A 60 f
HC12 N/A 56 m
Table 1. Sample details. HC: Healthy control; N/A: Not Applicable; n.o.s.: not otherwise specified; PT: patient; m: 
male; f: female
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population (M-MDSCs), which is characterized by a CD11b+Gr-1highLy-6G-Ly-6ChighCD49d+ 
phenotype (Movahedi, Guilliams et al. 2008; Youn, Nagaraj et al. 2008). In humans, various 
studies have used different criteria for recognizing different phenotypes of MDSCs (Solito, 
Marigo et al. 2014). Most commonly, MDSCs are defined by the expression of the myeloid 
markers CD33 and/or CD11b and the absence or low expression of HLA-DR. Similar to mu-
rine MDSCs, there are monocytic and granulocytic subpopulations of human MDSCs that ex-
press CD14 or CD15, respectively. Both populations are present in low numbers in the blood 
of healthy donors (Lindau, Gielen et al. 2013). Interestingly, in patients with tumours, either 
CD14+ M-MDSCs or CD15+ PMN-MDSCs were most abundantly increased in the blood de-
pending on the tumour type (Lindau, Gielen et al. 2013). To date, human MDSCs have often 
been assessed in peripheral blood mononuclear cells (PBMCs) samples after depletion of 
mature neutrophils by separation using a ficoll gradient. In addition, most studies have in-
vestigated the presence of either PMN-MDSCs or M-MDSCs in peripheral blood, whereas 
both populations might be important to sustaining an immunosuppressive network in both 
the tumour as well as in peripheral blood of tumour patients. 
MDSCs can suppress T-cell function by several mechanisms, including production and se-
cretion of arginase, nitric oxide and reactive oxygen species (Lindau, Gielen et al. 2013). 
In addition, several myeloid markers, including CD80, PD-L1, CD124 and CD40, have been 
shown to be expressed on murine (Yang, Cai et al. 2006; Youn, Nagaraj et al. 2008; Pan, Ma 
et al. 2010) as well as human (Mandruzzato, Solito et al. 2009; Poschke, Mougiakakos et al. 
2010; Zhang, Wang et al. 2013) MDSCs. For murine MDSCs, CD80 and CD40 were found to 
be important for their suppressive capacity and induction of Tregs, respectively (Yang, Cai et 
al. 2006; Pan, Ma et al. 2010). For human MDSCs, however, the expression of these markers 
has not been determined in detail and may differ for different tumour types. Because these 
cells may interfere with the proper induction of an immune response after immunotherapy, 
it is important to map their presence and phenotype, to determine their role in the tumour 
environment and to link their presence to therapeutic efficacy. 
We therefore studied MDSC subsets in blood and in tumour tissue of patients with glioma. 
MDSCs were defined by a lack of major histocompatibility complex class II (MHC-II) expres-
sion and the presence of the myeloid markers CD33 (in blood) or CD11b (in tumour tissue). 
We found an increase in both PMN- and M-MDSCs in the blood of patients with GBM com-
pared with the blood of healthy controls. In contrast, only PMN-MDSCs were highly preva-
lent in tumour tissue, suggesting that these cells are the main MDSC population contribut-
ing to the immunosuppressive tumour microenvironment within glial neoplasms. 
Materials and Methods
Patient material
Peripheral blood samples were collected from 12 healthy individuals and from 21 patients with glioma who were undergoing neurosurgical resection or biopsy of the tumour at 
the Radboud University Medical Center (Radboudumc). None of the patients received neo-
adjuvant therapies before sampling; the blood of patients was drawn during surgery. Fresh 
tumour tissue was obtained, via ultrasonic aspiration, from 13 of these latter patients. Most 
patients had started a 3x 5mg dexamethasone (Centrafarm, Etten-Leur, the Netherlands) 
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regime on the day before surgery, whereas other patients received dexamethasone at an 
earlier point to reduce edema. All donors signed an informed consent form, and the study 
was approved by our Institutional Review Board and performed according to their guide-
lines. Sample processing was started immediately after the blood and fresh tumour tissue 
samples were obtained. Flow cytometry measurements were performed within 24 hours.
Tissue handling
Fresh brain tumour material was obtained by excision and by ultrasonic aspiration. As-pirates were collected in a closed system. Tumour cell suspensions were prepared as 
described previously (Jacobs, Idema et al. 2009). Briefly, tumour fragments were filtered 
and washed to discard blood and suction fluid. Tumour fragments were incubated with col-
lagenase type IA (50 µg/ml) (Sigma-Aldrich, St Louis, MO), DNAse type I (10 μg/ml) (Roche, 
Mannheim, Germany) and trypsin inhibitor (1 μg/ml) (Sigma) in Hank’s Balanced Salt So-
lution (HBSS) (Gibco, Invitrogen, Leek, the Netherlands) at 37 oC followed by mechanical 
disruption by pipetting. Tumour cell suspensions were placed on a ficoll gradient (Lucron 
Bioproducts, Gennep, the Netherlands) to remove granulocytes, including potential mature 
granule rich neutrophils. Similarly, PBMCs were obtained from freshly obtained blood using 
a ficoll gradient.
Flowcytometry
PBMCs or tumour suspensions were washed twice with phosphate buffered saline (PBS) and stained with fixable viability dye eFluor 780 (eBioscience, San Diego, CA) for 30 min-
utes on ice. Subsequently, cells were washed twice in PBA (PBS containing 0.5% bovine 
serum albumin (Roche, Indianapolis, IN) and 0.01% sodium azide) with 2% human serum 
(Sanquin, Nijmegen, the Netherlands), and incubated with directly conjugated monoclo-
nal antibodies (mAbs) for 20 minutes on ice. mAbs were obtained from Becton, Dickinson 
and Company (BD, San Jose, CA) (CD33-APC, HLA-DR,DP,DQ-Fitc, CD15-PE-Cy-7, CD124-PE, 
CD80-PE-Cy7, CD86-PE-Cy7), Pelicluster (Amsterdam, the Netherlands)(CD14-PE), Milte-
nyi (Bergisch Glasbach, Germany)(CD14-PerCP), IO-Test (Beckman Coulter, Fullerton, CA) 
(CD11b-PE, CD40-PE) and Biolegend (San Diego, CA) (CD45-PerCP). Isotope controls were 
obtained from BD (IgG1-APC, IgG1-PE-Cy7, IgG2a-PE, IgG2a-Fitc, and IgG1-PE) and Bioleg-
end (IgM-PE-Cy7, IgG2a-PerCP). Cells were washed in PBS and fixed and resuspended in PBA 
and measured on a CyAn (Beckman Coulter) or Gallios (Beckman Coulter) flowcytometer. 
Data were analysed using FlowJo 9.2 where events were gated on single viable cells for 
further analysis.
Immunohistochemistry
Consecutive 4 µm histological sections of formalin-fixed paraffin-embedded tissue were subjected to hematoxylin and eosin (H&E) staining or immunohistochemistry double 
staining against CD15 (BD) and either HLA-DR,DP (Q5/13)(Quaranta, Walker et al. 1980) 
or CD34 (ImmunoLogic, Duiven, the Netherlands). For the immunohistochemistry staining, 
slides were deparaffinised and rehydrated using Xylol, alcohol and water successively. Heat-
induced epitope retrieval (HIER) was performed in TRIS/EDTA buffer pH 9,0 (Klinipath) for 10 
minutes in a microwave oven at 100 oC. Slides were treated with 3% H2O2 in PBS at room 
Page 76
4
temperature for 10 minutes. Slides were washed in PBS and stained with the anti-CD15 
antibody, diluted in Normal antibody Diluent (ImmunoLogic) and incubated for 1 hour at 
room temperature. Slides were subsequently washed with PBS and incubated with Poly-AP-
GAM/R/R IgG (Immunologic) for 30 minutes at room temperature before being detected 
with PermaRed/AP (ITK Diagnostics, Uithoorn, the Netherlands). Slides were washed with 
PBS and steps were repeated starting with HIER to stain with anti HLA-DR,DP (using the 
same secondary antibody) and detection of antibody with PermaBlue/AP (ITK Diagnostics). 
The slides were washed with water, dried, and mounted with Kaisers glycerine. Alterna-
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tively, similar double staining was performed, using anti-CD34 antibody (ImmunoLogic) as 
primary and Poly-HRP-GAM/R/R IgG as secondary staining, before detection with DAP, fol-
lowed by anti-CD15 staining using AP-GAM/R/R IgG before detection with PermaRed/AP. Af-
ter washing with PBS, the nuclei were stained with hematoxylin and the slides were washed 
with water, dried and mounted with Imsol (Klinipath, Duiven, the Netherlands).
Statistical analysis
Data is displayed in grouped column scatters, and statistical comparison between groups was performed using a One-way analysis of variance with a Tukey post-hoc test. Correla-
tion analysis were done in Graphpad Prism.
Results
Patient and tumour characteristics
Blood was obtained from 12 healthy individuals and 21 patients with glioma. Tumour ma-terial was obtained from 13 of these 21 patients. Patient and tumour characteristics are 
provided in table 1. Patient data were grouped based on the malignancy grade of the tu-
mour, as determined by neuropathologists of the Radboudumc according to the WHO 2007 
Classification of tumours of the Central Nervous System (Louis, Ohgaki et al. 2007). Eleven 
patients were diagnosed as having a WHO grade IV glial tumour (GBM, in one of the patients 
with a predominant gliosarcoma phenotype), 6 patients were diagnosed as having an ana-
plastic/WHO grade III glioma and 4 patients were diagnosed as having a low grade/WHO 
grade II glioma. PBMC yield was reduced for glioma patients compared to healthy controls, 
with no difference between the GBM and patients with lower grade glioma. 
Patients with a GBM have increased numbers of CD33+MHC-II- blood cells
The percentage of CD33+MHC-II- cells in PBMCs of patients with glioma and healthy con-trols were determined by flow cytometry. Subpopulations were further defined by CD14 
and CD15 expression. As shown in figure 1A, both CD14+CD33+MHC-II- cells (correspond-
ing to the phenotype of M-MDSCs) and CD15+CD33+MHC-II- cells (corresponding to the 
phenotype of PMN-MDSC) were readily detected in blood samples. Both these populations 
Figure 1. Increased number of cells with an MDSC phenotype in blood of patients with GBM. (A) Gating strategy 
for MDSCs. Freshly isolated PBMCs were stained as described, and single viable cells were plotted for CD33 and 
MHC-II expression (left top panel). CD33+MHC-II- cells were further plotted for CD14 and CD15 (right top panel). 
Three cell populations could be discriminated based on CD14 and CD15 expression; these were each plotted for 
CD11b (lower panels). The grey histograms represent isotype control from gated MDSCs (B, C, D, E). Percentages 
of cells with an MDSC (HC vs Grade II/III: p=0.38; HC vs GBM: p=0.0019; Grade II/III vs GBM: p=0.062) (B), PMN-
MDSC (HC vs Grade II/III: p=0.66; HC vs GBM: p=0.015; Grade II/III vs GBM: p=0.12) (C), M-MDSC (HC vs Grade II/
III: p=0.25; HC vs GBM: p=0.001; Grade II/III vs GBM: p=0.072) (D) or lineage negative CD14-CD15- MDSCs (HC vs 
Grade II/III: p=0.22; HC vs GBM: p=0.55; Grade II/III vs GBM: p=0.77). (E) Phenotype gated as for Figure 1A shown 
as a percentage of total PBMCs. Data points were displayed in grouped column scatters from healthy controls (black 
diamonds, n=12), patients with a grade II or III glioma (blue triangles, n=10) and patients with a GBM (red dots, 
n=11). Each point indicates a single individual and asterisks represent statistical significance (*:p<0.05, **:p<0.01; 
***:p<0.001). F: Percentage of PMN-MDSCs was plotted against percentage of M-MDSCs from all patients with a 
glioma. 
Page 78
4
express high levels of the myeloid marker CD11b, whereas the CD14-CD15- (lineage nega-
tive) CD33+MHC-II-population is CD11b-intermediate or CD11b-negative (figure 1A lower 
panels). 
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The total number of CD33+MHCII- cells was significantly increased within the PBMCs of 
patients with a GBM compared to PBMCs from healthy controls (p<0.01) (figure 1B). Within 
PBMCs of patients with a grade II or III tumour, the amount of CD33+MHC-II- cells was slight-
ly increased compared with that of healthy controls without reaching statistical significance. 
Further analysis revealed that both MDSC subpopulation phenotypes (i.e. PMN-MDSCs and 
M-MDSCs) were significantly increased in patients with GBM compared with healthy indi-
viduals (PMN-MDSC p<0.05; M-MDSC p<0.001) (figure 1C and D). In healthy donors, the 
percentage of cells with a PMN-MDSC and M-MDSC phenotype varied between 0.03 and 2.4 
percent and between 0 and10 percent of total PBMCs, respectively. In patients with a GBM, 
the PMN-MDSC increased up to 10 percent of the PBMCs (4.081 +/- 3.232 percent) (figure 
1C), whereas the M-MDSCs were increased up to 33 percent of PBMCs (12.71 +/- 8.904 
percent) (figure 1D). The specificity of these observations is underscored by the finding that 
the percentage of lineage negative CD33+MHC-II- cells detected in the blood was similar 
for all patient groups and healthy controls (figure 1E). For patients with a WHO grade II and 
grade III gliomas, we found no significant difference in the percentage of cells with a PMN-
MDSC phenotype relative to healthy controls. The percentage of M-MDSCs in these patients 
was slightly elevated compared to healthy controls; however, this difference did not reach 
statistical significance. Of note, there were differences in the duration of dexamethasone 
treatment between patients with a grade II/III glioma and some GBM patients before sam-
pling (see Supplementary figure 1. Finally, a weak but significant correlation between the 
percentage of the two MDSC populations was found upon analysis of blood results for all 
patients with glioma (p=0.0030 R2=0.3792) (Figure 1F). 
CD86, CD124 and CD40 are not increased on blood-MDSCs of patients with a glioma
To further characterize the CD33+MHC-II- cells in blood of patients with a glioma and healthy controls, we phenotyped these cells using the myeloid (activation) markers 
CD80, CD86, PD-L1, CD40 and CD124 (Figure 2A).
CD80 and PD-L1 expression were undetectable on CD33+MHC-II- cells of both healthy con-
trols and patients with a glioma (figure 2A; data not shown). Low levels of CD124 could be 
detected on a small population of CD33+MHC-II- cells of both healthy controls and patients 
with glioma (WHO grade II/III or GBM) (Figure 2A-C). Although the percentage CD124+ 
cells is somewhat reduced within CD33+MHC-II- cells of patients with GBM compared with 
healthy controls (figure 2B), the amounts of CD124+CD33+MHC-II- cells as a percentage of 
PBMCs are similar (figure 2C) because of the increase in CD33+MHC-II- cells in the blood of 
patients with GBM.
Both CD40 and CD86 expression were detected on CD33+MHC-II- cells of healthy controls 
Figure 2: Similar expression of myeloid markers on cells with an MDSC phenotype from patients and healthy 
controls. (A) Freshly isolated PBMCs from blood of patients with a glioma were stained as Figure 1A with addi-
tional markers (as indicated in the figure) analysed using flowcytometry. The grey histograms represent the isotype 
control from gated MDSCs. (B and D) Percentage of cells expressing CD124 (B) or CD40 (D) within total number of 
cells with an MDSC phenotype were plotted from healthy controls (black diamonds, n=11 and n=9 respectively), 
patients with a grade II or III glioma (blue triangles, n=7 and 6 respectively) and patients with a GBM (red dots, n=8 
and 9 respectively). Each point indicates a single individual. (C and E) Cells with an MDSC phenotype expressing 
CD124 (C) or CD40 (E) were plotted as percentage of PBMCs. (F) Cells with a PMN-MDSC, M-MDSC and lineage 
negative MDSC phenotype were plotted for the expression of CD86 or CD40 (representative image of 8 (CD40) and 
4 (CD86) samples). The grey histograms represent the isotype control from gated MDSCs.
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and patients with a glioma (figure 2A; data not shown). Much variation in CD40+ cells as 
percentage of CD33+MHC-II- cells was observed, and there were no significant differences 
between healthy donors and patients with glioma (figure 2D, E). Furthermore the level of 
CD40 expression (defined by mean fluorescence intensity (mfi)) on CD33+MHC-II- cells did 
not differ between healthy controls and patients with a glioma (data not shown). The num-
ber of CD40+CD33+MHC-II- cells as percentage of PBMCs was higher in patients with a GBM 
than in healthy controls due to an increased number of CD33+MHC-II- cells in these patients 
(figure 2E). Further analysis revealed that CD40 was mainly expressed by cells with an M-
MDSC phenotype (figure 2F). Nonetheless, low levels of CD40 expression were also found 
on cells with a PMN-MDSC and lineage negative MDSC phenotype (figure 2F). Analysis of 
CD86+ expression on CD33+MHC-II- cells was performed on a limited number of patients 
(n=4) but showed similar trends as CD40 expression (figure 2F; data not shown). 
Detection of cells with PMN-MDSC phenotype within tumour cell suspension
Our group previously reported the use of surgically obtained ultrasonic aspirates as a source of glioma material and showed that the results of Tregs analysis were compa-
rable in aspirated and resected tumour material (Jacobs, Idema et al. 2009). We now used 
Figure 3. Cells with a PMN-MDSC phenotype in glioma tissue. (A) Single cell suspensions from ultrasonic tumour 
tissue aspirates were stained and analysed. Single, viable cells were plotted for CD45 expression against the side-
ward scatter (SS) (left top panel). CD45+SSlow cells were plotted for CD3 (lower panel); the grey histogram repre-
sents the isotype control for the CD45+SSlow cells. Remaining CD45 cells were plotted for CD11b and MHC-II (top 
middle panel). CD11b+MHC-II- cells were plotted for CD15 (top right panel); the grey histogram represents the 
isotype control for the CD45+MHC-II- cells. (B) Percentage of CD45+CD11b+MHC-II- cells as a percentage of viable 
cells are plotted. Percentages in tumours from patients with grade II or III glioma are displayed as blue triangles. 
Percentages in tumours from patients with a GBM are displayed as red dots. Each point indicates a single patient. 
(C) Percentages of CD15+ cells within the CD45+CD11b+MHC-II- cells are plotted.
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brain tumour aspirates to study the infiltration of cells with an MDSC phenotype within 
tumours. Of note, before further analysis, the aspirated tumour fragments were thoroughly 
filtered and washed to discard blood and suction fluid. Using CD45 as an immune cell mark-
er, we identified two CD45+ populations (figure 3A). Cells with a low sideward scatter (SS) 
and high CD45 expression consisted mainly of CD3-positive T-cells (figure 3A left panels). 
The remaining CD45+ cells were analysed for the presence of MDSCs. Because CD33 did not 
show a signal above background on complete tumour cell suspensions, CD11b was used as 
a myeloid marker in combined with MHC-II. As expected, this staining revealed that most 
of the CD45+ cells exhibited the CD11blowMHC-II+ expression profile characteristic for mi-
croglia and/or infiltrating macrophages (figure 3A; supplementary figure 2). In addition, a 
population of CD11bhighMHC-II- cells was present in up to two percent of the total viable 
tumour cell suspension (figure 3A and B). Strikingly, tumours with the highest number of 
these cells were all GBMs (0.7023 +/- 0.6367), whereas in WHO grade II and III gliomas, only 
up to 0.4 percent (0.1713 +/- 0.1189) of the total number of viable cells consisted of CD11b-
highMHC-II- cells. Looking at the MDSC subpopulation expression markers, between 77 and 
99 percent of these cells consisted of CD15+ cells (figure 3C). These data show that the cells 
with an MDSC-like phenotype found in tumour material are almost exclusively CD15+. 
CD15+MHC-II- cells are present in viable tumour material
To determine the location of cells with a PMN-MDSC phenotype within the tumour, we performed double-staining immunohistochemistry for CD15 and MHC-II on paraffin em-
bedded tumour tissue sections of 11 glioma samples. H&E staining was used for histological 
assessment of regions of interest.
Immunohistochemistry double stainings revealed cells with bright CD15 staining (red/pink) 
with no or very low MHC-II staining (blue). These CD15+ cells were localized in necrotic 
tumour tissue (long arrowhead), in viable tumour tissue (arrow) and in the lumen of blood 
vessels (short arrowhead) (figure 4 A-D). Double staining with anti-CD15 antibody and en-
dothelial cell marker anti-CD34 antibody further proved that these cells were localized ex-
travascular within the tumour tissue (figure 4H). Although CD15 immunostaining might be 
expected to be mainly expressed on the cell surface, we often found the staining to cover 
the complete cell body, indicating intracellular presence of CD15 as well. This observation 
is in line with results of immunohistochemical anti-CD15 staining on glioma and colorectal 
cancer tissue samples shown by Sippel et al. and Jang et al., respectively (Sippel, White et al. 
2011; Jang, Park et al. 2013). Upon staining of histologically normal brain tissue (obtained 
by surgery for epilepsy), we could also detect CD15+ staining, but this staining was restricted 
to cells within (small) blood vessels (figure 4E&F). Thus, our data thus indicate that brain 
infiltrating CD15+ cells with no or low expression of MHC-II are increased in glioma tissue 
and rare or absent in normal brain tissue. 
Discussion
In this study, we analysed blood and tumour tissue of patients with glioma for the presence of two subsets of recently described immune cell populations: the M- and PMN-MDSCs. 
Our data demonstrate that cells with the M-MDSC phenotype and cells with the PMN-MDSC 
phenotype are significantly increased in blood of patients with GBM versus healthy controls. 
Page 82
4
Figure 4. CD15+ cells are present in viable and necrotic glioma tissue. Four micrometre-thick sections of glioma 
(A-D & G-H) or control brain (E-F) were subjected to H&E staining (A,C,E,G), immunohistochemistry double stain-
ings with anti-CD15 and anti-HLA-DR,DP antibodies (B,D,F) or triple stained with anti-CD15 antibody, anti-CD34 an-
tibody, and hematoxylin (H). Three symbols are used to highlight some CD15+MHC-II- cells. Short arrowhead marks 
cells in blood vessels; arrow marks cells in viable tumour and long arrowhead marks cells in necrotic tissue. Original 
magnifications are x100 (A & B) and x200 (C-H). (Shown are 2 representative examples of 9 GBM donors examined).
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Cells with the M-MDSCs phenotype were the most abundant MDSC subpopulation in the 
blood, whereas cells with the PMN-MDSC phenotype represented the dominant population 
in glioma tissue. 
MDSC populations are increased in the blood of patients with various tumours, and their 
presence is associated with immunosuppression (Lindau, Gielen et al. 2013; Solito, Marigo et 
al. 2014). These studies have defined up to 6 MDSC populations, using different criteria and 
markers (Walter, Weinschenk et al. 2012; Lindau, Gielen et al. 2013). However, the definitive 
‘taxonomy’ of different (sub)populations of MDSCs remains to be established. Meanwhile, 
based on CD15 and CD14 expression, within the group of cells with a CD33+CD11b+MHC-
II- phenotype, three populations can be distinguished: PMN-MDSCs, M-MDSCs and line-
age- MDSCs. The distribution of PMN-MDSCs and M-MDSCs differs with tumour type (i.e. 
M-MDSCs were reported to be increased in blood of patients with melanoma and hepato-
cellular carcinoma, whereas enrichment of PMN-MDSCs was found in blood of patients with 
renal cell and breast carcinoma) (Filipazzi, Valenti et al. 2007; Hoechst, Ormandy et al. 2008; 
Diaz-Montero, Salem et al. 2009). We report an increase in cells with the PMN-MDSCs and 
cells with the M-MDSC phenotype in blood of patients with GBM, while the number of line-
age- MDSCs remained constant. An increase in cells with the PMN-MDSC phenotype in the 
blood of GBM patients was also reported by Sippel et al. and Raychaudhuri et al. (Raychaud-
huri, Rayman et al. 2011; Sippel, White et al. 2011). However, they either did not analyse 
the M-MDSC subpopulation or reported no effects on cells with the M-MDSC phenotype. 
Another study also did not find an increase in M-MDSCs defined as CD124+CD14+HLA-DR- 
cells, whereas the study of Gustafson did find an increase in M-MDSC defined as CD14+HLA-
DR- cells (Gustafson, Lin et al. 2010; Kohanbash, McKaveney et al. 2013). Neither of the 
latter two studies determined PMN-MDSCs in their patients with GBM. The reason for the 
discrepancies reported for M-MDSCs in blood of patients with GBM may be related to the 
patient populations studied, the source and processing of the PBMCs, and the antibody 
cocktails used (Brandau, Moses et al. 2013). Because it has been shown that MDSC popula-
tions can be affected by cryopreservation (Kotsakis, Harasymczuk et al. 2012; Duffy, Zhao et 
al. 2013), we used freshly isolated PBMCs in our analyses. 
In our study, we found a significant increase cells with an MDSC phenotype, especially in 
patients with GBM. Gustafson et al. also observed an increase of cells with the M-MDSC 
phenotype (CD14+HLA-DR-) in the blood of patients with GBM, but only when patients also 
received dexamethasone (Gustafson, Lin et al. 2010). Patients included in our study were all 
treated with dexamethasone at least one day before sample collection, but some patients 
received dexamethasone for a longer period of time to reduce edema. In our study, an in-
creased number of (both subpopulations of) MDSCs in blood was especially found in patients 
with GBM who received dexamethasone for a longer period (supplementary figures 1A-C). 
One possible explanation is that patients with large tumour volume have more MDSCs in 
their blood and also require dexamethasone treatment for a longer period because of the 
relatively large tumour volume. Alternatively, dexamethasone (alone or in combination with 
the tumour) could cause the observed increase in number of cells with an MDSC phenotype. 
Indeed, dexamethasone has multiple and diverse effects on immune cells, and initial studies 
indicated that dexamethasone-mediated immune effects may be altered in cancer patients 
(Gustafson, Lin et al. 2010; Dietrich, Rao et al. 2011). The role of dexamethasone on MDSCs 
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in the murine system is also disputed (i.e. both an increase and decrease in number and 
activation of MDSCs attributable to dexamethasone have been described) (Varga, Ehrchen 
et al. 2008; Moon, Ryu et al. 2014). Obviously, understanding the role of dexamethasone on 
MDSCs in glioma requires a significant numbers of patients as well as suitable control sam-
ples. Furthermore, it will be essential to evaluate the impact of dexamethasone on myeloid 
regulatory cell prevalence and function in future studies.
MDSCs are generally defined in blood samples from (tumour) patients and healthy individu-
als, and relatively little is known regarding their presence in human tumour tissue. We were 
able to generate fresh tumour cell suspensions from a number of patients for analysis of 
immune-infiltrating cells. Interestingly, we were able to detect cells with an MDSC pheno-
type that almost exclusively also expressed the PMN-MDSCs identifier CD15. Comparing 
MDSC percentages in blood and tumour tissue within the same patients, we did not find a 
significant correlation, indicating that the number of MDSCs detected in blood not necessar-
ily reflects the number of such cells within the tumour. A very recent paper by Raychaudhuri 
et al. supports our finding that PMN-MDSCs are predominant over M-MDSCs, however, the 
PMN-MDSC percentages they report are somewhat higher, but this might have been caused 
by differences in the Ficoll separation step to exclude mature neutrophils (Raychaudhuri, 
Rayman et al. 2015). Immunohistochemistry revealed that the CD15+ cells found in the tu-
mour were localized in both viable and necrotic tumour areas. Sippel et al. also showed in-
filtration of CD15+ cells in GBM tissue, mainly in areas of acute necrosis (Sippel, White et al. 
2011). Because of the lack of one discriminating marker, it is not possible to identify MDSCs 
directly by immunohistochemistry. Kohanbash and colleagues described glioma infiltrating 
MDSCs defined as CD124+CD14+HLA-DR- cells by flowcytometry (Kohanbash, McKaveney 
et al. 2013). These cells were not increased in blood of these glioma patients. We analysed 
5 tumour-derived cell suspensions for CD124 (supplementary figure 3). In three of these 
samples, a CD124+MHC-II- population was found. This population was mainly CD15+, simi-
lar to the CD11b+MHC-II- cells we identified in the tumour tissue. Unfortunately, co-stain-
ing of CD124 with either CD11b or CD14 was not possible because of staining limitations. 
However, when CD124+MHC-II- cells were present, their percentage within the tumour was 
similar or lower than the percentage of CD11b+MHC-II- cells, indicating that the former 
cells may be a subpopulation of the latter. In addition, in some of the latter tumour samples 
we combined CD14 and CD15 stainings and found that there were hardly any CD14+CD15- 
cells within the CD11b+MHC-II- population, whereas CD15+ cells could express low levels of 
CD14. Whether these cells are similar to the ones described by Kohanbash and colleagues, 
or whether CD124 renders these cell more immunosuppressive remains to be elucidated. In 
addition, it is not clear why we found almost exclusively cells with a PMN-MDSC phenotype 
in tumour tissue, whereas both PMN- and M-MDSCs are increased in the blood of patients 
with GBM. We hypothesize that cells with an M-MDSC phenotype either do not infiltrate 
the tumour or change their phenotype after infiltration. Prosniak et al. described infiltration 
of monocytic cells or macrophages in glioma (Prosniak, Harshyne et al. 2013). Indeed, the 
MHC-II+ (and thus non-MDSC) cells within the CD45+ population found in the tumour tissue 
expressed CD14 and may correspond with those described by Prosniak et al.
In conclusion, this study reports an increase of cells with the M- and cells with the PMN-
MDSC phenotype in the blood of patients with a GBM, whereas in tumour cell suspensions, 
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the MDSC population consisted almost exclusively of CD15+ cells. Acknowledging the im-
munosuppressive effect of MDSCs, we find that longitudinal monitoring of composition of 
these cells in blood sample from patients with glioma may be highly rewarding, particularly 
when considering immunotherapy.
Acknowledgements
We thank all the patients and healthy volunteers participating in this research. We thank Dr. 
Erkan Kurt, Dr. Alfred Koetsveld, Prof. Dr. André Grotenhuis and Dr. Hans Delye (neurosur-
geons from the Radboudumc) for their collaboration. 
References
Brandau, S., K. Moses, et al. (2013). “The kinship of neutrophils and granulocytic myeloid-derived suppressor cells 
in cancer: cousins, siblings or twins?” Semin Cancer Biol 23(3): 171-182.
Carson, M. J., J. M. Doose, et al. (2006). “CNS immune privilege: hiding in plain sight.” Immunological reviews 213: 
48-65.
Couzin-Frankel, J. (2013). “Breakthrough of the year 2013. Cancer immunotherapy.” Science 342(6165): 1432-1433.
Diaz-Montero, C. M., M. L. Salem, et al. (2009). “Increased circulating myeloid-derived suppressor cells correlate 
with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.” Can-
cer immunology, immunotherapy : CII 58(1): 49-59.
Dietrich, J., K. Rao, et al. (2011). “Corticosteroids in brain cancer patients: benefits and pitfalls.” Expert Rev Clin 
Pharmacol 4(2): 233-242.
Duffy, A., F. Zhao, et al. (2013). “Comparative analysis of monocytic and granulocytic myeloid-derived suppressor 
cell subsets in patients with gastrointestinal malignancies.” Cancer immunology, immunotherapy : CII 62(2): 
299-307.
Fecci, P. E., D. A. Mitchell, et al. (2006). “Increased regulatory T-cell fraction amidst a diminished CD4 compartment 
explains cellular immune defects in patients with malignant glioma.” Cancer research 66(6): 3294-3302.
Filipazzi, P., R. Valenti, et al. (2007). “Identification of a new subset of myeloid suppressor cells in peripheral blood 
of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitu-
mor vaccine.” J Clin Oncol 25(18): 2546-2553.
Finocchiaro, G. and S. Pellegatta (2011). “Immunotherapy for glioma: getting closer to the clinical arena?” Curr Opin 
Neurol 24(6): 641-647.
Gabitass, R. F., N. E. Annels, et al. (2011). “Elevated myeloid-derived suppressor cells in pancreatic, esophageal and 
gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 
cytokine interleukin-13.” Cancer immunology, immunotherapy : CII 60(10): 1419-1430.
Gielen, P., P. van der Valk, et al. (2014). Immune Responses to Tumours in the CNS. Neuroinflammation and CNS 
Disorders, John Wiley & Sons, Ltd: 363-384.
Gousias, K., M. Markou, et al. (2010). “Frequent abnormalities of the immune system in gliomas and correlation 
with the WHO grading system of malignancy.” J Neuroimmunol 226(1-2): 136-142.
Grauer, O. M., P. Wesseling, et al. (2009). “Immunotherapy of diffuse gliomas: biological background, current status 
and future developments.” Brain Pathol 19(4): 674-693.
Gustafson, M. P., Y. Lin, et al. (2010). “Systemic immune suppression in glioblastoma: the interplay between 
CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.” Neuro-oncology 12(7): 631-644.
Hanahan, D. and R. A. Weinberg (2011). “Hallmarks of cancer: the next generation.” Cell 144(5): 646-674.
Heimberger, A. B., M. Abou-Ghazal, et al. (2008). “Incidence and prognostic impact of FoxP3+ regulatory T cells in 
human gliomas.” Clinical cancer research : an official journal of the American Association for Cancer Research 
14(16): 5166-5172.
Hoechst, B., L. A. Ormandy, et al. (2008). “A new population of myeloid-derived suppressor cells in hepatocellular 
carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.” Gastroenterology 135(1): 234-243.
Jacobs, J. F., A. J. Idema, et al. (2010). “Prognostic significance and mechanism of Treg infiltration in human brain 
tumors.” J Neuroimmunol 225(1-2): 195-199.
Jacobs, J. F., A. J. Idema, et al. (2009). “Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppres-
sion in malignant human brain tumors.” Neuro-oncology 11(4): 394-402.
Jang, T. J., J. B. Park, et al. (2013). “The Expression of CD10 and CD15 Is Progressively Increased during Colorectal 
Page 86
4
Cancer Development.” Korean J Pathol 47(4): 340-347.
Kohanbash, G., K. McKaveney, et al. (2013). “GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrat-
ing Myeloid Cells through Interleukin-4 Receptor-alpha.” Cancer research 73(21): 6413-6423.
Kotsakis, A., M. Harasymczuk, et al. (2012). “Myeloid-derived suppressor cell measurements in fresh and cryopre-
served blood samples.” Journal of immunological methods 381(1-2): 14-22.
Lindau, D., P. Gielen, et al. (2013). “The immunosuppressive tumour network: myeloid-derived suppressor cells, 
regulatory T cells and natural killer T cells.” Immunology 138(2): 105-115.
Louis, D. N., H. Ohgaki, et al. (2007). WHO Classification of Tumours of the Central Nervous System. Lyon, Interna-
tional Agency for Research on Cancer.
Mandruzzato, S., S. Solito, et al. (2009). “IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.” 
Journal of immunology 182(10): 6562-6568.
Marsh, J. C., J. Goldfarb, et al. (2013). “Current status of immunotherapy and gene therapy for high-grade gliomas.” 
Cancer control : journal of the Moffitt Cancer Center 20(1): 43-48.
Moon, E. Y., Y. K. Ryu, et al. (2014). “Dexamethasone inhibits in vivo tumor growth by the alteration of bone marrow 
CD11b(+) myeloid cells.” Int Immunopharmacol 21(2): 494-500.
Movahedi, K., M. Guilliams, et al. (2008). “Identification of discrete tumor-induced myeloid-derived suppressor cell 
subpopulations with distinct T cell-suppressive activity.” Blood 111(8): 4233-4244.
Pan, P. Y., G. Ma, et al. (2010). “Immune stimulatory receptor CD40 is required for T-cell suppression and T regula-
tory cell activation mediated by myeloid-derived suppressor cells in cancer.” Cancer research 70(1): 99-108.
Poschke, I., D. Mougiakakos, et al. (2010). “Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma 
patients are Stat3hi and overexpress CD80, CD83, and DC-sign.” Cancer research 70(11): 4335-4345.
Prosniak, M., L. A. Harshyne, et al. (2013). “Glioma grade is associated with the accumulation and activity of cells 
bearing M2 monocyte markers.” Clinical cancer research : an official journal of the American Association for 
Cancer Research 19(14): 3776-3786.
Quaranta, V., L. E. Walker, et al. (1980). “Purification of immunologically functional subsets of human Ia-like anti-
gens on a monoclonal antibody (Q5/13) immunoadsorbent.” Journal of immunology 125(4): 1421-1425.
Raychaudhuri, B., P. Rayman, et al. (2015). “Myeloid derived suppressor cell infiltration of murine and human glio-
mas is associated with reduction of tumor infiltrating lymphocytes.” J Neurooncol.
Raychaudhuri, B., P. Rayman, et al. (2011). “Myeloid-derived suppressor cell accumulation and function in patients 
with newly diagnosed glioblastoma.” Neuro-oncology 13(6): 591-599.
Sippel, T. R., J. White, et al. (2011). “Neutrophil degranulation and immunosuppression in patients with GBM: res-
toration of cellular immune function by targeting arginase I.” Clinical cancer research : an official journal of the 
American Association for Cancer Research 17(22): 6992-7002.
Solito, S., I. Marigo, et al. (2014). “Myeloid-derived suppressor cell heterogeneity in human cancers.” Annals of the 
New York Academy of Sciences 1319(1): 47-65.
Varga, G., J. Ehrchen, et al. (2008). “Glucocorticoids induce an activated, anti-inflammatory monocyte subset in 
mice that resembles myeloid-derived suppressor cells.” Journal of leukocyte biology 84(3): 644-650.
Walter, S., T. Weinschenk, et al. (2012). “Multipeptide immune response to cancer vaccine IMA901 after single-
dose cyclophosphamide associates with longer patient survival.” Nature medicine 18(8): 1254-1261.
Yang, R., Z. Cai, et al. (2006). “CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ 
myeloid cells.” Cancer research 66(13): 6807-6815.
Youn, J. I., S. Nagaraj, et al. (2008). “Subsets of myeloid-derived suppressor cells in tumor-bearing mice.” Journal of 
immunology 181(8): 5791-5802.
Zhang, B., Z. Wang, et al. (2013). “Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients 
with colorectal carcinoma.” PLoS One 8(2): e57114.
Page 87
4
Supplementary figures
Supplementary figure 1. Patients with increased MDSCs often had prolonged Dexamethasone treatment. The 
number of days of dexamethasone treatment before surgery was plotted against the percentage of total MDSCs 
(A), M-MDSCs (B) or PMN-MDSCs (C). Each point indicates a single individual. Percentages of MDSCs from patients 
with a grade II or III glioma are displayed as triangles. Percentages of MDSCs from patients with a GBM are dis-
played as circles.
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Supplementary figure 2 (providing more detailed information compared to fig. 3). CD11b+MHC-II- are the only 
CD15+ cells in the tumour. Gated populations were plotted for CD15 and CD11b. In the plots expression of indi-
cated markers is shown by the black line, isotype control is in grey.
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Supplementary figure 3. CD124+ MDSCs in tumour cell suspension. Single cell suspensions from ultrasonic tu-
mour tissue aspirates were stained and analysed using flowcytometry as described in Materials and Methods. 
Single, viable cells were gated for CD45 expression as shown in figure 3 and supplementary figure 2. CD45+ cells are 
plotted for CD124 and MHC-II, revealing a small CD124+MHC-II- population in 3 of these patients. These popula-
tions are plotted for CD15 expression (right panels).
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Elevated levels of PMN-MDSCs in patients 
with GBM highly express S100A8/9 and argi-
nase and suppress T cell function
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Abstract
Gliomas are primary brain tumours that and associated with a poor prognosis. The introduction of new treatment modalities (including immunotherapy) for these neo-
plasms in the last three decades has resulted in only limited improvement in survival. 
Gliomas are known to create an immunosuppressive microenvironment that hampers the 
efficacy of (immuno)therapy. One component of this immunosuppressive environment 
is the myeloid derived suppressor cell (MDSC). We set out to analyse the presence and 
activation state of MDSCs in blood (n=41) and tumour (n=20) of glioma patients by meas-
uring S100A8/9 and arginase using flow cytometry and qPCR. Inhibition of T cell prolifera-
tion and cytokine production after stimulation with anti-CD3/anti-CD28 coated beads was 
used to measure in vitro MDSC suppression capacity. We report a trend toward a tumour 
grade-dependent increase of both monocytic (M-) and polymorphonuclear (PMN-) MDSC 
subpopulations in the blood of patients with glioma. M-MDSCs of glioma patients have 
increased levels of intracellular S100A8/9 compared to the M-MDSCs in healthy controls 
(HCs). Glioma patients also have increased S100A8/9 serum levels, which correlates with 
increased arginase activity in serum. PMN-MDSCs in both blood and tumour tissue dem-
onstrated highly expressed arginase. Furthermore, we assessed blood-derived PMN-MD-
SC function and showed that these cells have potent T cell suppressive function in vitro. 
These data indicate a tumour grade dependent increase of MDSCs in the blood of patients 
with a glioma. These MDSCs exhibit an increased activation state compared with MDSCs 
in HCs, independent of tumour grade. 
Introduction
Glioblastomas (GBMs) are the most malignant primary brain tumours. Despite multimod-al treatment including surgical resection, irradiation and chemotherapy, median surviv-
al is about 14.5 months (Stupp, Hegi et al. 2009; Johnson and O’Neill 2012). Immunotherapy 
offers the opportunity to specifically target residual tumour cells without damaging healthy 
neighbouring brain cells (Grauer, Wesseling et al. 2009). Multiple immunotherapeutic treat-
ment strategies have been exploited to treat glioma patients (Finocchiaro and Pellegatta 
2011). Data from phase 1 and 2 trials suggests that immunotherapy can result in a mean-
ingful and sometimes durable response for GBM patients. So far, however, immunological 
responses could only be measured in a limited number of patients (as reviewed in (Grauer, 
Wesseling et al. 2009; Wheeler and Black 2011; Wang, Zhao et al. 2014)). Probably, the oc-
currence of limited responses in patients is the result of an immunosuppressive network 
implemented by the tumour (Grauer, Wesseling et al. 2009; Hanahan and Weinberg 2011; 
Jackson, Ruzevick et al. 2011; Lindau, Gielen et al. 2013).
We and others have previously described the presence and suppressive activity of regula-
tory T cells within glioma (Fecci, Mitchell et al. 2006; Jacobs, Idema et al. 2009; Jacobs, 
Idema et al. 2010). More recently, the increase of cells with a myeloid-derived suppres-
sor cell (MDSC) phenotype (CD33+MHC-II-), both the monocytic (M-)(Gielen, Schulte et al. 
2015) and polymorphonuclear (PMN-) MDSCs (Raychaudhuri, Rayman et al. 2011; Gielen, 
Schulte et al. 2015) subpopulations has been described. Additionally, MDSCs within tumour 
tissue have been described, however, the findings are not consistent and additional data 
is required (Kohanbash, McKaveney et al. 2013; Gielen, Schulte et al. 2015; Raychaudhuri, 
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Rayman et al. 2015). Therefore, it is unknown if MDSC numbers in blood are correlated with 
MDSC numbers within the tumour.
We have previously reported the expression of various myeloid markers on MDSCs of 
healthy controls (HCs) and of patients with glioma (Gielen, Schulte et al. 2015). Additionally, 
there are intracellular markers that are important for MDSC development, recruitment and 
activation. One of these factors is heterodimer S100A8/9 (calprotectin)(Cheng, Corzo et al. 
2008; Ramachandran, Martner et al. 2013). S100A8/9 can be expressed by various myeloid 
cells and tumour cells, including glioma, where it can promote tumour cell growth and mi-
gration at low concentrations (5 or 10 µg/ml) or apoptosis at high concentration (Ghavami, 
Rashedi et al. 2008; Ehrchen, Sunderkotter et al. 2009; Vogl, Gharibyan et al. 2012). 
 MDSCs can suppress T cell function by several mechanisms (as reviewed elsewhere (Lindau, 
Gielen et al. 2013)), with the expression of arginase being the most frequently investigated 
mechanism. Arginase acts by decreasing the level of L-arginine, an amino acid critical for the 
re-expression of the T-cell co-receptor CD3zeta and thereby T cell function (Rodriguez, Zea 
et al. 2002). The activation status of MDSCs may therefore be an important prognostic factor 
for response to immunotherapy. Furthermore, interference with MDSC presence of function 
may enhance immune-mediated tumour cell killing.
Here we studied MDSC prevalence and expression of S100A8/9 and arginase in blood, se-
rum and tumour tissue of glioma patients. In addition, we determined the immunosuppres-
sive capacity of MDSCs from glioma patients. Further elucidation of such glioma-initiated 
suppressive mechanisms will be important for improving the efficacy of immunotherapeutic 
protocols.
Materials and Methods
Blood and tumour samples
Peripheral blood samples were collected from 17 healthy individuals and 41 patients un-dergoing neurosurgical resection or biopsy for intracranial tumours at the Radboud Uni-
versity Medical Center, Nijmegen, The Netherlands (Radboudumc). All patients had histolog-
ically proven brain tumours diagnosed by neuropathologists of the Radboudumc according 
to the WHO 2007 Classification of tumours of the Central Nervous System (Louis, Ohgaki 
et al. 2007). The brain tumours consisted of 8 WHO grade II gliomas (astrocytoma n=2, 
oligodendroglioma n=2, oligo-astrocytoma n=2, ependymoma n=1, glioma not otherwise 
specified n=1), 13 WHO grade III tumours (anaplastic astrocytoma n=2, anaplastic oligo-
dendroglioma n=8, anaplastic oligoastrocytoma n=2, anaplastic ganglioglioma n=1) and 20 
WHO grade IV tumours (glioblastoma n=18, gliosarcoma n=2). Tumour tissue samples were 
obtained from 21 patients. Donor characteristics can be found in table 1. Most patients had 
started a 3x 5mg dexamethasone regime on the day before surgery, while other patients 
received dexamethasone at an earlier time point to reduce edema. All donors signed an 
informed consent that allowed for further use of tumour tissue and relevant clinical data for 
research purposes and the study was approved by our Institutional Review Board. Immedi-
ately after the blood and fresh tumour tissue samples were obtained, processing of these 
samples was started. Flow cytometry measurements were performed within 24 hours.
Page 94
5
Tissue handling
Fresh brain tumour material was obtained by excision and by ultrasonic aspiration. Tu-mour cell suspensions were prepared as described previously (Jacobs, Idema et al. 2009). 
Briefly, tumour fragments were filtered, washed and incubated with collagenase type-IA (50 
µg/ml) (Sigma-Aldrich, St Louis, MO), DNAse type-I (10 μg/ml) (Roche, Mannheim, Germa-
ny) and trypsin inhibitor (1 μg/ml) (Sigma) in Hank’s Balanced Salt Solution (HBSS) (Gibco, 
Invitrogen, Leek, the Netherlands) at 37 oC followed by mechanical disruption. Tumour cell 
suspensions were placed on a ficoll gradient (Lucron Bioproducts, Gennep, the Netherlands) 
to remove death cells and potential mature granule rich neutrophils. Similarly, a Ficoll gradi-
ent was used to obtain peripheral blood mononuclear cells (PBMCs) from freshly obtained 
blood, where samples from the HCs and the patients with glioma were processed abreast 
when possible.
Prior to FACS sorting or cytospins, tumour samples were enridged for immune cells (CD45) 
or myeloid cells (CD11b) by MACS sorting. Samples were blocked using Fc receptors (FcR)-
block (Miltenyi 120-000-442). For CD11b selection, cells were stained in MACS buffer with 
directly APC conjugated antibodies against CD11b (Beckman Coulter, IO-Test, Fullerton, CA). 
Cells were washed with MACS buffer (PBS containing 1% Bovine serum albumin and 2 mM 
EDTA). Cells were incubated with either anti-APC beads (Miltenyi 130-090-855) or anti-CD45 
coated beads (Miltenyi 130-090-855) for 20 minutes and washed with MACS buffer. MACS 
isolation was performed according to manufacturer’s instructions using a LS MACS column 
(Miltenyi 130-042-401). Immune cell enridged cell suspensions were used for facs sorting as 
described below or were used to produce cytospins. Cytospin preparations were fixed with 
4% PFA before and stored at 4oC until immunohistochemistry.
Fluorescent-activated cell sorting analysis and sorting
PBMCs or single cell tumour tissue suspensions were stained with fixable viability dye eFluor 780 (eBioscience, Vienna, Austria). After washing, cells were stained with directly 
conjugated monoclonal antibodies (mAbs) for 20 minutes on ice. Directly fluorescent con-
jugated mAbs were obtained from Becton, Dickinson and Company (BD) Biosciences (San 
Jose, CA) (CD33-APC, HLA-DR,DP,DQ-Fitc, CD15-PE-Cy-7 (tumour)), Pelicluster (Amsterdam, 
the Netherlands) (CD14-PE), Miltenyi (Bergisch Glasbach, Germany)(CD14-PerCP), Beckman 
 HC Grade II Grade III Grade IV
# blood samples 17 8 13 20
# tumour samples N/A 5 6 10
average age +/- Standard devia-
tion
40.9 +/- 15.2 41.4 +/- 16.3 46.6 +/- 8.4 61.1 +/-7.3
male 11 6 10 8
female 6 2 3 12
# patients with >1 day Dex 
treatment before surgery
N/A 1 2 14
Table 1. Donor characteristics. HC: Healthy Control; Dex: Dexamethasone; N/A: not applicable
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Coulter (IO-Test, Fullerton, CA) (CD11b-APC) and Biolegend (San Diego, CA)(CD45-PerCP, 
CD15-PE-Cy7 (blood)). Isotype controls were obtained from BD (IgG1-APC, IgG1-PE-Cy7, 
IgG2a-PE, IgG2a-Fitc, and IgG1-PE) and Biolegend (IgM-PE-Cy7, IgG2a-PerCP). Cells were 
washed and fixed and permeabilised according to manufacturer’s instructions (eBioscience 
00-5523-00). Intracellular staining was performed with S100A8/9 (Hycult, Uden, the Neth-
erlands) followed by anti-IgG-A563 (Life Technologies, Merelbeke, Belgium) staining. Cells 
were resuspended in PBA and measured on a CyAn (Beckman Coulter) or Gallios (Beckman 
Coulter) flow cytometer. Data was analysed using FlowJo 9.2 where events were gated on 
single viable cells for further analysis. For sorting from PBMCs, cells were stained with HLA-
DR,DP,DQ-Fitc, CD33-APC, CD14-PE and CD15-PE-Cy7 without fixing and sorted on a FACS 
Aria (BD). For sorting from CD45 enridged immune cell suspension, cells were stained with 
HLA-DR,DP,DQ-Fitc, CD45-PerCP, CD11b-APC, and CD15-PE-Cy7 without fixing and sorted on 
a FACS Aria (BD)
Quantitative Polymerase Chain Reaction
PBMCs, FACS sorted cells or single cells of tumour tissue suspension were pelleted and re-suspended in RNA lysis buffer (Zymo Research, Orange, CA) and stored at -80oC till further 
use. RNA isolations were performed using the ZR RNA isolation kit (Zymo Research) accord-
ing to manufacturer’s instructions. Remaining DNA was removed using DNAse I (amplifica-
tion grade; Invitrogen, Breda, the Netherlands). cDNA was synthesized as described else-
where (Schulte, Kers-Rebel et al. 2013). Briefly, cDNA synthesis from RNA was performed by 
reverse transcriptase using random hexamers and Moloney murine leukemia virus reverse 
transcriptase (Invitrogen). To exclude genomic DNA contamination we included a “-RT” con-
trol in which the reverse transcriptase was replaced with RNase-free water. cDNA was stored 
at -20°C until further use. cDNA amplification of genes of interest was measured by SYBR 
Green (Applied Biosystems, 
Bleiswijk, the Netherlands) 
using a Biorad (Hercules, 
CA) CFX apparatus. Primers 
(Sigma) sequences originat-
ed from the Harvard Primer 
Bank database (Mandru-
zzato, Solito et al. 2009) 
and can be found in table 
2. Data were normalized 
against porphobilinogen 
deaminase (PBGD) or hy-
poxanthine phosphoribosyl 
transferase (HPRT) expres-
sion for blood or tumour, 
respectively, because HPRT 
has been found to be a rep-
resentative gene in tumour 
tissue (de Kok, Roelofs et al. 
2005).
Arginase Fw primer CCCTGGGGAACACTACATTTTG
Arginase Rv primer GCCAATTCCTAGTCTGTCCACTT
S100A8 Fw primer AAGGGGAATTTCCATGCCGT
S100A8 Rv primer TGCCACGCCCATCTTTATCA
S100A9 Fw primer GGAATTCAAAGAGCTGGTGCG
S100A9 Rv primer AGCTGCTTGTCTGCATTTGTG
PBGD Fw Primer GGCAATGCGGCTGCAA
PBGD Rv primer GGGTACCCACGCGAATCAC
HPRT Fw primer TGACACTGGCAAAACAATGCA
HPRT Rv primer GGTCCTTTTCACCAGCAAGCT
Table 2. Primers. Fw: forward primer; Rv: reverse primer
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Immunohistochemistry (IHC)
Consecutive 4 µm histological sections of formalin-fixed paraffin-embedded tissue were subjected to immunohistochemistry double staining against CD15 (BD) and Arg-1 (Hy-
cult HM2162). For the immunohistochemistry staining, slides were deparaffinised and re-
hydrated using Xylol, alcohol and water successively. Heat-induced epitope retrieval (HIER) 
was performed in TRIS/EDTA buffer pH 9,0 (Klinipath) for 10 minutes in a microwave oven 
at 100 oC. Slides were treated with 3% H2O2 in PBS at room temperature for 10 minutes. 
Slides were washed in PBS and stained with the anti-CD15 antibody (BD), diluted in Normal 
antibody Diluent (ImmunoLogic) and incubated for 1 hour at room temperature. Slides were 
subsequently washed with PBS and incubated with Poly-AP-GAM/R/R IgG (Immunologic) 
for 30 minutes at room temperature prior to detection with PermaRed/AP (ITK Diagnostics, 
Uithoorn, the Netherlands). Slides were then washed with PBS and steps were repeated 
starting with HIER to stain with anti Arg-1 (Hycult HM2162), using the same secondary an-
tibody, and detection of antibody with PermaBlue/AP (ITK Diagnostics). The slides were 
washed with water, dried and mounted with Kaisers Glycerine.
Similarly, cytospins were stained after HIER with primary antibodies against CD15 (BD) or 
CD14 (Cell Marque, Rocklin, CA). Appropriate biotinylated secondary antibodies were used 
for detection using the Avidine Biotin Complex method (Vector Laboratories). Nuclei were 
stained using 3,3’-diaminobenzidine.
Suppression assay
PBMCs were depleted for either CD15+ or CD20+ cells by magnetic-activated cell sorting (MACS). Fc receptors (FcR) on PBMCs were blocked with FcR-block (Miltenyi 120-000-
442) and cells were stained in MACS buffer with directly FITC conjugated antibodies against 
either CD15 (Miltenyi 130-081-101) or CD20 (BD 345792). Cells were washed with MACS 
buffer (PBS containing 0.5% Bovine serum albumin and 2 mM EDTA. Cells were incubated 
with anti-FITC beads (Miltenyi 130-048-701) for 20 minutes and washed with MACS buffer. 
MACS isolation was performed according to manufacturer’s instructions using a LS MACS 
column (Miltenyi 130-042-401). Purity of isolated cells and depleted PBMCs was checked 
using flow cytometry analysis. Total PBMCs or depleted PBMCs were placed in a 96 wells 
plate in IMDM with 2% human serum. Cells were activated with anti-CD3/anti-28 conju-
gated dynabeads (Gibco 11131D) in concentrations 1:1 and 1:4 (beads:PBMCs) and isolated 
cells were added (1:1, 1:2 or 1:4 (isolated cells:PBMCs)). Supernatant was collected after 60 
hours, proliferation was measured by tritium incorporation after 4 days as described before 
(Schulte, Gielen et al. 2015).
Enzyme-linked Immunosorbent Assay
IFN-γ was determined by Enzyme-linked Immunosorbent Assay (ELISA) (coating antibody: Thermo Scientific (Rockford, IL) M700A; detection antibody: Thermo scientific M701B; 
horseradish peroxidase conjugated streptavidin: Life Technologies S911) using recombinant 
IFN-γ as a reference (Thermo scientific RIFNG50). Absorbance was measured on a BioRad 
iMark microplate reader.
S100A8/9 and Arginase activity was measured in serum of the samples mentioned above 
Page 97
5
and seven additional serum samples obtained from patients with glioma (1 WHO grade II 
glioma; 1 WHO grade II glioma and 5 WHO grade IV gliomas). S100A8/9 was measured using 
the calprotectin human ELISA kit (Hycult) according to the manufacturer’s instructions. Argi-
nase activity was measured using a QuantiChromTM Arginase Assay kit (BioAssay Systems) 
according to the manufacturer’s instructions after depletion of small molecules using Ami-
con (Carrigtwohill, Ireland) Ultra 0.5 ml 10K centrifugal filter devices (Millipore UFC501024).
Statistical analysis
Statistical comparison between two groups was performed using an unpaired t test. One-way ANOVA with a Tukey post-hoc test was used for statistical comparison between more 
than 2 groups. A Pearson correlation analysis was performed using Graphpad Prism.
Results
MDSC number in blood and tumour tissue of patients with grade IV glioma
In our previous study, we measured and characterized cells with the MDSC phenotype in the blood of 18 patients with glioma (Gielen, Schulte et al. 2015). Here we extended the 
study with an additional 23 participants with glioma, and measured changes in myeloid ac-
tivation markers and functional suppression. MDSCs were defined within PBMCs as CD33+ 
and MHC-II- (figure 1A, left panel), which could be further divided into M-MDSCs (CD14+) 
and PMN-MDSCs (CD15+) (Figure 1A, right panel). Both MDSC subpopulations were signifi-
cantly increased in the blood of patients with grade IV glioma compared to HCs (figure 1B 
and C). Although not significant, there was a trend toward increasing MDSC percentage with 
increasing tumour grade for both subpopulations.
Because CD33 is not optimal for staining tumour material, we used CD11b in combination 
with MHC-II to discriminate MDSCs within tumour, which were mainly PMN-MDSCs (figure 
1D) and corroborating our previous results (Gielen, Schulte et al. 2015). Although the his-
togram of the intratumoural MDSCs suggested that PMN-MDSCs might also express CD14, 
we could not detect a CD14 signal over isotype for these PMN-MDSC (figure 1D, upper right 
panel), similar to PMN-MDSCs found in blood (supplementary figure 1A). These results were 
confirmed by IHC of CD11b enriched tumour tissue cells suspension, in which cells with a 
polymorphic nuclei stained positive for CD15, but no signal for CD14 was observed for these 
cells (supplementary figure 1B).
There was no difference in PMN-MDSC infiltration between grade II and grade III tumours 
(with means of 0.2 and 0.1 percent of total viable cells respectively), but higher PMN-MDSC 
numbers were found in some grade IV tumours (with a mean of 1.5 percent)(figure 1E), 
although this difference did not reach statistical significance. We did not observe a clear cor-
relation between the number of MDSCs in blood and tumour, suggesting that MDSC num-
bers in blood do not necessarily reflects the situation within the tumour (Supplementary 
figure 1C). Since patients received dexamethasone before sample collection, we plotted the 
duration of dexamethasone treatment before sample collection against the percentage of 
MDSCs in the blood or tumour of patients with a glioma. There was a statistically significant 
correlation between the duration of dexamethasone treatment and percentage of MDSCs 
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in blood, but not in tumour, either as the total of MDSCs or the separate subpopulations 
(figure 1F, supplementary figure 2 and data not shown). Altogether, these data showed in-
creased numbers of MDSCs in the blood as well as in the tumour tissue, particularly from 
the grade IV glioma patients.
Figure 1. Increased myeloid-derived suppressor cell numbers in blood and tumour tissue of patients with glioma. 
(A) Gating strategy for MDSCs. Peripheral blood mononuclear cells (PBMCs) were stained as described, and single, 
viable cells were plotted for CD33 and MHC-II expression (left panel). CD33+MHC-II- cells were further plotted for 
CD14 and CD15 (right panel). (B and C) The percentages of Polymorphonuclear (PMN) MDSC (B) or Monocytic 
(M) MDSC (C) are shown as a percentage of total PBMCs. Data points were displayed in grouped column scatters 
separating the healthy controls (HCs; (n=17)) and patients with a grade II (n=8), grade III (n=13) or grade IV (n=20) 
glioma. Asterisks represent statistical significance (* p<0.05; ** p<0.01; *** p<0.001). (D) Tumour tissue single 
cell suspensions were stained as described and single, viable cells were plotted for CD45 expression against the 
sideward scatter (SS)(left panel). CD45+ cells excluding lymphocytes were plotted for CD11b and MHC-II (second 
panel). CD11b+MHC-II- cells were plotted for CD14 and CD15 (third panel). PMN-MDSCs or M-MDSCs were plotted 
for CD14 expression with displaying the isotype staining displayed in grey (CD15- MDSCs displaying the isotype of 
M-MDSCs). (E) Percentage of CD45+CD11b+MHC-II- cells plotted as a percentage of the total number of viable cells. 
(F) The percentage of MDSCs in blood plotted against the number of days of dexamethasone treatment before 
surgery. Relevant statistics of all glioma samples combined are incorporated within figure 1F.
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Increased S100A8/9 protein expression in myeloid cells of patients with glioma
To determine whether the MDSCs found in the blood of patients with a glial brain tumour are more activated compared with MDSCs from the HCs, we performed stainings for 
intracellular S100A8/9. MDSCs were gated as described above (figure 1A). A statistically sig-
nificant increase of intracellular S100A8/9 was observed in MDSCs of glioma patients com-
pared with the HCs (figure 2A), the increase already being present in patients with a grade II 
glioma and not significantly increasing with tumour grade (figure 2B). The lack of significant 
Figure 2. Increase of S100A8/9 expression in myeloid cells. (A and B) CD33+MHC-II- cells were gated as in figure 
1A. S100A8/9 mean fluorescent intensity (mfi) data are displayed in whisker plots. Data of glioma patients were 
either combined (A) or divided based on malignancy (B) and compared to healthy controls (HCs). Asterisks repre-
sent statistical significance (*p<0.05; ** p<0.01; *** p<0.001). (C) Myeloid derived suppressor cells (MDSCs) from 
either HC (top panels) or glioma patients (PT; lower panels) were gated on in Polymorphonuclear (PMN)-MDSC (left 
panel) or Monocytic (M) MDSC (middle panel) subpopulations and plotted for S100A8/9. Additionally, CD33+MHC-
II+ cells were plotted for S100A8/9 expression (right panels). Representative histograms of 17 HC and 20 patients 
with glioma (5 grade II; 4 grade III; 10 grade IV) are shown with the black line displaying the S100A8/9 staining and 
the grey histogram displaying the isotype. (D, E, F) Whisker plots of mfi of S100A8/9 in PMN-MDSCs (D), M-MDSCs 
(E) and CD33+MHC-II+ (F) cells. 
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increase in MDSCs from patients with a grade III glioma was most likely caused by the small 
sample size. Subsequently, S100A8/9 expression was analysed in the MDSC subpopulations 
and CD33+MHC-II+ cells (figure 2C), the latter population mainly consisting of monocytes 
and macrophages. Up to now, intracellular S100A8/9 has been described as a general MDSC 
activation marker There was no statistical significant difference in S100A8/9 expression level 
in PMN-MDSCs of glioma patients compared with the HCs (Figure 2D). Strikingly, S100A8/9 
was expressed at higher levels in M-MDSCs and CD33+MHC-II+ cells from glioma patients 
(figure 2E and F. These data indicate that S100A8/9 might be differentially regulated by the 
MDSC subpopulation.
Figure 3. Increase of S100A8/9 levels and arginase activity in serum of patients with glioma. (A and B) S100A8/9 
levels (A) and arginase activity (B) in serum was plotted in a whisker plot for healthy controls (HCs) (n=12) and 
glioma patients (9 grade II; 14 grade III; 23 grade IV). Asterisks represent statistical significance (** p<0.01; *** 
p<0.001). (C) Arginase activity was plotted against S100A8/9 serum levels. Patients with a grade II, III or IV glioma 
represented by blue triangle, green inverted triangle or red dots respectively and the line represents the cor-
relation. (D and E) The S100A8/9 concentration (D) and the arginase activity (E) were plotted against the time of 
preoperative dexamethasone treatment. Relevant statistics of all glioma samples combined are incorporated into 
C, D and E.
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 Increased S100A8/9 levels and arginase activity in serum of patients with glioma
Since S100A8/9 can be secreted, S100A8/9 serum levels were determined. S100A8/9 se-rum levels were increased in the patients with a glioma compared to HCs (figure 3A). This 
increase seemed to be already increased in the serum of patients with a grade II glioma but 
had a statistically significant increased in the patients with grade III or IV glioma. Arginase 
activity in the serum of glioma patients showed a similar increase (figure 3B) and we found 
a correlation between these values (figure 3C). These data indicate a systemic immune sup-
pression in glioma patients which, similar as the intracellular S100A8/9 expression, seems 
already present before the increase of MDSC numbers and was not correlated with the 
number of MDSCs found in tumour tissue (data not shown). Additionally, no correlation was 
found for the days of preoperative dexamethasone treatment and S100A8/9 serum levels 
or arginase (figure 3D and E).
PMN-MDSCs are the main arginase expressing population within PBMCs
Since arginase activity was increased in the serum of glioma patients, we set out to de-termine which cell populations within PBMCs are the main producers of arginase. An in-
crease in arginase-1 (Arg-1) expression was found in PBMCs from glioma patients compared 
with PBMCs from the HC (figure 4A). Further analysis revealed that Arg-1 expression was 
only significantly increased in total PBMCs of patients with a grade IV glioma (figure 4B). Arg-
1 expression of FACS-sorted myeloid cells revealed a relative low expression in CD33+MHC-
II+ cells and with a somewhat higher expression in M-MDSCs, (figure 4C). Strikingly, with 
expression levels over 1700 times as high as M-MDSCs, PMN-MDSCs showed extremely high 
levels of Arg-1 mRNA. Furthermore, Arg-1 mRNA expression within PBMCs was found to be 
correlated with the percentage of PMN-MDSCs (figure 4D), but not with the percentage of 
M-MDSCs (figure 4E). Preliminary data does not suggest a difference in Arg-1 mRNA levels in 
PMN-MDSCs from glioma patients with different tumour grades, which would be consistent 
with the arginase activity in serum.
PMN-MDSCs in tumour tissue express S100A8/9 and arginase
Since S100A8/9 has been described as a chemoattractant for MDSCs, we determined that S100A8/9 protein expression in tumour tissue aspirates of 6 tumour samples by flow 
cytometry. Due to staining limitations, we were unable to maintain the staining strategy of 
figure 1D. We detected S100A8/9 positive cells within viable cells from the tumour tissue 
cell suspension (Figure 5A, left panel). Further analysis revealed that this S100A8/9 expres-
sion originated from MHC-II-CD15+ cells (PMN-MDSCs)(figure 5A lower right panel), since 
no signal for S100A8/9 above background was found in the other populations (figure 5A 
remaining panels). 
Furthermore, we found expression of S100A8, S100A9 and Arg-1 mRNA by qPCR within 
tumour tissue (figure 5B - D). S100A8 and -A9 expression was very high in tissue samples 
of two grade IV glioma patients, but the S100A8 and -A9 expression in the remaining grade 
IV glioma samples were more similar to those in grade II and III glioma samples. Of note, 
these two samples with the highest S100A8 and A9 expression were not the samples with 
the highest Arg-1 expression. Arg-1 mRNA expression measured in GBM correlated to the 
amount of PMN-MDSCs in the tumour (supplementary figure 3A). Additionally, high expres-
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sion of Arg-1 was found in sorted PMN-MDSCs from two grade IV glioma patients (data not 
shown), with expression levels of roughly one-fourth of Arg-1 expression blood derived MD-
SCs. Finally, IHC was used to observe CD15 and arginase double positive cells within tumour 
tissue (figure 5 E, F and supplementary figure 3). As observed previously (Gielen, Schulte et 
al. 2015), the majority of these cells were present in necrotic areas. These data indicated 
(similar to PMN-MDSCs from the blood) that tumour-infiltrating PMN-MDSCs also express 
arginase and S100A8/9.
Figure 4. Arginase is highly expressed by polymorphonuclear myeloid derived suppressor cells. (A and B) Ex-
pression measured by quantitative Polymerase Chain Reaction (qPCR) with Ct values of arginase were plotted as 
relative value to porphobilinogen deaminase (PBGD). Data of glioma patients was either combined (A) or divided 
based on tumour malignancy (B)(grade II (n=8; blue triangles), III (n=6; green inverted triangles) or IV glioma (n=11; 
red dots)) and compared to healthy controls (HCs; (n=18; black dots)). Asterisks represent statistical significance 
(*p<0.05; **p<0.01). (C) Arginase expression of fluorescent activated cell sorting (FACS) sorted myeloid cells of 
glioma patients were measured by qPCR and plotted as relative value to PBGD. Plotted is mean with standard 
error of the mean (SEM) of 6 patients. (D and E) The percentage of PMN-MDSCs (D) or M-MDSCs (E) in the blood 
was plotted against Arg-1 mRNA expression in total PBMCs. Relevant statistics of all glioma samples combined are 
incorporated into D-F.
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PMN-MDSCs suppress T cell function
Since PMN-MDSCs are the main glioma infiltrating MDSC subpopulation and PMN-MDSC numbers are increased in the blood of GBM patients, we set out to explore their potency 
to contribute to a suppressive tumour micro-environment. T cells within PBMCs depleted of 
CD15+ cells were stimulated with anti-CD3/anti-CD28 conjugated beads (Figure 6A, lower 
left panel). As a control, CD20+ B cells were depleted to correct for the MACS procedure 
Figure 5. S100A8/9 and arginase expression in tumour tissue. (A) Tumour tissue single cell suspensions were 
stained as described and analysed using flow cytometry. Single, viable cells were plotted for S100A8/9 (top left 
panel) and subsequently plotted for CD45 expression against the sideward scatter (SS)(top second panel). CD45+ 
cells excluding lymphocytes were plotted for CD15 and MHC-II (top third panel). Lymphocytes (CD45+SSlow) (bot-
tom left panel), tumour cells (CD45-) (bottom second panel), CD45+MHC-II+ (top right panel), CD45+MHC-II-CD15- 
(bottom third panel) and PMN-MDSCs (CD45+CD15+MHC-II-)(bottom right panel) were plotted for S100A8/9 ex-
pression. A representative plot from 6 donors measured is displayed. (B-D) S100A8 (B), S100A9 (C) and arginase 
(D) expression of tumour tissue single cell suspension was measured by qPCR with Ct values plotted relative to 
HPRT in a scattered plot. Grade II (n=4; blue triangles), grade III (n=6; green triangles) or grade IV gliomas (n=7; red 
dots) were grouped. (E&F) H&E staining (E) or IHC double staining (F) with CD15 (pink) and arginase (blue) (original 
magnification x50) of glioma histological sections. Arrows highlight some CD15+arginase+ cells. Three frames from 
the IHC double staining are further enlarged (x400).
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(figure 6A, lower right panel). CD15-depleted PBMCs produced more IFN-γ than total PB-
MCs or CD20-depleted PBMCs when stimulated, showing that the CD15+ cells can efficiently 
suppress IFN-γ production (figure 6B).
Additionally, CD15+ isolated cells (figure 6A, upper left panel) were used to supplement the 
CD15-depleted PBMCs. IFN-γ secretion by stimulated PBMCs was dose-dependently inhib-
ited by the CD15+ cells (figure 6C). Adding equal amounts of isolated CD20+ cells (Figure 
6A, upper right panel) to compensate for the total number of cells, did not reduce IFN-γ 
secretion (figure 6C). Proliferation data measured by tritium incorporation showed similar 
results for both experiments (figure 6D and data not shown). These data show that cells 
with a PMN-MDSC phenotype from the blood of glioma patients efficiently suppress T cell 
function in vitro.
Discussion
Induction of immune suppression by a neoplasm sustains tumour growth while hampering anti-cancer therapies, especially immunotherapy. In this study, the prevalence and activa-
tion status of MDSC populations in blood and tumour tissue of patients with glioma were 
investigated. Our data showed significant increase of both M-MDSCs and PMN-MDSCs in 
the blood of GBM patients and a possible trend towards increasing MDSCs with increas-
ing tumour grade. Intracellular expression of S100A8/9 was already increased in M-MDSCs 
from low grade glioma patients (similar to S100A8/9 serum values and arginase activity); 
however, these values were not predictable for the percentage of intra-tumoural MDSCs. 
Within tumour tissue, predominantly PMN-MDSCs were found which express high levels of 
S100A8/9 and arginase mRNA and were comparable to what we found for blood-derived 
PMN-MDSCs. Additionally, we showed that blood-derived PMN-MDSCs potently suppressed 
T cell function in vitro. Our data implicate that both PMN-MDSCs and M-MDSCs might be 
involved in the tumour induced immune suppression in blood, while PMN-MDSCs are most 
likely the MDSC subpopulation involved in the local immune suppression in the tumour. Fu-
ture research should reveal whether one subset is more important than the other.
For several solid tumours, increased MDSC percentage was found to be associated with re-
duced survival (Diaz-Montero, Salem et al. 2009; Gabitass, Annels et al. 2011; Zhang, Wang 
et al. 2013; Weide, Martens et al. 2014). In our study, the mean percentages of MDSCs in 
blood was significantly increased in GBM patients when compared with the HCs; however, 
not all GBM patients had increased MDSC numbers in their blood. Although not all survival 
data are yet known, no statistically significant difference was observed between patients 
surviving longer or shorter than one year (supplementary figure 4), although there was a 
trend towards higher percentage of MDSCs in the blood of patients with a shorter survival. 
Beside the tumour grade, it will be interesting to see whether increase of MDSCs correlates 
with one of the molecular subtypes of gliomas described by Verhaak et al 2010 (Verhaak, 
Hoadley et al. 2010; Jeuken, Sijben et al. 2011).
Dexamethasone is a strong glucocorticosteroid drug with anti-inflammatory and immuno-
suppressant effects. It is administered to brain-tumour patients one day prior to surgery in 
order to reduce edema (Dietrich, Rao et al. 2011). After surgery the use is quickly tapered. 
Some patients received dexamethasone for a longer period of time before surgery, because 
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of symptoms resulting from extensive edema. The duration of dexamethasone treatment 
was correlated to the increase of MDSCs in blood of glioma patients, a phenomenon dis-
cussed by us previously (Gielen, Schulte et al. 2015) and also described in mice (Varga, 
Ehrchen et al. 2008). It remains to be elucidated whether the dexamethasone treatment is 
responsible for the increase of blood MDSC observed or whether patients with a higher tu-
mour burden who require dexamethasone longer before surgery have a higher percentage 
of MDSCs in their blood due to their higher tumour load. Furthermore, Liao et al. described 
a role for dexamethasone in MDSC recruitment and increased MDSC-suppressive activity in 
mice (Liao, Wang et al. 2014). We did not find a correlation between dexamethasone and 
MDSC accumulation within tumour tissue, nor could we find an effect of the duration of 
dexamethasone treatment on S100A8/9 or arginase expression. This indicates that dexa-
methasone might be involved in MDSC accumulation in the blood (possibly by recruitment 
from the bone marrow) but so far evidence for involvement of dexamethasone in activation 
Figure 6. Polymorphonuclear Myeloid derived suppressor cells from glioma patients suppress T cell function. 
(A) Representative histograms of positively (top panels) and negatively (bottom panels) MACS-sorted populations, 
sorted for CD15 (left panels) or CD20 (right panels). (B) Secreted IFN-y of peripheral blood mononuclear cells (PB-
MCs) not stimulated or stimulated with anti-CD3/anti-28 beads in a 1:1 or 1:4 ratio (1 bead: 4 cells). Data of total 
PBMCs (light grey), CD15 depleted PBMCs (white) or CD20 depleted PBMCs (dark grey) with error bars representing 
SEM. (C and D) Secreted IFN-y and tritium incorporation (D) of CD15 depleted PBMCs. Data are shown for CD15 
depleted PBMCs (white), CD15 depleted PBMCs + CD15+ cells (1:4(light grey), 1:2 (grey) or 1:1 (dark grey)), CD15 
depleted PBMC’s + CD20+ cells (1:1 (black)). Cell ratio 1:2 (or 1:4) represents ratio of CD15 depleted PBMCs:CD15+ 
cells. Data of three independent experiments with each three replicates are combined. Asterisks represent statisti-
cal significance (*p<0.05; **p<0.01; ***p<0.001) compared with CD15 depleted PBMC samples.
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of MDSCs or their recruitment to the tumour is lacking. 
Patients with GBM had increased activity of arginase and S100A8/9 serum values and had in-
creased percentages of MDSCs in their blood. Comparably, a correlation between S100A8/9 
plasma levels and circulating MDSC was already described for patients with gastric cancer 
(Wang, Chang et al. 2013). However, we could not find a correlation between the intracellu-
lar S100A8/9 expression and the observed serum values (data not shown). These data indi-
cate that MDSC function may be altered before the MDSC increase in number. In non-small 
cell lung cancer (NSCLC), the level of S100A9 expression by CD11b+CD14+ cells correlated 
with their suppressive ability (Feng, Lee et al. 2012). S100A8/9 can be upregulated in a STAT-
3 dependent manner, which can also regulate arginase expression (Vasquez-Dunddel, Pan 
et al. 2013; De Veirman, Van Valckenborgh et al. 2014; Gabrilovich and Hurwitz 2014). Al-
though we found increased expression of S100A8/9, it remains elusive whether MDSCs from 
glioma patients are more suppressive, or that solely the increase in number contributes to 
the immunosuppressive environment. 
Beside expression in MDSCs, S100A8 and S100A9 expression has also been described for 
various tumour cells, including glioma (Hermani, De Servi et al. 2006; Nemeth, Stein et al. 
2009), and S100A8/9 levels have been measured within glioma tissue. However, it is not 
clear whether these proteins originated from tumour or tumour-infiltrating immune cells 
(Deininger, Pater et al. 2001; Huang, Chen et al. 2013). In our intracellular S100A8/9 FACS 
staining of tumour tissue, we could only observe a signal above background in CD45+MHC-
II-CD15+ cells, indicating that PMN-MDSCs are the only cells in glioma tissue expressing 
this heterodimer, although we cannot exclude that other cells potentially express S100A8/9 
at much lower levels or have already secreted this protein at the time of staining. Indeed, 
low levels of S100A8/9 can be advantageous for the tumour by promoting cell growth and 
angiogenesis (Ghavami, Rashedi et al. 2008; Turovskaya, Foell et al. 2008; Li, Li et al. 2012), 
whereas high concentrations cause cell death, especially in tumour cells (Ghavami, Kerkhoff 
et al. 2008; Khammanivong, Wang et al. 2013).
Beside S100A8/9, tumour-derived PMN-MDSCs express arginase and blood-derived PMN-
MDSCs are by far the dominant cell population expressing arginase and are very capable in 
suppressing T cell function. This is in line with arginase being an important mechanism of 
suppression for MDSCs, especially for PMN-MDSCs (Zea, Rodriguez et al. 2004; Ochoa, Zea 
et al. 2007; Vasquez-Dunddel, Pan et al. 2013), and strongly suggestive that these cells can 
suppress T cells locally in the tumour microenvironment. Altogether, our data indicated that 
PMN-MDSCs are increased in blood and tumour tissue of GBM patients and that these cells 
are potent in suppressing T cell function, thereby hampering anti-cancer immunotherapy. 
By gaining a better in-depth understanding of the immune suppression in patients with a 
brain tumour, we may add to the increasing knowledge about the clinical effects of immu-
notherapy (Lindau, Gielen et al. 2013; Kroesen, Gielen et al. 2014).
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Supplementary figures
Supplementary figure 1. Blood MDSCs vs intratumoural MDSCs. (A) MDSCs from blood were gated as in figure 
1A. PMN-MDSCs and M-MDSCs were plotted for CD14 expression. The black line displaying the CD14 staining 
and the grey histogram displaying the isotype staining, with CD15- MDSCs displaying the isotype of M-MDSCs. (B) 
IHC stainings of CD15 (left) or CD14 (right) of cytospins of CD11b enridged tumour tissue cell suspension (original 
magnification 200x). Black arrows mark cells with a polymorph nucleus. (C)Percentages of MDSCs as viable cells 
in tumour tissue were plotted against the percentage of MDSCs in corresponding blood samples of the patients. 
Patients with a grade II, III or IV glioma are displayed as blue triangles, green triangles and red dots, respectively. 
Statistics are displayed within figure.
Supplementary figure 2. Both 
MDSC subpopulations correlate 
to dexamethasone treatment. 
The percentage of PMN-MDSCs 
or M-MDSC was plotted against 
the duration of dexamethasone 
treatment. Patients with a grade 
II, III or IV glioma are displayed 
as blue triangles, green triangles 
and red dots, respectively. 
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Supplementary figure 3. Arg-1 
expression within glioma. (A) 
Arg-1 mRNA levels measured by 
qPCR plotted against the num-
ber of PMN-MDSCs in grade IV 
glioma samples. Relevant statis-
tics are shown in the figure. (B)
Data supplementary to figure 5E. 
Four µm histological sections of 
glioma were subjected to CD15 
& arginase-1 double staining. 
Examples of IHC double staining 
with CD15 (pink) and arginase-1 
(blue) and double positive cells 
(purple)(original magnification 
400x).
Supplementary figure 4. Pre-
liminary survival data. Patients 
were divided in 2 groups based 
on the survival after sample col-
lection. The percentages of MD-
SCs within PBMCs in blood gated 
as for Figure 1A and shown as a 
percentage of total number of 
PBMCs.
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Abstract
Myeloid derived suppressor cells (MDSCs) are a heterogeneous, immature myeloid cell population that is increased under various pathological conditions, including can-
cer. In humans, these cells are defined by the expression of the myeloid markers Siglec-3 
(CD33) and/or CD11b and the absence or low expression of HLA-DR,DP,DQ. Siglec-3 is a 
member of the of the sialic acid-binding immunoglobulin-like lectin (Siglec) family and 
has recently been suggested to promote MDSC expansion. So far it is unknown if, next 
to Siglec-3, MDSCs express other members of the CD33-related Siglec family. Therefore 
we assessed Siglec expression in two MDSC subsets, polymorphonuclear-MDSCs (PMN-
MDSCs) and monocytic-MDSCs (M-MDSCs) isolated from blood and tumour material of 
glioma patients. Besides Siglec-3, both MDSC subsets isolated from blood of patients 
with glioma expressed Siglec-5, -7 and -9. While PMN-MDSCs expressed higher levels of 
Siglec-5, M-MDSCs showed higher expression of Siglec-7 and -9. Siglec expression on MD-
SCs isolated from blood of glioma patients were comparable to the expression found on 
MDSCs isolated blood of from healthy controls. Furthermore we found that PMN-MDSCs 
within glioma tissue display a Siglec expression profile comparable to their blood-derived 
counterparts. Strikingly, freshly isolated glioma cells predominantly expressed sialic acid 
ligands for Siglec-7 and -9 and to a lower extent ligands for Siglec-3 and -5. Altogether, 
our data show that MDSCs feature a distinct Siglec expression profile and imply possible 
Siglec-mediated interactions between MDSCs and glioma cells in the tumour microenvi-
ronment.
Introduction
Gliomas are the most frequently occurring primary brain tumours in adults arising from glial progenitor cells (Ho, Reijneveld et al. 2014). Patients with a glioblastoma, the most 
malignant form of astrocytoma, have a dismal prognosis of only 14-16 months (Gousias, 
Markou et al. 2010). Since these tumours grow diffusively within healthy brain tissue, they 
often rapidly reoccur after surgical resection. Patients are therefore subsequently treated 
with radio- and chemotherapy to destroy residual tumour cells. Despite these measures, gli-
omas often develop therapy resistance leading to rapid reoccurrence of the disease (Sarka-
ria, Kitange et al. 2008; Gousias, Markou et al. 2010). 
At present, there are no effective treatment options available for radio- and chemotherapy-
resistant gliomas. Cancer immunotherapy, where the patient’s own immune system is acti-
vated to eradicate tumour cells, may be a promising approach to specifically destroy glioma 
cells. Several clinical trials have explored immunotherapy for the treatment of glioma show-
ing the induction of anti-tumour cytotoxic T cell responses and prolonged long term survival 
in a fraction of patients (Grauer, Wesseling et al. 2009; Okada, Kohanbash et al. 2009). How-
ever, gliomas can acquire multiple mechanisms to counteract anti-tumour immune respons-
es, e.g. by the production of immune inhibitory soluble factors, enzymes and/or cell surface 
molecules (Gielen, van der Valk et al. 2014). Additionally, various immunosuppressive cells 
are recruited to the tumour site resulting in the formation of an immunosuppressive tumour 
microenvironment (Lindau, Gielen et al. 2013).
We and others have previously reported an increase of myeloid derived suppressor cells 
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(MDSCs), but not of regulatory T cells (Tregs), in the blood of glioma patients (Jacobs, Idema 
et al. 2009; Jacobs, Idema et al. 2010; Raychaudhuri, Rayman et al. 2011; Gielen, Schulte et 
al. 2015). MDSCs lack markers of mature myeloid cells (MHC-II molecules HLA-DR,DP,DQ), 
but express the myeloid lineage markers Siglec-3 (CD33) and CD11b. There are two distinct 
MDSC populations, a monocytic (M-) and a polymorphonuclear (PMN-) MDSC population 
which are defined by the expression of CD14 or CD15, respectively. Both populations are 
increased in the blood of glioma patients, with PMN-MDSCs being the main population de-
tected in the tumour tissue (Gielen, Schulte et al. 2015; Raychaudhuri, Rayman et al. 2015). 
We have previously shown that PMN-MDSCs from glioma patients are potent suppressors of 
T cell function(Gielen, Schulte et al. 2016) possibly contributing to the immunosuppressive 
microenvironment. To interfere with this suppression, a better understanding of the induc-
tion of MDSCs and their suppressive phenotype is necessary. One of the cell surface markers 
used to discriminate MDSCs is Siglec-3, a member of the Sialic acid-binding immunoglobu-
lin-like lectin (Siglec) family. 
The human Siglec family is comprised of more than 14 members and can be divided into 
two groups: Those that are conserved across mammals and the CD33-realted Siglecs which 
show substantial high sequence variability across species. CD33-related Siglecs are virtu-
ally expressed by all cells of the immune system, but which Siglecs are expressed by MD-
SCs apart from Siglec-3 is largely unknown. CD33-related Siglecs are type I transmembrane 
proteins with an N-terminal sialic-acid binding domain and a C-terminal, cytoplasmic im-
munoreceptor tyrosine-based inhibitory motif (ITIM). Sialic acids usually are present in the 
glycans of membrane glycoproteins and glycolipids of all vertebrate cells. They play an im-
portant physiological role at the molecular level (e.g. regulation of glycoprotein and glycolip-
id stability and function) and cellular level (e.g. cell-cell interactions) (Varki 2007; Varki and 
Schauer 2009). In general, the interaction between a Siglec with a sialic acid ligand initiates 
a suppressive signal in the immune cell that is mediated via the ITIMs (Macauley, Crocker 
et al. 2014). Thereby, Siglecs can dampen immune cell activation and possibly contribute 
to immunological homeostasis (Miyazaki, Sakuma et al. 2012). Recent studies demonstrate 
the strong immunosuppressive function of Siglecs. For instance, binding of Siglec-2 to its 
sialic acid ligand has been shown to suppress B cell activation and enforces B cell toler-
ance to membrane antigens (Macauley, Pfrengle et al. 2013; Macauley and Paulson 2014). 
Similarly, sialic acid binding to Siglec-7 has been reported to dampen NK cell activation and 
function (Hudak, Canham et al. 2014; Jandus, Boligan et al. 2014). Strikingly, it was shown 
that Siglec-3 signalling in MDSCs induced the secretion of the immunosuppressive cytokines 
TGF-β and IL-10 and thereby promoted MDSC expansion (Chen, Eksioglu et al. 2013). 
In general, tumour cells express aberrantly high levels of sialic acids that potentially trigger 
Siglec signalling to modulate immune cell function (Bull, den Brok et al. 2014; Bull, Stoel et 
al. 2014). It was already proposed about 5 decades ago that this high expression of sialic 
acid sugar-carrying glycans, which is commonly found on tumour cells, allows the tumour 
cells to escape immune recognition (Bagshawe and Currie 1968). Here we report that both 
the M-MDSCs and the PMN-MDSCs isolated from blood of healthy controls and glioma pa-
tients express multiple members of the CD33-related Siglec family. The Siglec expression 
profile in blood PMN-MDSCs could be confirmed in glioma infiltrating PMN-MDSCs. Moreo-
ver, using recombinant Siglec receptors we identified expression of Siglec ligands on glioma 
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cell lines as well as freshly isolated glioma cells. Altogether, these data suggest sialic acid/
Siglec interactions between PMN-MDSCs and glioma cells in the tumour microenvironment, 
which may contribute to the immunosuppressive role of MDSCs in glioma patients.
Materials and methods
Blood and tumour sample
Peripheral blood samples were collected from 9 healthy individuals and from 14 glioma patients undergoing neurosurgical resection or biopsy for their tumour at the Radboud 
University Medical Center (Radboudumc). All patients had a histologically proven glial  brain 
tumours diagnosed by neuropathologists of the Radboudumc according to the WHO 2007 
Classification of tumours of the Central Nervous System(Louis, Ohgaki et al. 2007). The brain 
tumours consisted of 2 WHO grade II tumours (1 oligo-astrocytoma and 1 oligodendroglio-
ma), 4 WHO grade III tumours (all anaplastic oligodendroglioma) and 8 WHO grade IV (glio-
blastoma n=5, gliosarcoma n=2, oligodendroglioma n=1). Additional tumour tissue samples 
for research were obtained from 5 patients by sonic aspiration. 8 patients had started a 
3x 5mg dexamethasone regime on the day before surgery, while 6 patients received dexa-
methasone at an earlier time point to reduce edema. All donors signed an informed consent 
and the study was approved by our Institutional Review Board. Immediately after the blood 
and fresh tumour tissue samples were obtained, processing of these samples was started. 
Flowcytometry measurements were performed within 24 hours.
Tissue handling
Fresh brain tumour material was obtained by excision and by ultrasonic aspiration. As-pirates were collected in a closed system. Tumour cell suspensions were prepared as 
described previously (Jacobs, Idema et al. 2009). Briefly, tumour fragments were filtered 
and washed to discard blood and suction fluid. Tumour fragments were incubated with col-
lagenase type-IA (50 µg/ml) (Sigma-Aldrich, St Louis, MO), DNAse type-I (10 μg/ml) (Roche, 
Mannheim, Germany) and trypsin inhibitor (1 μg/ml) (Sigma) in Hank’s Balanced Salt So-
lution (HBSS) (Gibco, Invitrogen, Leek, the Netherlands) at 37 oC followed by mechanical 
disruption by pipetting. Tumour cell suspensions were placed on a Ficoll gradient (Lucron 
Bioproducts, Gennep, the Netherlands) to remove granulocytes, including potential mature 
granule rich neutrophils. Similarly, a Ficoll gradient was used to obtain peripheral blood 
mononuclear cells (PBMCs) from freshly obtained blood.
FACS analysis and sorting
FACS stainings were performed as described elsewhere (Gielen, Schulte et al. 2015) and (Jandus, Boligan et al. 2014). For lectin staining, cells were stained with biotinylated lec-
tins MALII (Maackia amurensis lectin II), SNA-I (Sambucus nigra agglutinin) and PNA (Pea-
nut agglutinin) in carbo-free blocking buffer (Vector Laboratories, Burlington, NO) for 40 
minutes, washed and incubated with PE-conjugated Streptavidin (BD, Franklin Lakes, NJ). 
Alternatively for Siglec ligand staining, recombinant human Siglec-Fc (R&D systems, Min-
neapolis, MN) was mixed with Alexa Fluor 647-conjugated goat anti-human IgG (H+L) an-
tibody (Life Technologies, Burlington, Ontario, Canada). Cells were washed and incubated 
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for 40 minutes with 0.4µg/ml recombinant Siglec Fc chimeras pre-conjugated with Alexa 
Fluor 647 goat anti-human IgG antibodies in carbo-free blocking solution containing 1 mM 
CaCl2+ and 1 mM MgCl2+ at 4 °C. Cells incubated with Alexa Fluor 647 goat anti-human IgG 
antibody only served as control. Subsequently, PBMCs, glioma cell lines or single cell tumour 
tissue suspensions were stained with fixable viability dye eFluor 780 (eBioscience, Vienna, 
Austria). After washing, cells were stained with directly conjugated monoclonal antibodies 
(mAbs) for 20 minutes on ice. Directly fluorescent conjugated mAbs were obtained from 
Becton, Dickinson and Company (BD) (San Jose, CA)(CD33-APC, HLA-DR,DP,DQ-FITC, CD14-
PerCP), Pelicluster (Amsterdam, the Netherlands) (CD14-PE), IO-Test (CD11b-PE), Biolegend 
(San Diego, CA) (CD15-PE-Cy7, CD45-PerCP, Siglec-5-PE, Siglec-7-PE, Siglec-10-PE), Sigma 
(St Louis, MO) (Siglec-2-PE) and R&D systems (Siglec-9-PE). Isotype controls were obtained 
from BD (IgG1-APC, IgG1-PE-Cy7, IgG2a-PE, IgG2a-Fitc, and IgG1-PE) and Biolegend (IgG2a-
PerCP). Cells were resuspended in PBA and measured on a CyAn (Beckman Coulter) or Gal-
lios (Beckman Coulter) flow cytometer. Data was analysed using FlowJo 9.2 where events 
were gated on single viable cells for further analysis. For sorting, cells were stained with 
HLA-DR,DP,DQ-FITC, CD33-APC, CD14-PE and CD15-PE-Cy7 and sorted on a FACS Aria (BD)
Quantative PCR (qPCR)
PBMCs, FACS sorted cells or cells of single cells tumour tissue suspension were pelleted and resuspended in RNA lysis buffer (Zymo Research (R1055)) and stored at -80oC till fur-
ther use. RNA isolations were done using the ZR RNA isolation kit (Zymo Research) according 
to manufacturer’s instructions. Remaining DNA was removed using DNAse I (amplification 
grade; Invitrogen). cDNA was synthesized as described elsewhere (Schulte, Kers-Rebel et al. 
2013). Briefly, cDNA synthesis from RNA was performed by reverse transcriptase by using 
random hexamers and Moloney murine leukemia virus reverse transcriptase (Invitrogen). 
To exclude genomic DNA contamination we included a “-RT” control in which the reverse 
transcriptase was replaced with RNase-free water. cDNA was stored at -20°C until further 
use. cDNA amplification of genes of interest was measured by SYBR Green (Applied Biosys-
tems) using a Biorad CFX apparatus. Primers (Sigma) sequences originated from the Harvard 
Primer Bank database (Mandruzzato, Solito et al. 2009) and can be found in table 2. Data ob-
tained from RNA isolation from blood cells or tumour tissue cell suspension was normalized 
against PBGD or HPRT expression respectively, since HPRT was found to be a representative 
gene in tumour tissue (de Kok, Roelofs et al. 2005). 
Glioma cell culture
Human glioma cell lines U87, T98G and U251 (ATCC, Manassas, VA) were grown in Dulbec-co’s Modified Eagle’s Medium (Gibco) to confluency and passaged using trypsin. Cells 
were harvested for flow cytometry analyses by washing with PBS and subsequent cold PBS 
for five minutes. 
Results
Blood MDSCs express several CD33-related Siglec family members
Myeloid cells can express several members of the CD33-related Siglec family, but MD-
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Figure 1. Siglec expression on MDSCs from blood of glioma patients and healthy controls. (A) Gating strategy 
for MDSCs. PBMCs freshly isolated from blood were stained as described and single, viable cells were plotted for 
CD33 and MHC-II expression (left panel). CD33+MHC-II- cells were further plotted for CD14 and CD15 (right panel), 
separating PMN-MDSCs (CD14-CD15+) and M-MDSCs (CD14+CD15-). (B&C) Siglec transcripts from FACS sorted 
M-MDSCs (B) and PMN-MDSCs (C) were measured by qPCR. (D) Representative histogram of cell surface Siglec 
expression as measured by flow cytometry. MDSC subpopulations were gated as in Figure 1A and Siglec expression 
was plotted in a histogram. (E-H) Column bar graphs of cell surface Siglec expression of 9 individual experiments on 
M-MDSCs (E&G) or PMN-MDSCs (F&H) of MDSCs from glioma patients (E&F) or healthy controls (G&H).
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SCs have so far only been shown to express Siglec-3. Therefore, we investigated wheth-
er, apart from Siglec-3, MDSCs express other CD33-related Siglecs. To this end, M-MDSCs 
(CD33+MHC-II- CD14+) and PMN-MDSCs (CD33+MHC-II- CD15+) were purified from PBMCs 
of patients with a glioma using FACS-sorting (Figure 1A) and analysed for their Siglec expres-
sion profile. As expected, Siglec-3 mRNA was readily detected in both M- and PMN-MDSCs 
(Figure 1B & C). Additionally, M-MDSCs expressed mRNAs of Siglecs-5, -7, -9, -10, -11, -14, 
and -16 with Siglec-9 being the highest Siglec expressed. PMN-MDSCs showed a similar ex-
pression profile, but also expressed Siglec-6, -8, and -12. Additionally, expression of Siglec-5 
was more than 4 times higher in PMN-MDSCs compared to M-MDSCs. 
Next we examined the Siglec protein expression on the cell surface of the two MDSC 
subpopulations (Figure 1D) using the available Siglec antibodies. The phenotypic marker 
Siglec-3 could be detected on the cell surface of both subpopulations (Figure1E&F), with a 
higher expression on M-MDSCs. As expected, Siglec-2, a conserved Siglec known to be B-cell 
specific, was not detected on either M- or PMN-MDSCs. Siglec-5, -7 and -9 were detected on 
both M- and PMN-MDSCs, but in contrast to the qPCR data, there was little or no expression 
of Siglec-10 protein on the cell surface. The mean fluorescent intensity (mfi) for Siglec-5 in 
PMN-MDSCs was comparable to M-MDSCs, whereas cell surface expression of Siglec-7 and-
9 was lower. 
Previously, we described that MDSC from glioma patients are in a more activated state than 
those of healthy individuals, indicated by an increase in intracellular expression of S100A8/9 
(Gielen, Schulte et al. 2016). To determine whether this increased activation is accompanied 
by aberrant expression of cell surface Siglecs, we compared Siglec expression on MDSC from 
glioma patients with those of healthy donors. MDSCs from healthy donors showed a compa-
rable Siglec expression, indicating that the increased activation does not result in aberrant 
Siglec expression (Figure 1G-H).
Glioma-infiltrating PMN-MDSCs express Siglec-5, -7, and -9  
We previously described that the MDSCs population present in glioma tissue consisted almost exclusively of PMN-MDSCs (Gielen, Schulte et al. 2015; Gielen, Schulte et al. 
2016). Therefore, Siglec expression on tumour infiltrating PMN-MDSCs was analysed. Single 
cell suspensions derived from tumour tissue was stained for MDSC markers and Siglecs. Sin-
gle viable cells were gated on CD45 expression (Figure 2A, left panel) and further plotted for 
CD11b and MHC-II expression (Figure 2A, second panel). As described previously, MDSCs in 
glioma tissue were defined as CD11b+MHC-II-, as no clear Siglec-3 signal above background 
can be detected on these tumour infiltrating MDSCs (Gielen, Schulte et al. 2015). These 
data show that Siglec expression on the cell surface of tumour infiltrating PMN-MDSCs was 
similar to PMN-MDSCs in the blood, albeit with a lower mean fluorescent intensity (mfi) for 
Siglec-5 (Figure 2A and 2B).
Besides MDSCs, other myeloid cells are present within glioma tissue. These cells express 
CD45, CD11b and MHC-II and resemble tumour infiltrating monocytes, tumour-associated 
macrophages and/or microglia. These cells expressed Siglec-7 and -9 to a similar extent 
as monocytes derived from blood, but have much lower expression of Siglec-5 (Figure 2C)
(Supplementary Figure 1). Altogether, these data show that tumour-infiltrating PMN-MDSCs 
display a similar Siglec expression profile compared to their blood counterparts.
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6 Expression of cis Siglec ligands on MDSCsHaving determined the expression of Siglec receptors, we next investigated the expres-sion of sialic acids on MDSCs of healthy controls using the biotinylated lectins MAL-II, 
SNA-I and PNA that recognize α2,3-linked, α2,6-linked sialic acids or glycans without sialic 
acids, respectively. PMN-MDSCs and M-MDSCs were gated as in Figure 1A and plotted for 
lectin staining. M-MDSCs expressed higher levels of sialic acid-carrying glycans on their cell 
surface relative to PMN-MDSCs (Figure 3A-C). Interestingly, also PNA binding to M-MDSCs, 
but not to PMN-MDSCs could be observed. These data indicate that both cells express sialic 
acids that can potentially interact in cis with Siglec receptors on the surface of MDSCs. 
In order to determine which Siglec receptors could potentially form cis interactions, PBMCs 
were stained with recombinant human Siglec-Fc chimeras (Siglec-2, -3, -5, -7, -9 and -10) 
complexed with AF647-conjugated anti-human IgG antibodies and analysed by flow cytom-
etry (Figure 3D). A signal above controls for ligands of Siglec-7 and -9 could be detected on 
both M-MDSCs and PMN-MDSCs of healthy controls (Figure 3 E & F), with higher signals de-
tected for ligands of Siglec 9. Additionally, signals of ligands for Siglec-7 and -9 were higher 
on M-MDSCs than on PMN-MDSCs.
Figure 2. Siglec expression on tumour infiltrating PMN-MDSCs. (A) Single cell tumour suspension was stained as 
described. Single, viable cells were plotted for CD45 expression against the sideward scatter (SS) (left panel). CD45+ 
cells were plotted for CD11b and MHC-II (second upper panel). CD11b+MHC-II- cells were plotted for CD15 (lower 
right panel). Tumour infiltrating PMN-MDSCs were plotted for Siglec expression, representative histograms are 
shown for 3 individual experiments (Right panels). (B&C) Column bar graphs of cell surface Siglec expression on 
tumour infiltrating PMN-MDSCs (B) and CD45+MHC-II+ cells (C).
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Figure 3. MDSCs of healthy controls and glioma patients express Siglec-5, -7, -9 cis ligands. (A) PMN-MDSCs and 
M-MDSCs were gated as in Figure 1A and plotted for lectin expression. Representative histograms are shown for 3 
stainings with lectin staining in dark gray and isotype in light gray. (B & C) Column bar graphs of lectin staining on 
PMN-MDSCs (B) and M-MDSCs (C) is shown combining three experiments. (D) PMN-MDSCs from glioma patients 
were gated as in figure 1A and plotted for Siglec ligands. Representative plots are shown from four experiments. (E-
G) Column bar graphs of cell surface Siglec ligand expression on M-MDSCs (E) and PMN-MDSCs (F) obtained from 
healthy controls (HC) and (G) PMN-MDSCs obtained from the blood of patients with glioma.
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Figure 4. Glioma cell lines and freshly resected glioma cells express trans ligands for Siglecs expressed on CD14+ 
and CD15+ MDSCs. (A) Single cell suspensions of three glioma cell lines were stained as described and analysed 
for Siglec ligand expression by flow cytometry. Mean fluorescent intensity (mfi) is shown in bar graphs. (B) Single 
cell tumour suspension was stained as described. Single, viable cells were plotted for CD45 expression against the 
sideward scatter (SS) as shown in figure 2A. CD45- cells were gated and plotted for Siglec ligand expression. Rep-
resentative plots of four experiments are shown. (C) Column bar graphs of the mean fluorescent intensity of cell 
surface Siglec ligand expression on tumour cells.
Similarly, PBMCs from patients with glioma were stained for ligands of Siglecs on PMN-
MDSCs and signals were detected for Siglec ligands-7 and -9 (Figure 3G). Furthermore, a 
somewhat higher signal was detected for Siglec ligand-5 compared to control staining. How-
ever, the data shown in Figure 3D indicates that this staining is present on a sub-population 
of cells and additional research is necessary to determine the nature of these Siglec ligand-5 
expressing cells. Contrary to healthy controls, the signals for Siglec ligands-7 and -9 were 
comparable. When corrected for the control staining, these data indicate that PMN-MDSCs 
from glioma patients have lower levels of Siglec ligand-9 on their cell surface. 
Although no signal was obtained for the ligand of Siglec-3, this does not necessarily mean 
it is not present, since MDSCs also express Siglec-3 which can bind to its ligand and thereby 
prevent binding of the recombinant Siglec. Since no expression of Siglec-2 on RNA and on 
protein levels on the cell surface was detected, we can exclude that these cells express 
ligands for Siglec 2. Furthermore we can conclude that PMN-MDSCs express ligands for 
Siglec-5, -7 and -9 and may form cis interactions with the Siglec receptors which are also 
present on these cells. 
Glioma-derived cell lines and freshly obtained glioma cells express trans Siglec ligands
Various tumours have aberrant expression of sialic acid sugar-carrying glycans, which could possibly interact with Siglecs expressed on MDSCs and other infiltrating immune 
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cells. Three different human glioma cell lines (U87, T98G and U251) were stained with re-
combinant human Siglec-Fc chimeras complexed with AF647-conjugated anti-human IgG 
antibodies and measured by flow cytometry (Figure 4A). While no staining for ligands of 
Siglec-2, -3, and -10 was observed, ligands for Siglec-7 were detected on all three cell lines. 
Additionally, Siglec-5 ligand expression could only be detected on U251 cells and Siglec-9 
ligands could be detected on U87 and T98G cells, but was absent from U251. Noteworthy, 
expression of Siglec receptors themselves on the cell surface of glioma cells was not de-
tected (data not shown). 
To resolve whether Siglec ligands expressed by glioma cell lines resembles the expression 
freshly obtained glioma cells, single cell suspensions of glioma tissue of five patients were 
stained with anti-CD45 antibody and recombinant human Siglec-Fc chimeras complexed 
with AF647-conjugated anti-human IgG antibodies and measured by flow cytometry. Events 
were gated on single viable cells and subsequently gated CD45- tumour cells. High expres-
sion of ligands for Siglec-7 and -9 and low expression of ligands for Siglec-3 and -5 was de-
tected (Figure 4B, C). Additionally, ligands for Siglec-7 appear to be present on all gated cells, 
where ligands for Siglec-3, -5 and 9 are only present on a fraction of cells. In summary these 
data show that especially sialic acid ligands for Siglec-7 and -9 are expressed by glioma cell 
lines and isolated glioma cells from patients. Interestingly, Siglec-7 and -9 were the Siglecs 
predominantly expressed by M-MDSCs and PMN-MDSCs, indicating a possible trans interac-
tion between glioma cells and tumour infiltrating MDSCs.
Discussion
MDSCs are increased in the blood of patients with glioma and can be detected in glioma tissue. Siglec-3 is widely used as MDSC marker and Siglec signalling is involved in im-
mune suppression (Chen, Eksioglu et al. 2013; Macauley, Pfrengle et al. 2013; Hudak, Can-
ham et al. 2014; Jandus, Boligan et al. 2014; Macauley and Paulson 2014). Expression of 
Siglec-3 on MDSCs is now well established, but expression of other Siglecs on MDSCs had 
not been described yet. Here, we report the expression of Siglec-5, -7 and -9 on the cell 
surface of M-MDSCs and PMN-MDSCs derived from blood of glioma patients. PMN-MDSCs 
express Siglec-3, -7 and -9 to a lower extent than M-MDSCs, with no significant difference 
in expression on MDSCs from patients with glioma versus healthy controls. PMN-MDSCs 
derived from tumour tissue display a similar Siglec expression profile compared to their 
blood counterparts. Additionally, we show that glioma cells express high levels of ligands for 
Siglec-7 on the majority of cells and ligands for Siglec-9 on a subpopulation of cells. These 
data imply that Siglec-ligand interactions between glioma cells and PMN-MDSCs in the tu-
mour microenvironment can occur, which could affect MDSC function.
MDSCs are immature myeloid cells that are released in increased numbers from the bone 
marrow in pathological conditions, such as cancer (Gabrilovich and Nagaraj 2009). We com-
pared MDSC cell surface Siglec expression to the expression profile of fully differentiated 
and more mature myeloid cells in blood. Monocytes are known to express Siglec-3, -5, -7 
and -9 (Lock, Zhang et al. 2004; Jellusova and Nitschke 2011). Here we showed that M-
MDSCs had comparable expression levels of Siglec-3, -5, -7 and -9 compared to monocytes 
(Figure 1E & Supplementary Figure 1). However, the cell surface expression of Siglec 5 we 
found on both populations might be an overrepresentation, since the antibody is cross reac-
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tive to Siglec-14, leaving the possibility that these cells differ in Siglec-5 and -14 expression 
but that the sum of these receptors on the cell surface is comparable (Varki and Crocker 
2009). PMN-MDSCs are considered the immature counterparts of mature granulocytic cells 
like neutrophils (Fridlender, Sun et al. 2012; Ko, Rayman et al. 2014). Expression of Siglec-3, 
-5 and -9 has been described on neutrophils (von Gunten, Yousefi et al. 2005; Ali, Fong et 
al. 2014; Macauley, Crocker et al. 2014) and low expression levels of Siglec-7 has been de-
scribed for granulocytes (Nicoll, Ni et al. 1999).
For Siglec-3, -5, -7 and -9, we found RNA transcripts as well as cell surface protein expression 
on both M-MDSCs and PMN-MDSCs. mRNA transcripts for Siglec-10 were detected in both 
M-MDSC and PMN-MDSCs, but no protein expression could be detected on the cell surface. 
There are many mechanisms involved in regulating translation and protein trafficking, which 
may explain the difference found in mRNA levels and cell surface expression. Additionally, 
cell surface proteins can be shielded from the detection antibody by binding of cis ligand. 
This shielding can also occur for the Siglec receptors we did detect, suggesting that the 
actual cell surface expression might be higher than measured. Sialidase treatment removes 
sialic acids from glycoproteins and glycolipids and can increase the Siglec cell surface stain-
ing signal of various CD33-related Siglecs (Nguyen, Ball et al. 2006), including Siglec-3, -7 
and -9 (data not shown). This indicates that part of Siglecs is indeed be bound by cis ligands 
under physiological conditions and that cell surface expression on both MDSCs derived from 
blood and tumour may be higher than we measured. Sialidase might therefore also potenti-
ate Siglec-3 as a MDSC marker for tumour derived MDSCs. Additionally, we have previously 
shown that S100A9 is expressed by PMN-MDSCs in both blood and glioma tissue (Gielen, 
Schulte et al. 2016). This myeloid related protein can form a functional ligand/receptor pair 
with Siglec-3 (Chen, Eksioglu et al. 2013). It would be interesting to know whether binding 
of S100A9 to Siglec blocks binding of the anti-Siglec-3 antibody and whether ligands for 
Siglec-3 other than S100A9 have similar results on MDSC cell signalling and suppressive 
capacity.
CD33-related Siglecs have one or more ITIM motifs and signalling can dampen immune re-
sponses. Siglec signalling can induce secretion of suppressive cytokines after forming a func-
tional ligand/receptor pair, for example with S100A9 (Chen, Eksioglu et al. 2013; Jandus, Bo-
ligan et al. 2014; Macauley and Paulson 2014). We have previously shown that serum from 
patients with glioma contains increased levels of S100A8/9 (Gielen, Schulte et al. 2016), sug-
gesting that MDSCs in glioma patients could gain a more suppressive capacity when CD33/
S100A9 interactions are present. We could only detect low levels of ligands for Siglec-3 on 
fresh glioma cells, but high levels of ligands for Siglec-7 and -9 were observed. Recognition 
of ligands by Siglec-7 or Siglec-9 on NK cells can dampen NK cell activation (Nicoll, Avril 
et al. 2003; Hudak, Canham et al. 2014; Jandus, Boligan et al. 2014). Whether this down 
regulation of NK cells also occur within glioma’s remains to be determined. It will also be 
interesting to investigate if interaction of Siglec-7 and Siglec-9 with their ligands will also 
render MSDCs more suppressive. If blocking Siglec-Ligand interactions inhibits MDSC expan-
sion and or function, it might improve immunotherapeutic therapies. The fact that reduc-
tion of MDSC expansion and improved survival was observed after blocking Ligand-receptor 
interaction of another glycoprotein-receptor (CD200/CD200R) in brain tumour bearing mice 
provides support for this proposition (Moertel, Xia et al. 2014). 
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In summary, we showed that next to Siglec-3, also Siglec-5, -7 and -9 are expressed on MD-
SCs from glioma patients. Freshly isolated glioma cells highly express ligands for Siglec-7 and 
Siglec-9, indicating a possible interaction between glioma cells and MDSCs in the tumour mi-
croenvironment. It will be extremely important to elucidate whether this interaction occurs 
in the tumour and if it influences the suppressive function of MDSCs as this may provide op-
portunities to interfere with MDSC function and thus may potentiate anti-glioma immunity.
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Supplementary figure
Supplementary figure 1. Siglec expression on 
CD33+MHC-II+ cells. PBMCs freshly isolated from 
blood were stained as described and single, viable 
cells were plotted for CD33 and MHC-II as shown in 
Figure 1A. CD33+MHC-II+ cells were further plotted 
for Siglec expression. Column bar graphs of the mean 
fluorescent intensity of cell surface Siglec expression 
combining 9 individual experiments is shown.
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Summary
Gliomas are a heterogeneous group of primary brain tumours originating from the glial cell or its progenitor. The most aggressive form, glioblastoma, represents 15-20% of all 
intracranial tumours and approximately 50% of astrocytic tumours in adults. Chapter 1 pro-
vides a concise overview of glioma, the immunological microenvironment and its possible 
role in prognosis, with myeloid derived suppressor cells (MDSCs) and their role within the 
tumour microenvironment more elaborately discussed in Chapter 2. Despite advancements 
in surgical procedures and treatment regimens, including radiotherapy and chemotherapy, 
the vast majority of gliomas remain incurable and patients with glioblastoma have a median 
survival of only 14,5 months (Stupp, Mason et al. 2005; Stupp, Hegi et al. 2009; Johnson 
and O’Neill 2012; Zong, Verhaak et al. 2012). Temozolomide (TMZ), the most commonly 
used chemotherapeutic agent to treat patients with glioma, is a DNA alkylating agent that 
causes DNA damage and induces cell death. Unfortunately, glioma cells often rapidly de-
velop resistance to TMZ treatment via various pathways, including, but not limited to DNA 
repair pathways (Sarkaria, Kitange et al. 2008; Fan, Liu et al. 2013). In Chapter 3, we show 
the effect of increased expression levels of the gap junction protein connexin 43 (Cx43) 
on the resistance to TMZ treatment in glioma cell lines. Connexins are tetraspan integral 
plasma membrane proteins with cytoplasmic amino (NH2) and carboxyl-terminal (CT) tail 
domains. Connexins can form hexameric oligomers to form a hemichannel, and hemichan-
nels of two neighbouring cells can form gap junctions, allowing small ions and molecules to 
pass between neighbouring cells. This process is required for a broad range of physiological 
processes (Naus, Elisevich et al. 1992). The Cx43 mediated TMZ resistance involves both 
channel dependent and independent functions and expression of Cx43 prevented increase 
of the Bax/Bcl-2 ratio and the subsequent release of cytochrome C after TMZ treatment. Our 
data raises the possibility of increasing TMZ efficacy by targeting the Cx43 protein. However, 
due to the diversity of TMZ resistance mechanisms that can be exploited by glioma, it might 
be more rewarding to look for alternative treatment options for glioma patients.
For long the brain has been regarded as an immune-privileged site based on the presence of 
the blood-brain-barrier (BBB), lack of conventional lymphatics and low immune cell traffick-
ing (Grauer, Wesseling et al. 2009). Recent studies now show that the brain rather is a spe-
cialized immune site where lymphocyte homing (adhesion/chemokine receptor expression) 
and immune response induction are tightly controlled and regulated in a unique fashion. 
More recently, evidence for a functional lymphatic vessel lining the dural sinuses has been 
published (Louveau, Smirnov et al. 2015). These findings further support the ongoing devel-
opment of immunotherapeutic intervention strategies. Various immunotherapeutic options 
have been evaluated in the last three decades in patients with glioma, including dendritic 
cell (DC) vaccination, peptide vaccination and antibody therapy, of which DC therapy is the 
most evaluated strategy in humans. Studies using DC vaccination generally show the induc-
tion of cytotoxic T cell response to autologous tumour cells and result in prolonged long 
term survival in a fraction of patients (Yu, Liu et al. 2004; Wheeler and Black 2011; Van Gool 
2015). However, as discussed in Chapter 1 and 2, gliomas are known to create an immuno-
suppressive microenvironment that hampers the efficacy of (immuno)therapy. By gaining 
a better understanding of this immunosuppressive network, pathways might be found to 
interfere with this network and that thereby potentiate the efficacy of (immuno)therapeutic 
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strategies. 
In this thesis, we further explore this immunosuppressive environment by focusing on the 
MDSC. The term MDSC was introduced in 2007 (Gabrilovich, Bronte et al. 2007; Yang 2007), 
with a monocytic (M-) and granulocytic (G-) subpopulation described and characterized in 
2008 (Youn, Nagaraj et al. 2008). The latter granulocytic population has a polymorphonu-
clear morphology and is also designated as polymorphonuclear (PMN-) MDSCs. In Chapter 
4, the increase of both MDSC subpopulations in the blood of patients with glioblastoma is 
described in a first set of patients. These cells expressed similar levels of the myeloid cell 
surface activation markers CD124, CD86, CD40, CD80 and PD-L1 as MDSC obtained from the 
blood of healthy donors. Additionally, cells with a PMN-MDSC but not an M-MDSC pheno-
type, can be found within tumour tissue, where these PMN-MDSCs are mainly detected in 
necrotic regions. However, they can also be found within viable tumour tissue.
In Chapter 5, these observations are confirmed with an additional set of patients and we 
further explore the potential of MDSCs to suppress an immune response. In this chapter, 
we show a trend towards increasing numbers of MDSCs in the blood of glioma patients 
with increasing malignancy grade. Interestingly, the intracellular expression of the myeloid 
activation marker S100A8/9 was increased in blood-derived M-MDSCs of patients with gli-
oma compared to M-MDSCs from healthy donors. No statistical significant difference was 
observed in its expression in the PMN-MDSC subset. Additionally, serum values of this het-
erodimer were increased in patients with glioma compared to healthy controls, with no 
statistical significant difference observed in serum values of patients with different glioma 
grades. Interestingly, there was a correlation between S100A8/9 serum values and serum 
activity of arginase, an enzyme produced mainly by PMN-MDSCs that is involved in T cell 
suppression. Furthermore, the blood derived PMN-MDSCs were potent in suppressing T cell 
proliferation and functioning and were comparable to the PMN-MDSCs detected in tumour 
tissue with respect to S100A8/9 and arginase expression. These data indicate a tumour 
grade dependent increase of MDSCs in the blood of patients with a glioma, where MDSCs 
exhibit an increased activation state compared to MDSCs in healthy controls, independent 
of tumour grade. 
The pathways by which tumours induce accumulation and activation of MDSCs is still un-
known. Chen et al. recently described the involvement of one of the MDSC phenotypic 
cells surface markers, CD33 (also known as Sialic acid-binding immunoglobulin-like lectin 
(Siglec)-3), in this process (Chen, Eksioglu et al. 2013). The Siglec family consist of more than 
14 members but next to Siglec-3, no other members of this family have been described to 
be expressed by MDSCs. In Chapter 6, we describe the expression of Siglec-5, -7 and -9 on 
both blood-derived MDSC subsets, with no difference observed in cell surface Siglec ex-
pression on MDSCs from glioma patients compared to healthy controls. While PMN-MDSCs 
expressed higher levels of Siglec-5, M-MDSCs showed higher expression of Siglec-7 and -9. 
Furthermore we found that PMN-MDSCs within glioma tissue display a comparable Siglec 
expression profile comparable to their blood-derived counterparts. Strikingly, freshly iso-
lated glioma cells predominantly expressed sialic acid ligands for Siglec-7 and to a lower 
extent ligands for Siglec-3, -5 and -9. These data indicate possibilities for binding interaction 
between glioma cells and tumour infiltrating MDSCs which may contribute to the tumour 
suppressive microenvironment.
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Since conventional therapies have hardly improved the dismal prognosis of patients with 
glioma, other strategies are highly desirable. When one wants to exploit the immune sys-
tem to eradicate the tumour (or rather the remaining tumour cells after surgery), one might 
need to counteract the tumour induced immune suppression. In this thesis we indicate that 
MDSCs contribute to this immune suppressive environment. By depleting MDSC accumula-
tion or function, e.g. by interfering with Siglec signalling, the efficacy of immunotherapeutic 
approaches may be improved.
Discussion
MDSC accumulation in blood; where do they come from?
Currently, the increased number of MDSCs in blood of patients with various solid tumours is more and more established, with different MDSC subpopulations described for vari-
ous solid tumours (e.g. patients with melanoma have increased M-MDSCs numbers in their 
blood, but no increase of PMN-MDSCs (Ostrand-Rosenberg and Sinha 2009)). In the blood 
of patients with glioblastoma, an increase in both PMN-MDSCs (Raychaudhuri, Rayman et 
al. 2011; Dubinski, Wolfer et al. 2015; Raychaudhuri, Rayman et al. 2015) and M-MDSCs 
(Kohanbash, McKaveney et al. 2013; Dubinski, Wolfer et al. 2015) has been described. It is, 
however, not clear where these MDSCs come from. Up till now, there are two hypotheses 
1) expansion of MDSCs is promoted through stimulation of myelopoiesis and inhibition of 
myeloid cell differentiation by tumour derived factors (Gabrilovich and Nagaraj 2009); 2) 
MDSCs arise from dedifferentiated mature myeloid cells. Both hypotheses can be explained 
by cytokines, chemokines and other tumour derived factors secreted by tumours, and these 
hypotheses do not exclude each other. 
The data in this thesis shows an increase of both PMN-MDSCs and M-MDSCs within the pe-
ripheral blood mononuclear cells (PBMCs) of patients with glioma. If this increase would be 
the result of increased myelopoieses, as suggested by the first hypothesis, one would expect 
that other cell populations would be decreased within total PBMCs. Indeed, we did observe 
that the number of T cells was reduced, especially in blood of glioblastoma patients (data 
not shown). This does not exclude the second hypothesis, especially since we and others 
also observed the reduction of MHC-II expression on myeloid cells from glioma patients (our 
unpublished data and (Zou, Morford et al. 1999)). Reduced MHC-II expression on monocytes 
results in an increase of cells with an M-MDSC phenotype. This reduced MHC-II expression 
can either be the result of the inhibition of differentiation and maturation of myeloid cells 
(as suggested by the first hypothesis) or by reduced expression by monocytes caused by 
factors secreted by the tumour cells (as suggested by the second hypothesis). Similarly, the 
increase in CD15+ cells (PMN-MDSCs) within PBMCs can either be explained by improper 
differentiation of granulocytic cells or by dedifferentiation of mature granulocytes. A third 
possibility for the increase of PMN-MDSCs is that M-MDSCs can further differentiate into 
PMN-MDSCs (Youn, Kumar et al. 2013).
The data in this thesis lend support to both hypotheses. Furthermore, it might also be pos-
sible that accumulation of the MDSC subpopulations in blood are regulated differently; e.g. 
the pre-dominant increase of either one of the MDSC subpopulations might be caused by 
the different composition of cytokines produced by different types of tumours, including 
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different levels of G-CSF and GM-CSF (Gabrilovich and Nagaraj 2009; Dolcetti, Peranzoni et 
al. 2010; Lechner, Liebertz et al. 2010; Marigo, Bosio et al. 2010; Rodrigues, Gonzalez et al. 
2010; Meyer, Sevko et al. 2011). Although analysing cytokine levels in blood and tumour of 
patients with various malignancies might reveal some clues about the increase of the two 
MDSC subpopulations, it is very well possible that the cause for the observed increase is 
more complex, for example through the influence of secreted exosomes or cell-cell contact. 
Increased MDSC activation and implications for suppression
Besides accumulation, increased activation of MDSCs from tumour bearing patients is de-scribed. S100A8/9 is a heterodimer consisting of two myeloid related proteins (MRP) 
(MRP-8 (S100A8) and MRP-14 (S100A9)) and increased expression of S100A8 and S100A9 
in MDSCs prevents differentiation and promotes expansion (Sinha, Okoro et al. 2008). The 
heterodimer S100A8/9 has been suggested as a marker for MDSC activation (Cheng, Corzo 
et al. 2008; Ramachandran, Martner et al. 2013). S100A8 and S100A9 expression can be 
upregulated via STAT-3. Additional evidence for this suggestion is the finding that STAT-3 also 
regulates the expression of other MDSC activators such as reactive oxygen species (ROS) and 
arginase (Kortylewski, Kujawski et al. 2005; Vasquez-Dunddel, Pan et al. 2013). Although the 
increase of MDSCs in the blood has been described for patients with various tumours, the 
difference in activation between MDSCs from tumour bearing patients and healthy controls 
is poorly described. It therefore remains an open question whether the MDSC induced im-
mune suppression is primarily caused by their accumulation, or whether these cells are 
also more activated in patients with a malignancy. In this thesis, we showed the increase of 
intracellular S100A8/9 in MDSC. This increase was already present in MDSCs obtained from 
grade II glioma patients and did not show a correlation with tumour grade. However, we 
could only detect a statistically significant increase of MDSCs in the blood of glioblastoma 
patients compared to healthy controls. No statistically significant difference in the amount 
of MDSCs was observed between healthy controls and patients with a World Health Or-
ganisation (WHO) grade II or grade III glioma. These data indicate that MDSCs might first 
be activated and that accumulation occurs at a later stage, as schematically visualized in 
figure 1. This hypothesis is also in line with the observed arginase activity in the serum of 
patients with glioma, which was already elevated in the serum of patients with a low grade 
(WHO grade II) glioma and did not further increase with increasing tumour grade. These 
data suggest that MDSCs from glioma patients might be more immunosuppressive than 
MDSCs in healthy donors. For MDSCs isolated from the blood of patients with gastric can-
cer, an enhanced suppression of T cell function was observed compared to blood-derived 
MDSCs from healthy donors (Wang, Chang et al. 2013). Whether this is also true for MDSCs 
isolated from patients with other malignancy is still an open question and more experiments 
are required to prove whether the observed intracellular S100A8/9 expression indeed cor-
relates with increased immunosuppressive capacity of MDSCs. 
MDSCs within tumour tissue
Although for most solid tumours elevated numbers of MDSCs have been described in the blood of patients, their presence within the tumour itself is poorly described. One of 
the reasons for this is the lack of a unique MDSC marker. In murine studies, Gr-1 is used to 
define MDSCs, both in spleen and in tumour tissue (Youn, Nagaraj et al. 2008). Of note, this 
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specifically phenotype MDSCs might be difficult due to the plasticity of the immune system. 
Nonetheless, it will be important to map the MDSC infiltration for different solid tumour 
types. Up till now, it is unknown i) whether MDSCs infiltrate all solid tumours, ii) whether 
there is a tumour-type dependent difference in infiltration of subpopulations similarly to the 
situation in blood, iii) in which part of the tumour MDSCs infiltrate and iv) whether the sup-
pressive capacity of tumour-infiltrating MDSCs is comparable to their counterparts in blood. 
In this thesis, glioma infiltrating MDSC are defined as CD45+MHC-II-CD11b+ cells where this 
population consisted almost exclusively of PMN-MDSCs. These PMN-MDSCs were detected 
in glioma tissue at low levels in all samples measured, with some higher percentages found 
Schematic overview of proposed tumour induced MDSC accumulation
Figure 1. In patients with a glioma, the serum value of S100A8/9 and MDSC intracellular S100A8/9 can be in-
creased. Additionally, increased activity of arginase can be measured in patients with glioma. In patients with 
more malignant gliomas, an increase in MDSCs can be measured in the blood. Altogether, this increase in MDSCs, 
arginase activity and S100A8/9 can support tumour growth and development.
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in glioblastoma samples. Additionally, the intratumoural PMN-MDSCs were comparable to 
their blood derived counterparts with respect to S100A8/9 expression. The lack of a unique 
marker for human MDSCs leaves the possibility that these cells are similar to the already 
described tumour associated neutrophils (TANs) (Fridlender and Albelda 2012; Fridlender, 
Sun et al. 2012). TANs have been described to be present in glioma tissue (Liang, Piao et al. 
2014), where they can exert an anti-tumorigenic or a pro-tumorigenic role. Although we 
processed the tumour material over a Ficoll gradient to exclude mature granulocytes, we 
do not know whether this also excludes TANs since it is not clear whether these cells co-
purify with mononuclear cells (Schmielau and Finn 2001; Sippel, White et al. 2011). Either 
way, both PMN-MDSCs and TANs are reported to suppress anti-tumour immune responses 
(Fridlender and Albelda 2012), which makes it important to get a better insight in their 
quantity and functionality and to find parameters in blood that can predict tumour infiltrat-
ing suppressive cells like MDSCs, especially when considering immunotherapy. In our set 
of data, preliminary data from Chapter 5 did not show a correlation between the MDSC 
percentage found in blood and the percentages detected in the tumour. Additionally, we 
could not detect a correlation with tumour infiltrating MDSCs and any of the MDSC markers 
measured in blood, e.g. serum levels of S100A8/9 or Arginase activity. These data indicate 
that other factors are important for recruitment of MDSCs into the tumour.
Dexamethasone
Dexamethasone is a strong glucocorticosteroid drug which is administered to brain-tu-mour patients one day prior to surgery in order to reduce edema (Dietrich, Rao et al. 
2011). After surgery the use is quickly tapered. Some patients received dexamethasone for 
a longer period of time before operation to treat symptoms as a result of extensive edema. 
Dexamethasone is part of the standard therapy of care, however, its effects on efficacy of 
standard therapy or experimental therapies like immunotherapy are not clear and should 
be considered.
Dexamethasone can have effects on conventional glioma therapy by increasing chemo re-
sistance in tumour cells. In a rat hepatoma cell line, dexamethasone treatment resulted in 
the upregulation of mRNAs encoding methylguanine-DNA methyltransferase (MGMT) and 
a set of enzymes active in the base excision repair pathway: apurine endonuclease (APE) 
and DNA polymerase β (Pol β)(Grombacher, Mitra et al. 1996). These genes are involved in 
DNA alkylation damage repair and may have a profound effect on resistance of cells towards 
alkylating agents like TMZ. It might be important to confirm whether these DNA repair en-
zymes are also increased in human glioma cells and how long these effects are sustained 
after treatment. Additionally, it will be interesting to examine the effect of dexamethasone 
on the Cx43 expression in glioma cells, especially since we showed in Chapter 3 that in-
creased Cx43 expression confers TMZ resistance and Zhuo and colleagues showed an in-
creased expression of Cx43 after dexamethasone treatment in human trabecular meshwork 
cells (Zhuo, He et al. 2010). The possible increase of mRNA of DNA repair enzymes after 
dexamethasone treatment and the correlation between MDSC increase and the duration of 
dexamethasone treatment, suggest it might be advantageous to look for alternative drugs 
to reduce edema.
Furthermore, as dexamethasone has anti-inflammatory and immunosuppressive effects, 
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this compound is likely to hamper immunotherapeutic approaches. For various solid tu-
mours, a correlation has been reported between the percentage of MDSCs in the blood 
and poor prognosis (Gabitass, Annels et al. 2011; Zhang, Wang et al. 2013; Wang, Zhang et 
al. 2015). In Chapter 4 and 5 we describe a statistically significant correlation between the 
duration of dexamethasone treatment and the increase of two MDSC subpopulations in the 
blood of patients with glioma. Our data set could not provide statistical proof that increased 
MDSC levels were associated with poor prognosis, but there was a clear trend that patients 
with reduced survival had increased numbers of MDSCs in their blood. One may argue that 
patients receiving dexamethasone for a longer period of time to treat symptoms of edema 
also have larger or more advanced tumours, and therefore have a worse prognosis. It will 
therefore be important to examine whether the increase in MDSCs is caused by prolonged 
dexamethasone treatment, high tumour burden or a combination thereof.
MDSCs as therapeutic target
As already described above, a high percentage of MDSCs in blood is correlated with poor prognosis for various solid tumours (Gabitass, Annels et al. 2011; Zhang, Wang et al. 
2013; Wang, Zhang et al. 2015), and possibly also for patients with glioblastoma (Chapter 
5). This correlation can be due to fact that MDSCs secrete factors that can directly promote 
tumour growth and development, examples being S100A8/9, vascular endothelial growth 
factor, basic fibroblast growth factor, transforming growth factor beta and matrix metallo-
peptidase 9 (Bunt, Sinha et al. 2006; Ostrand-Rosenberg and Sinha 2009; Ye, Yu et al. 2010; 
Tartour, Pere et al. 2011; Sevko and Umansky 2013). Furthermore, as already discussed 
above, MDSCs can suppress an anti-tumour immune reaction (Chapter 2), making MDSCs 
an interesting target to improve therapeutic efficacy in cancer patients.
Inhibiting MDSC activation or suppressive mechanisms
Since MDSCs can potentiate tumour growth by suppressing an anti-tumour immune re-action, inhibiting the suppressive mechanisms of MDSCs might reduce tumour growth. 
Chalmin and colleagues reduced MDSC activation by inhibiting exosomes using amiloride 
(Chalmin, Ladoire et al. 2010). Treating patients with metastatic colorectal cancer for three 
weeks reduced the capacity of autologous serum to induce STAT3 phosphorylation in MDSCs 
and blunted MDSC suppressor function. Interestingly, amiloride can kill malignant glioma 
cells (Hegde, Roscoe et al. 2004) and is currently used in treatment of high blood pressure 
or cardiac edema and can prevent intracranial pressure (Plangger and Volkl 1995). However, 
due to the hydrophilic nature of amiloride, it cannot pass the blood brain barrier (Tai and 
Truong 2013) and its use in reducing symptoms of edema in the brain might be limited. 
Other MDSC activation inhibitors targeting arginase, NO or ROS expression or activation 
have mainly been explored in vitro, where the inhibition of MDSC function resulted in in-
creased T cell activation. Inhibiting ROS via increased expression of antioxidants and the 
inhibition of STAT-3 by bardoxolone methyl in pancreatic cancer patients resulted in signifi-
cantly increased T cell responses without reducing the number of MDSCs (Nagaraj, Youn et 
al. 2010). Inhibiting the upregulation of arginase by blocking PGE2 synthesis also resulted in 
improved antitumor T cell responses in both mice and human (Zea, Rodriguez et al. 2005; 
Talmadge, Hood et al. 2007). Furthermore inhibition of PGE2 synthesis with a COX-2 blocker 
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reduced the number of tumour-infiltrating MDSCs and potentiated DC-immunotherapy in a 
murine model for mesothelioma (Veltman, Lambers et al. 2010). The phosphodiesterase 5 
(PDE5) inhibitor tadalafil, which acts similarly to COX inhibitors and is already in clinical use 
for treatment of erectile dysfunctions, pulmonary hypertension and cardiac hypertrophy, 
reduced peripheral MDSC numbers and increased antitumor immunity in patient with end 
stage multiple myeloma and head and neck squamous cell carcinoma (Noonan, Ghosh et al. 
2014; Califano, Khan et al. 2015). 
Although multiple clinical trials with PDE5 inhibitors are currently ongoing (NCT02544880, 
NCT01697800, NCT02466802) and arginase-, NO- or ROS-inhibitors have been explored in 
vivo in various murine models (Wesolowski, Markowitz et al. 2013), most clinical trials focus 
on reducing MDSC accumulation rather than limiting their suppressive activity.
Reducing MDSC accumulation
Depleting MDSCs from spleen and blood in a murine tumour model using anti-Gr-1 anti-bodies generally improves antitumor immune activity and can improve survival (Peka-
rek, Starr et al. 1995; Watanabe, Deguchi et al. 2008; Li, Han et al. 2009; Srivastava, Zhu 
et al. 2012; De Veirman, Van Valckenborgh et al. 2014). As there is no human Gr-1, other 
strategies are explored to inhibit MDSC accumulation, e.g. by inhibiting myelopoiesis or by 
inducing further differentiation/maturation of MDSCs (Wesolowski, Markowitz et al. 2013; 
Draghiciu, Lubbers et al. 2015; Katoh and Watanabe 2015). Various compounds that pos-
sibly reduce or inhibit MDSC accumulation have been investigated as reviewed elsewhere 
(Najjar and Finke 2013; Wesolowski, Markowitz et al. 2013), of which three promising can-
didates will be highlighted here: 1α, 25-hydroxyvitamin D3, all-trans retinoic acid (ATRA) and 
colony stimulating factor receptor 1 (CSF-R1) inhibitor PLX3397.
Patients with non-small cell lung carcinoma (NSCLC) were treated with 1α, 25-hydroxyvita-
min D3 for three weeks prior to surgery (Kulbersh, Day et al. 2009; Walsh, Clark et al. 2010). 
Tumours of treated patients had reduced CD34+ (a marker sometimes used to define MD-
SCs) cells and increased mature DCs and lymphocytes, both CD4+ and CD8+. Additionally, 
median recurrence after surgery was more than three times longer in the group of patients 
who received this treatment. It is also known that 1α, 25-hydroxyvitamin D3 can influence 
NSCLC cell proliferation directly and therefore the observed effect may not be exclusively 
the result of its effect on MDSC differentiation (Upadhyay, Verone et al. 2013). 
More evidence showing that reducing MDSC accumulation may be beneficial for treating 
cancer patients comes from studies with ATRA. ATRA is a metabolite of vitamin A with ago-
nistic activity towards nuclear receptors. These retinoid-activated transcriptional regula-
tors activate target genes that lead to maturation of early myeloid cells into their fully dif-
ferentiated (and hence less immunosuppressive) forms (Bastien and Rochette-Egly 2004). 
Treatment of patients with metastatic renal cell carcinoma or small cell lung cancer with 
ATRA reduced the number of circulating MDSCs (Mirza, Fishman et al. 2006; Iclozan, Anto-
nia et al. 2013) and improved immune responses. Furthermore, treatment with ATRA ad-
ditional to a combination of cisplatin and paclitaxel for patients with small cell lung cancer 
improved median survival compared to the combination of cisplatin and paclitaxel alone 
(Arrieta, Gonzalez-De la Rosa et al. 2010). Although in murine systems ATRA has been shown 
to lead to differentiation from MDSCs to DCs and might also induce regulatory T cells (Tregs) 
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(Kusmartsev, Cheng et al. 2003; Kusmartsev, Su et al. 2008; Ma, Liu et al. 2014), no increase 
in the proportion of conventional DCs or Tregs was observed in patients with small cell lung 
carcinoma (Iclozan, Antonia et al. 2013). 
As an alternative, MDSC accumulation and recruitment to the tumour site can be inhib-
ited by blocking the CSF-R1 with a small molecule inhibitor (PLX3397) or using anti-CSF-R1 
antibodies (IMC-CS4). In murine models, blocking the CSF-R1 inhibited the recruitment of 
MDSCs and tumour associated macrophages (TAMs) into the tumour and led to reduced  tu-
mour growth in irradiated animals compared to irradiated animals not treated with CSF-R1 
inhibitor (Priceman, Sung et al. 2010; Xu, Escamilla et al. 2013). Of 23 patients with Teno-
synovial giant cell tumour treated with 1000 mg PLX3397 per day, 12 patients showed a 
partial response and 7 patients had stable disease (Tap, Wainberg et al. 2015). In this study, 
blood or tumour samples were not analysed for myeloid cell composition. In 37 patients 
with recurrent glioblastoma, a daily dose of 1000 mg PLX3397 was well tolerated and readily 
crossed the blood tumour barrier, but did not show an increase in 6-month progression free 
survival or overall survival (Butowski, Colman et al. 2015). It remains an open question if and 
how PLX3397 alters the myeloid cell composition within tumours, especially since PLX3397 
is used in murine studies to deplete microglia (Mok, Tsoi et al. 2015). 
All in all, the beneficial effect of targeting MDSCs as a single treatment is still matter of dis-
pute and it may well be more beneficial to target MDSCs as part of a combination treatment, 
e.g. combined with immunotherapy.
Rationale for Immunocombination therapy
For patients with glioma, the most evaluated immunotherapeutic approach is dendritic cell based vaccinations. The studies in this field demonstrated that administration of den-
dritic cell vaccines is safe and feasible with prolonged long-term survival in a small fraction 
of the patients (Antonios, Everson et al. 2015; Van Gool 2015). Yet, it is not fully understood 
why only a subset of patients respond to dendritic cell based vaccines and how to discrimi-
nate responders vs. non-responders before treatment is given. We have shown that MDSC 
percentages are significantly increased in the blood of patients with glioblastoma. However, 
we also showed that some glioblastoma patients had an increase of MDSCs in their blood, 
while others had MDSC levels comparable to healthy donors. This phenomenon may have 
contributed to the fact that dendritic cell therapy was more effective in some patients than 
in others. The same might be true for other immunotherapeutic strategies. For instance, in 
patients with melanoma treated with a peptide vaccine, a correlation was found between 
survival and the percentage of M-MDSCs and PMN-MDSCS in blood (Walter, Weinschenk 
et al. 2012). High numbers of MDSCs were also associated with poor survival in melanoma 
patients treated with an anti-PD-1 monoclonal antibody (nivolumab) in a phase I/II study 
(Weber, Gibney et al. 2016) and melanoma patients with low levels of MDSCs were more 
likely to respond to anti-CTLA-4 treatment (Kitano, Postow et al. 2014; Meyer, Cagnon et al. 
2014). The efficacy of immunotherapy might thus be increased by a combinatorial approach 
of which relieving the MDSC-induced immune suppression is a component as well. 
This idea is supported by two studies using a murine glioma model. Thaci and colleagues 
treated glioma bearing mice with a replication deficient adenoviral vector that transduces 
GL261 glioma cells resulting in the induction of biological active IL-12. This treatment re-
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sulted in a 50% reduction of MDSCs in the brain and the induction of interferon synthesis 
in CD8+ T cells as well as a long term survival in 60% of the animals. Interestingly, reducing 
the MDSC numbers further with an anti-Gr-1 antibody did not further improve survival in 
this model. Although treatment with the adenoviral vector resulted in decreased tumour-
infiltrating MDSCs, it has to be kept in mind that IL-12 has multiple effects on the immune 
system and it is not possible to discriminate the effect of the reduced number of MDSCs in 
this study (Thaci, Ahmed et al. 2014). In another study, treatment of glioma bearing mice 
with a CD200R antagonist resulted in the inhibition of MDSC expansion (Moertel, Xia et al. 
2014). Inclusion of this antagonist in a glioma tumour lysate-derived vaccine significantly 
enhanced survival in this model. These two studies do indicate that targeting MDSCs may 
represent a valuable contribution to reduce tumour growth, which might even be more 
potent in combination with immunotherapy.
An international phase III trial in which patients with an EGFRvIII positive glioblastoma re-
ceived Rindopepimut has recently be terminated. In this study, a peptide based vaccine is 
combined with GM-CSF as an adjuvant in order to elicit an EGFRvIII specific humoral and cel-
lular response (Babu and Adamson 2012). In a previous phase II study, patients vaccinated 
with Rindopepimut had improved median overall survival compared to matched controls, 
with some of the patients showing long-term survival (Babu and Adamson 2012; Zussman 
and Engh 2015). However, the phase III study was prematurely terminated due to a lack 
of efficacy. We hypothesized that MDSC percentage might be predictive for response to 
Rindopepimut. Indeed, the MDSC flowcytometry analysis we developed was implemented 
as immune-monitoring in one participating centre in the phase III trial. Although the sample 
numbers are too limited to draw any conclusions yet, the protocol is feasible and can be 
used in future studies to monitor MDSCs in immunotherapeutic trials. 
Challenges for immunocombination therapy in glioma
Where generally either one of the MDSC subpopulations is increased in the blood of patients with a solid tumour, we and others have shown that both subpopulations 
are increased in the blood of patients with glioblastoma (Chapter 4, 5 and (Dubinski, Wolfer 
et al. 2015)). It is, however, not known whether targeting either one of the subpopulations 
can sufficiently relieve the immunosuppressive environment or whether both need to be 
targeted. Furthermore, it is unknown whether targeting MDSCs in the blood is sufficient to 
potentiate immunotherapeutic strategies, or that intratumoural MDSCs also need to be tar-
geted. The observed glioma infiltrating PMN-MDSC were mainly located near necrotic areas 
and expressed similar levels of intracellular S100A8/9 as blood derived PMN-MDSCs and 
also expressed high levels of arginase mRNA. These findings suggest that these MDSCs play 
a role in immunosuppression within the tumour microenvironment. Further elucidation of 
this role is important, especially since PMN-MDSCs are predominantly located at necrotic 
areas, while cytotoxic T cells are more diffusely mingled with the tumour tissue (Barcia, 
Gomez et al. 2009). When considering targeting intratumoural MDSCs, it is important to 
realize that compounds need to pass a more or less defective BBB. It is not unlikely, that 
the best results will be obtained by targeting both M-MDSCs and PMN-MDSCs in peripheral 
blood as well as within the tumour.
Studies in both mice and men have shown that ATRA can have direct effects on MDSCs 
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by causing apoptosis of PMN-MDSCs and inducing differentiation of M-MDSCs into mature 
myeloid cells (Kusmartsev, Cheng et al. 2003; Kusmartsev, Su et al. 2008; Iclozan, Antonia et 
al. 2013). However, it is not known whether these effects observed in spleen/blood derived 
MDSCs also hold true for MDSCs in the tumour tissue. For example, Sunitinib treatment in a 
murine renal cell carcinoma model reduced the accumulation of both M-MDSCs as well as 
PMN-MDSCs in the spleen, but intratumoural MDSCs were not affected (Ko, Zea et al. 2009; 
Ko, Rayman et al. 2010). This Sunitinib effect on intratumoural MDSCs is compromised by 
GM-CSF produced by the tumour. In RCC patients, Sunitinib mediated reversal of MDSC ac-
cumulation and a decrease in the percentage of Tregs (Finke, Rini et al. 2008; Ko, Zea et al. 
2009). It will be important to determine whether GM-CSF in humans can also prevent the ef-
fect on MDSCs by STAT-3 targeting. This will especially be important in immune-combination 
therapies targeting MDSCs and inducing an immune response using GM-CSF as an adjuvant. 
For example, the Rindopepimut study mentioned above might therefore not be the best 
treatment to combine with Sunitinib and possibly other MDSC targeted therapies. The use 
of GM-CSF as an immune adjuvant without targeting MDSCs already needs to be handled 
with care, as meta-analysis of published trials using GM-CSF suggests that low levels of GM-
CSF (40-80 μg) applied for a short period (1-5 days) can improve cellular immune responses, 
while a systemic treatment with more than 100 μg did not enhance a peptide vaccine and 
resulted in expansion of immunosuppressive MDSCs (Kirner, Mayer-Mokler et al. 2014). The 
results of a phase III clinical trial in RCC patients combining Sunitinib with a multi peptide 
vaccine administered in combination with GM-CSF (NCT01265901), might shed more light 
on the effect of Sunitinib on MDSCs in combination with GM-CSF in humans (Walter, Wein-
schenk et al. 2013).
Multiple studies have reported that targeting MDSCs is beneficial for the treatment of can-
cer in combination with various other therapies, especially immunotherapy (Kusmartsev, 
Cheng et al. 2003; De Santo, Serafini et al. 2005; Chalmin, Ladoire et al. 2010; Veltman, 
Lambers et al. 2010; Bose, Taylor et al. 2011; Molon, Ugel et al. 2011; Kodumudi, Weber 
et al. 2012; Sevko, Kremer et al. 2012; Iclozan, Antonia et al. 2013) and other clinical trials 
are still ongoing (NCT01803125, NCT00843635, NCT02403778, NCT01697800). Inhibiting 
MDSC accumulation or function and thereby disrupting the immune suppressive environ-
ment, might thus potentiate active immunotherapy for patients with glioma. While there 
are many potent inhibitors of MDSC accumulation and/or function, the most optimal com-
bination therapy, timing and order of these therapies that optimally targets the tumour and 
at the same time eliminates or reverts the immunosuppressive tumour microenvironment, 
still needs to be identified. Defining the patients’ initial immune status and longitudinal 
monitoring of these parameters, including the level of inflammation, quantity and quality 
of different subsets of relevant immunosuppressive cells as well as effector T cells, antigen 
presenting cells and natural killer T cells is crucial for making progress in this respect.  
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Gliomen zijn een heterogene groep van primaire hersentumoren. De meest voorkomende 
primaire hersentumor is de meest agressieve vorm, glioblastoma. Hoofdstuk 1 geeft een 
overzicht van de verschillende gliomen, het immunologische milieu in gliomen en wat dit 
kan betekenen voor de prognose van patiënten met een glioom. Een van de cellen die hier 
een belangrijke rol in kan spelen is de “Myeloid Derived Suppressor Cell” (MDSC), een im-
mature myeloïde cel die de activiteit van het immuunsysteem kan onderdrukken. In hoofd-
stuk 2 wordt deze cel uitgebreid beschreven, inclusief de verschillende eigenschappen die 
deze cel kenmerkt. 
Ondanks ontwikkelingen in chirurgische procedures, chemotherapie en radiotherapeutische 
procedures, is de gemiddelde overleving van patiënten met een glioblastoma slechts 14,5 
maand (Stupp, Mason et al. 2005; Stupp, Hegi et al. 2009; Johnson and O’Neill 2012; Zong, 
Verhaak et al. 2012). De meest gebruikte chemotherapie voor patiënten met een glioom is 
Temozolomide (TMZ), een alkylerende stof die schade aan het DNA kan induceren, wat kan 
resulteren in cel dood. Helaas zijn glioom cellen in staat gebleken snel resistentie te ontwik-
kelen tegen TMZ door middel van het aanpassen van DNA herstel mechanismen (Sarkaria, 
Kitange et al. 2008; Fan, Liu et al. 2013). Echter zijn er ook andere factoren die mee spelen in 
de TMZ resistentie. In Hoofdstuk 3 laten we zien dat een verhoogde expressie van connexin 
43 (Cx43) de resistentie tegen TMZ kan verhogen. Connexins zijn een groep van eiwitten die 
viermaal door het plasmamembraan heen gaan. Zes van deze eiwitten kunnen een structuur 
in het membraan vormen waardoor een klein kanaal kan ontstaan. Twee van deze kanaal-
tjes van naburige cellen kunnen een zogenaamde “gap junction” vormen, waardoor kleine 
ionen en moleculen tussen cellen uitgewisseld kunnen worden (Naus, Elisevich et al. 1992). 
De Cx43 geïnduceerde resistentie tegen TMZ is deels afhankelijk van deze kanaal functie. De 
verhoogde Cx43 expressie voorkomt een verhoging van de Bax/Bcl ratio in cellen die behan-
deld zijn met TMZ. Een verhoging van deze ratio kan resulteren in het vrijkomen van Cytoch-
room C, wat tot activatie van de Caspasa cascade kan leiden, hetgeen apoptose induceert. 
Deze data suggereert dat een verhoogde expressie van Cx43 het induceren van apoptose 
door TMZ kan remmen en dat mogelijk de potentie van TMZ verhoogd kan worden door 
het remmen van Cx43. Doordat er nog vele andere mechanismen zijn die TMZ resistentie 
kunnen initiëren verwachten wij dat het waardevol is om ook alternatieve behandelingen 
te onderzoeken.
De hersenen zijn lang gezien als een “immune privileged” orgaan vanwege de bloed-hersen-
barrière en de afwezigheid van conventionele lymfevaten (Grauer, Wesseling et al. 2009). 
Recentere studies wijzen er echter op dat de hersenen een immuun gespecialiseerd orgaan 
is waar immuunreacties nauw gereguleerd worden, wat extra mogelijkheden biedt voor het 
gebruik van immuuntherapie bij patiënten met een glioom. In de afgelopen jaren zijn ver-
schillende immuun therapeutische interventies onderzocht, waarbij het gebruik van den-
dritische cellen (DC) vaccinatie de meest onderzochte optie is. Deze DC vaccinatie studies 
hebben laten zien dat het mogelijk is om cytotoxische T cellen tegen de autologe tumor te 
initiëren en dat er een verhoogde overleving is in een fractie van de patiënten (Yu, Liu et al. 
2004; Wheeler and Black 2011; Van Gool 2015). Echter, zoals in hoofdstuk 1 en 2 bespro-
ken, kunnen gliomen een immuun-onderdrukkend milieu ontwikkelen dat mogelijk het ef-
fect van (immuun) therapie kan hinderen. Om de efficiëntie van immuuntherapie te kunnen 
vergroten is het belangrijk om een beter inzicht te krijgen in dit immuun-onderdrukkende 
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milieu. 
In dit proefschrift focussen we op de MDSC. De term MDSC werd geïntroduceerd in 2007 
(Gabrilovich, Bronte et al. 2007; Yang 2007), waarbij een monocytaire (M-) en een granulaire 
populatie wordt onderscheiden (Youn, Nagaraj et al. 2008). De granulaire MDSCs hebben 
een gelobde kern, waardoor deze cellen ook worden omschreven als “polymorphonuclear” 
(PMN-) MDSCs. In hoofdstuk 4 beschrijven we de verhoging van beide populaties MDSCs 
in het bloed van patiënten met een glioom. Deze cellen hebben een vergelijkbare hoeveel-
heid van de myeloïde activatie markers CD124, CD86, CD40, CD80 en PD-L1 met MDSCs uit 
gezonde donoren. Tevens konden cellen met een MDSC fenotype worden gedetecteerd in 
glioom weefsel, waarbij deze populatie voornamelijk bestond uit cellen met het PMN-MDSC 
fenotype. Deze cellen waren voornamelijk aanwezig in necrotisch weefsel, maar konden ook 
worden gedetecteerd in levend tumor weefsel.
In hoofdstuk 5 worden deze bevindingen bevestigd met monsters van een extra set patiënt-
en met een glioom en onderzoeken we de immuun-onderdrukkende potentie van MDSCs 
geïsoleerd uit het bloed van deze patiënten. We laten een trend zien in een verhoogd aantal 
MDSCs in het bloed in relatie tot de maligniteit van de tumor. Verder laten we een verhoging 
zien van de intracellulaire myeloïde activatie marker S100A8/9 in M-MDSCs van patiënten 
met een glioom ten opzichte van M-MDSCs van gezonde donoren. Tevens laten we een ver-
hoging zien van de hoeveelheid S100A8/9 en arginase activiteit (een enzym wat betrokken 
kan zijn bij de onderdrukking van het immuun systeem) in serum van patiënten met een 
glioom ten opzichte van serum van gezonde donoren. Tot slot laten we zien dat PMN-MDSCs 
geïsoleerd uit de tumor vergelijkbaar zijn met de PMN-MDSCs geïsoleerd uit het bloed met 
betrekking tot S100A8/9 en arginase expressie en dat PMN-MDSCs geïsoleerd uit het bloed 
van patiënten met een glioom in staat zijn de autologe T cel functie te onderdrukken. Deze 
data suggereren dat een verhoging van het aantal MDSCs afhankelijk is van de maligniteit 
van het glioom, en dat een verhoogde activatie van MDSCs in patiënten met een glioom 
onafhankelijk is van de tumor maligniteit. 
De regulatiemechanismen betrokken bij deze verhoging van MDSC aantal en activiteit zijn 
nog onbekend. De groep van Chen beschrijft de betrokkenheid van CD33 (ook bekend als 
“Sialic acid-binding immunoglobulin-like lectin (Siglec)-3”) bij dit proces, een immuun mod-
ulatoire receptor op het celmembraan van MDSCs die gebruikt wordt om MDSCs te fenoty-
peren (Chen, Eksioglu et al. 2013). In totaal zijn er 14 Siglec eiwitten bekend die in mensen 
tot expressie kunnen komen, maar tot op heden is alleen de expressie van Siglec-3 beschre-
ven voor MDSCs. In Hoofdstuk 6 beschrijven we de expressie van Siglec-3, -7 en -9 op beide 
MDSC subsets, waarbij we geen verschil konden detecteren in de expressie op MDSCs van 
patiënten met een glioom ten opzichte van gezonde donoren. PMN-MDSCs hebben een 
hogere expressie van Siglec-5 en M-MDSCs hebben een hogere expressie van Siglec-7 en 
-9. PMN-MDSCs geïsoleerd uit tumor weefsel hebben een vergelijkbaar expressieprofiel van 
Siglecs met de PMN-MDSCs in het bloed. Tevens laten we zien dat de liganden voor Siglecs 
aanwezig zijn op het celmembraan van vers geïsoleerde tumor cellen, waarbij voornamelijk 
het ligand voor Siglec-7 tot expressie komt en de liganden voor Siglec-3, -5 en -9 in mindere 
mate. Deze resultaten laten de mogelijkheid zien voor een interactie tussen glioom cellen 
en tumor infiltrerende MDSCs wat mogelijk kan bijdragen aan het immuun-onderdrukkende 
milieu in gliomen.
Page 150
&
Ondanks conventionele therapieën hebben patiënten met een glioom nog steeds een 
erg beperkte levensverwachting. Het is daarom belangrijk dat er alternatieve therapieën 
ontwikkeld worden. Wanneer men het immuunsysteem wil gebruiken om de tumor (of de 
resten hiervan na operatie) op te ruimen, is het belangrijk dat men zich realiseert dat de tu-
mor verschillende mogelijkheden heeft om het immuunsysteem te onderdrukken. Dit proef-
schrift levert resultaten die erop wijzen dat MDSCs bijdragen aan het onderdrukken van 
het immuunsysteem. Het onderdrukken van de toename van MDSC aantallen of de MDSC 
functie, bijvoorbeeld door het remmen van de Siglec interacties met liganden op glioma 
cellen, kan mogelijke belangrijk zijn om de effectiviteit van immuuntherapieën te vergroten.
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Nadat een vier jaar een ruime vijf jaar was geworden, begon mijn boekje steeds meer vorm 
te krijgen en kan ik nu tevreden zeggen dat het af is. Ondanks dat ik nog nooit zo blij ben 
geweest dat iets afgerond is, kijk ik terug op een mooie periode waarin ik erg veel geleerd 
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heel erg gewaardeerd. Naast het nalezen van de manuscripten en het meedenken over ex-
perimenten en resultaten, kwam je ook altijd geïnteresseerd langs om te vragen hoe het 
ging. Je straalde altijd erg veel rust en positiviteit uit en ik vond het erg gezellig om met je 
samen te werken. Een PhD-er kan zich geen fijnere copromotor wensen.
Ondanks dat ik altijd hard mijn best heb gedaan, is toch gebleken dat je aan twee handen 
soms te weinig hebt. Gelukkig kon ik dan altijd op de hulp van Esther rekenen. Doordat het 
patiëntenmateriaal niet altijd fijn in de ochtend kwam, hebben wij menig avond flowkast 
aan flowkast lopen ploeteren om uit die (en nu citeer ik menig Tiller die ’s avonds nog wel 
eens wilde komen kijken) “vieze brei” een mooie representatieve celsuspensie te verkrij-
gen. Met een goed gevulde snoeppot, de muziek van Sky Radio en ons fantastische zang-
talent heb ik goede herinneringen aan deze avonden, die ook nog het materiaal hebben 
opgeleverd wat in drie van mijn manuscripten is gebruikt. Bedankt voor alle hulp tijdens de 
afgelopen vijf jaar en bedankt dat jij een van mijn twee paranimfen wil zijn. 
Beste Christian, naast het delen van jouw Siglec expertise, zowel theoretisch als praktisch, 
wil ik je vooral bedanken voor je optimisme, vrolijkheid en gezelligheid. Naast werkgerela-
teerd overleg, hebben we ook erg veel andere gezellige momenten meegemaakt, met miss-
chien wel als hoogtepunt ons “startup bedrijf”, wat toch al drie succesverhalen kent. Ik hoop 
nog vele succesverhalen hieraan toe te kunnen voegen.
Ook wil ik de andere mensen van de muizengroep bedanken. Ondanks dat ik geen muis 
gezien heb in mijn tijd bij TIL, was het een waar genoegen om deel uit te mogen maken van 
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mooie afdeling opgezet en dank dat ik hier deel van uit mocht maken.
Naast TIL, wil ik ook de mensen van Pathologie en Celbiologie (Wiljan en Annika) bedankt 
voor hun interesse, wanneer ik tijdens jullie moleculaire experimenten weer met immunol-
ogische resultaten aan kwam zetten. Anneke, William en Sandra Boots, bedankt voor het 
opzetten van de logistiek om tumor en bloed te verkrijgen voor het onderzoek. Dankzij al jul-
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vooral Kiek erg hard voor gewerkt. Telkens als jij dacht dat het eindelijk klaar was, kwam 
er toch weer een verzoek van onze kant. Dank voor al je inspanningen! Judith, de stage bij 
jou heeft mijn interesse in de complexiteit van gliomen opgewekt wat mij niet meer heeft 
losgelaten. Tevens heb jij me op de vacature voor dit onderzoek gewezen wat de eerste ken-
nismaking voor mij met dit project betekende.
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rurgen van het RadboudUMC. Dank voor alle keren dat ik materiaal heb mogen ontvangen. 
Ondanks dat het voor mij nooit genoeg was, werd het wel altijd erg gewaardeerd. Vooral 
Mark en Sandra Bossmann, die er voor gezorgd hebben dat ik regelmatig materiaal heb 
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Part of this work was performed while I was in Vancouver. Beside an intelligent and inspir-
ing research group, I found a second family there. Thanks for all the memories that still 
enlighten my life! Vince, you are one brilliant post doc with an excellent sense of humor. 
Thanks for sharing your knowledge and intelligence with me! Steve, your endless interest 
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science fun facts resulted in many interesting and enjoyable nights. Sin, your combined pas-
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and keep inspiring others along the way. Dear Lynne and John, you are doing a great job as 
mom and dad of this group by creating lots of learning opportunities alternated with lots of 
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in dit manuscript is gefinancierd met Grants van het Radboud Institute for Oncology en de 
stichting STOPhersentumoren (www.STOPhersentumoren.nl). Deze stichting zet zich met 
veel overgave in om geld voor onderzoek in te zamelen om zo de genezing van hersentu-
moren dichterbij te krijgen. Bedankt voor het vertrouwen in dit onderzoek. Ik hoop dat al 
jullie inspanningen voor de stichting snel niet meer nodig zullen zijn.
Aangezien het mij niet is gelukt mijn PhD af te ronden in de 40 uur per week die er voor 
stond, wil ik ook alle lieve vrienden van mijn studie en van Stuban bedanken voor het eeu-
wige geduld. Ik heb lang niet zo vaak bij sociale activiteiten kunnen zijn als ik zou willen, 
maar elke keer als ik er wel bij kon zijn voelde ik me welkom. Dank voor de vele gezellige 
momenten en de vele drankjes die we hebben moeten drinken op dat het wel goed zou 
komen. Vooral Paul Martens, super bedankt voor je begrip als ik weer eens moest werken 
en je eeuwige interesse. We hebben er een hele hoop op moeten drinken, maar het resul-
taat is er dan eindelijk! Tevens fijn dat ook jij eindelijk een baan hebt met fatsoenlijke werk-
tijden, waardoor jij nu ook eens verstek moet laten gaan. Verder wil ik ook Tim, Timothy 
en Wouter nog bedanken voor het doorsturen van artikelen waar ik niet bij kon vanuit de 
Radboud account!
Lieve Anja, ondanks dat we elkaar pas echt hebben leren kennen toen ik al klaar wat bij TIL, 
was mijn proefschrift nog lang niet af. Hierdoor moest ik van de spaarzame weekenden die 
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even tof, maar gelukkig kon jij je ook wel met werk en je woning vermaken en is het mede 
dankzij de hulp van Laluna nu allemaal goed gekomen met al het schrijven. 
Tot slot wil ik mijn lieve familie bedanken. Lieve Pap en Janet, bedankt voor alle interesse 
en support. Het was altijd erg fijn even te kunnen vertellen hoe het op het werk ging, zowel 
de successen en de leermomenten. Lieve Mam en Marie, dank voor de avondjes met wijn 
en gezelligheid die de PhD altijd even deden vergeten. Ondanks dat ik de deur bij mijn oud-
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ers niet heb plat gelopen, vond ik het erg fijn te weten dat jullie dichtbij waren en dat ik 
altijd aan kon kloppen! Lieve Anne en Jeroen, nadat jullie het goede voorbeeld al hadden 
gegeven, is het mij nu ook gelukt een boekwerk in elkaar te draaien. De dingen waar ik 
tegen aangelopen was kwamen jullie vaak bekend voor en het was fijn dit bij jullie te kunnen 
luchten. Ik weet dat ik Jeroen 3 pagina’s dankbetuiging had beloofd… maar aangezien 3 pa-
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Samenvattend, super bedankt allemaal voor een top tijd, de vele leermomenten, support 
en gezelligheid!
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    Project: Analysis of resistance to Temozolomide in six glioma cell
    lines
Sept 2007 - May 2008  Internship at Dept. of Medical Microbiology of the Nijmegen
    Centre for Molecular Life Sciences.
    Project: Analysis of Stem-loop 1 of the Mengovirus10
Experimental techniques: 
• Cell culture (including primary cells),  and
    transfection 
• Autologous T cell suppression Assay
• Multicolor flow cytometry (including 
    intracellular stainings) & FACS
• Magnetic activated cell sorting
• Immunohistochemistry
• ELISA
• Virus culture (working on ML-2 level)
• DNA/RNA extraction
• cDNA synthesis, RT PCR, quantitative PCR
• Cytotoxicity assays (MTT & BrdU)
• Sequence analysis
• Multiplex Ligation-dependent Probe 
    Amplification
• Western blot
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Grants:
• Travel Grant Radboud International office (2013)
• SNUF individual travel grand (2010)
• KWF internship grant for students (2010)
Conferences:
2014, Dutch Tumor Immunology Meeting, Breukelen, the Netherlands; Oral presentation
2014, NCMLS PhD retreat, Wageningen, the Netherlands; Oral presentation
2014, CIMT, Mainz, Germany; Poster presentation
2013, NCMLS PhD retreat, Wageningen, the Netherlands; Poster presentation
2013, CIMT Mainz, Germany; Poster presentation
2012, NVvI, Noordwijkerhout, the Netherlands; Poster presentation
2012, NCMLS PhD retreat, Wageningen, the Netherlands; Poster presentation
Extra-curricular activities: 
Jan 2008 - May 2010 Waiter/Barkeeper in a pub serving meals: café Thuis
Sept 2006 - Jan 2010 Trainer at Badminton Club Malden (BCM) and at NSBC Stuban
May 2006 - March 2007 Secretary of the Dutch Student Skiing Competition.
Dec 2005 - Jan 2008 Member of the PR and Activity Committee of NSBC Stuban of
    which the last year as chairman.
Sept 2004 - Dec 2007 Waiter in restaurant ‘t Lemke in Nijmegen.
Characteristics:
Knowledge of languages:  Dutch and English, fluent in writing and oral communication
   German (understanding only)
Skills:    Driver’s license (B)
Hobbies:   Badminton, mountain biking, road biking and cooking
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Curriculum Vitae supplementary:
Publications:
1  Lindau, D., Gielen, P., Kroesen, M. et al. The immunosuppressive tumour network: 
myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 
138, 105-15, doi:10.1111/imm.12036 (2013).
2  Gielen, P., van der Valk, P. & Wesseling, P. in Neuroinflammation and CNS Disorders 
363-84 (John Wiley & Sons, Ltd, 2014).
3  Gielen, P. R., Schulte, B. M., Kers-Rebel, E. D. et al. Increase in Both CD14-Positive 
and CD15-Positive Myeloid-Derived Suppressor Cell Subpopulations in the Blood of Pa-
tients With Glioma But Predominance of CD15-Positive Myeloid-Derived Suppressor Cells 
in Glioma Tissue. Journal of neuropathology and experimental neurology, doi:10.1097/
NEN.0000000000000183 (2015).
4 Gielen, P. R., Schulte, B. M., Kers-Rebel, E. D. et al. Elevated levels of polymor-
phonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express 
S100A8/9 and arginase and suppress T cell function. Neuro Oncol, doi:10.1093/neuonc/
now034 (2016).
5 Kroesen, M., Gielen, P., Brok, I. C. et al. HDAC inhibitors and immunotherapy; a 
double edged sword? Oncotarget 5, 6558-72 (2014).
6 Kroesen, M., Bull, C., Gielen, P. R. et al. Anti-GD2 mAb and Vorinostat synergize 
in the treatment of neuroblastoma. Oncoimmunology 5, e1164919, doi:10.1080/216240
2X.2016.1164919 (2016).
7 Schulte, B. M., Gielen, P. R., Kers-Rebel, E. D. et al. Enterovirus-Infected beta-Cells 
Induce Distinct Response Patterns in BDCA1+ and BDCA3+ Human Dendritic Cells. PloS one 
10, e0121670, doi:10.1371/journal.pone.0121670 (2015).
8 Schulte, B. M., Gielen, P. R., Kers-Rebel, E. D. et al. Enterovirus Exposure Uniquely 
Discriminates Type 1 Diabetes Patients with a Homozygous from a Heterozygous Melanoma 
Differentiation-Associated Protein 5/Interferon Induced with Helicase C Domain 1 A946T 
Genotype. Viral immunology, doi:10.1089/vim.2015.0140 (2016).
9 Gielen, P. R., Aftab, Q., Ma, N. et al. Connexin43 confers Temozolomide resistance 
in human glioma cells by modulating the mitochondrial apoptosis pathway. Neuropharma-
cology, doi:10.1016/j.neuropharm.2013.05.002 (2013).
10 Zoll, J., Hahn, M. M., Gielen, P. et al. Unusual loop-sequence flexibility of the 
proximal RNA replication element in EMCV. PLoS One 6, e24818, doi:10.1371/journal.
pone.0024818 (2011).
